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Abstract 
 
 
Following the discovery of the cannabinoid receptors, research in the field of 
cannabinoids has grown exponentially over the last two decades.  Cannabinoids have 
been shown to have tremendous therapeutic potential in the treatment of several 
pathological conditions ranging from inflammation to asthma, multiple sclerosis, 
Parkinson’s disease, epilepsy, glaucoma, septic shock, hemorrhagic shock, and cancer.  
Our research has focused on two major conditions for which cannabinoids hold great 
promise for drug development, namely, cancer and inflammation.  
Our focus in the field of cancer has been on the devastatingly lethal brain tumor 
glioblastoma multiforme.  Due to the high expression of the CB2 receptor in human 
gliomas, we chose to focus on two CB2 selective lead compounds for these studies: KM-
233 (CB2 antagonist) and HB-I-172 (CB2 inverse agonist).  Both compounds showed in 
vitro efficacy against four human glioma cell lines (EC50s = 2.27 ± 0.18µM to 6.34 ± 
4.10µM) while HB-I-172 also showed efficacy against prostate, lung, and colorectal 
tumor lines (2.38 ± 0.75µM to 5.22 ± 1.2µM).  Significant reductions in tumor load were 
also observed in vivo in both side flank and intracranial models of glioblastoma.  The 
anti-glioma efficacies of the two lead compounds were not altered by pharmacologic 
blockade of the CB1 and CB2 receptors which points to a non-CB1/CB2 mediated 
signaling pathway.  This pathway was examined in the human glioma line U-87 MG and 
determined to involve reductions in pMEK1/2, pERK1/2, pAkt, and p-p70S6K with 
increases in pGSK3B, p53, and cleaved caspases 3 and 9, and PARP.  
Immunohistochemical studies revealed loss of mitochondrial membrane polarization with 
release of cytochrome-C, DNA fragmentation and condensation, and alterations in 
cytoskeletal structure. 
The current focus in the field of cannabinoids as anti-inflammatory agents is on 
CB2 selective compounds which are devoid of the CNS side-effects which could limit 
their therapeutic usefulness.  We screened a variety of novel cannabinoids and the CB2 
inverse agonist HB-I-172 emerged as a lead.  In vitro treatment with HB-I-172 caused a 
significant reduction in a number of proinflammatory cytokines and chemokines in both 
neoplastic lung epithelial cell and macrophage models and in primary human lung 
epithelial and endothelial cells, macrophages, and microglia.  We believe that HB-I-172 
and other CB2 selective cannabinoids are promising treatments for a variety of 
inflammatory conditions from neuro-inflammatory disorders such as multiple sclerosis 
and Huntington’s disease to systemic conditions such as atherosclerosis and 
inflammatory pain. 
Finally, three new series of heterocyclic cannabinoid ligands were synthesized 
and screened.  The hexahydro pyrimidine classical, pyrimidine nonclassical, and 
furanopyrimidine cannabinoids were designed with CB2 selectivity in mind.  After many 
failed synthetic routes were abandoned, the three new classes were successfully 
generated.  Many of these compounds showed good CB2 selectivity (77-fold) and 
showed efficacy in both anti-glioblastoma and anti-inflammatory studies.  
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Chapter 1: Introduction 
 
 
1.1 History 
 
Cannabis sativa (marijuana) is one of the oldest known herbal drugs whose 
medicinal value has been exploited for centuries.  The use of Cannabis sativa 
preparations for treatment of a variety of pathological conditions in ancient Indian, 
Chinese, and Egyptian civilizations is well-documented.1  Ancient literature is rich with 
therapeutic indications for Cannabis such as its usage as an analgesic,2 an anesthetic,3 an 
appetite stimulant,4 an anti-inflammatory agent,5 and as a treatment for hemorrhoids.1  
Early in the nineteenth century there was a rapidly increasing interest in research 
of natural products, and several alkaloids such as morphine, cocaine, and strychnine were 
isolated from plant materials.  The search for the psychoactive constituent of marijuana 
began during this period of rapid growth in the field of pharmacognosy.  It was the 
common belief for many years that the principal active constituent of Cannabis sativa 
was in fact an alkaloid.  In 1896, however, Marshall and coworkers isolated a mixture of 
terpenes from an ethereal extract of Indian hemp,6 which produced the same 
pharmacological effects that are observed with Cannabis sativa use.  This provided the 
first evidence that the principal active compound was terpenoid in nature.  In the early 
1930s Cahn and coworkers isolated cannabinol (Figure 1.1) and determined a partial 
structure after conducting extensive chemical degradation studies.7  This discovery was 
quickly followed by the synthesis of several derivatives of cannabinol and ∆6a,10a–
tetrahydrocannabinol (∆6a,10a–THC) (Figure 1.1) by the Adams group in the US8 and the 
Todd group in Britain.9  The pharmacological activities of cannabinol and ∆6a,10a–THC, 
as tested by the Gayer areflexia test for suppression of corneal reflexes in the rabbit, were 
observed to be similar to those of the Cannabis extract, but were significantly less potent.   
The isolation and structural characterization of the principal active constituent of 
Cannabis sativa, ∆9–tetrahydrocannabinol (∆9–THC) (Figure 1.2), was reported in 1964 
by Gaoni and Mechoulam.10  The activity of this cannabinoid was subsequently studied in 
a number of animal models.  These studies ranged from evaluation of the cataleptic 
reaction in mice11 to the effects on motor activity and gross behavior in mice and rats.12  
There was also extensive experimentation in rhesus monkeys12 which ultimately led to 
the pharmacological characterization of cannabinoids.   
Following these reports, several other constituents of marijuana such as 
cannabidiol, cannabigerol, cannabichromene, cannabicyclol (Figure 1.2) and related 
cannabinoid acids were isolated and characterized.  The structural characterization of ∆9–
THC provided a springboard to stimulate interest in research on cannabinoids.  This 
resulted in the design and synthesis of several structurally diverse classes of 
cannabinoids.  Studies on the effects of various analogues in animal models showed a 
positive correlation between structure and biological activity indicating the possible 
involvement of a defined receptor for the cannabinoids.  This variety of compounds then 
aided in the discovery and cloning of the cannabinoid receptors and the subsequent 
identification of their endogenous ligands. 
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Figure 1.1:  Structures of cannabinol and ∆6a,10a–tetrahydrocannabinol   
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Figure 1.2:  Structures of ∆9–THC, cannabidiol, cannabigerol, cannabichromene, and 
cannabicyclol 
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1.2 Cannabinoid Receptors 
 
The beginning of the exponential growth seen in the field of cannabinoid research 
in the last 20 years can be traced to the identification, isolation and cloning of the 
cannabinoid receptors.  After the discovery of ∆9–THC, but before the discovery of the 
cannabinoid receptors, research on cannabinoids in the late 1970s and in the early 1980s 
was based on the assumption that the pharmacological effects attributed to cannabinoids 
were mediated not through specific receptors but by perturbation of cellular membranes.  
Due to their high lipophilicity, it was thought that cannabinoids behaved like general 
anesthetics in terms of their mechanism of action.13  However, the highly stereospecific 
activity associated with several cannabinoids14 suggested receptor mediated action.  
Then, in 1988, Devane and coworkers15 utilized a tritium labeled synthetic cannabinoid to 
tag specific sites in the brain and on neuronal cells.  This then identified the presence of a 
specific cannabinoid receptor in the rat brain.  This discovery was finally followed by the 
isolation of the cDNA of this receptor, its expression in Chinese hamster ovary (CHO) 
cells, and subsequent naming as the cannabinoid receptor type 1 (CB1).16  In 1993, a 
second cannabinoid receptor subtype, cannabinoid receptor type 2 (CB2), was isolated 
and cloned from the human promyelocytic cell line HL60 by Munro and coworkers.17  
An amino terminal variant of the human CB1 receptor has also been reported18 in which, 
a 167 base portion of the CB1 coding sequence is spliced out of the mRNA. This amino 
terminal variant of the CB1 receptor was named the CB1A receptor.   
Whether there are additional cannabinoid receptors is still a hotly debated topic 
among several researchers in this field.  This is, in part, due to the observation that the 
endogenous cannabinoid ligand, anandamide, induces spinal antinociception via a 
different mechanism than ∆9–THC.19  In 2000, Di Marzo and coworkers carried out 
studies20 using transgenic mice21 that lack the CB1 receptor to evaluate the CB1 mediated 
effects of anandamide and ∆9–THC.  They found that in these knockout mice anandamide 
still produced CB1-like effects such as catalepsy, analgesia, and loss of spontaneous 
activity whereas ∆9–THC did not.  This suggested the presence of a new cannabinoid 
receptor in the brain.  Recent studies have also shown that a number of the cannabinoid 
ligands bind to the orphan receptor GPR55.22  This receptor is reported to be expressed in 
several tissues and might function in regulation of vascular tone and immune-cell 
migration.22c  Anandamide is also known to act on other classes of receptors such as the 
vanilloid receptor TRPV1.  Anandamide activates the vanilloid receptor and produces 
membrane currents or increases in intracellular calcium levels.23  The presence of these 
multiple sites for cannabinoid action (along with the possibility for yet undiscovered 
sites) with several signaling pathways and associated second messengers is consistent 
with the complex pharmacology associated with cannabinoids. 
The cannabinoid receptors belong to the superfamily of G-protein coupled 
receptors11 (GPCRs) and are single polypeptides with seven transmembrane α-helices, an 
extracellular, glycosylated N-terminus and intracellular C-terminus.  The CB1 and CB2 
receptor subtypes posses 68% amino acid identity within their transmembrane regions but 
only 44% identity throughout the entire peptide.  The CB1 receptor is a 52.8 kDa, 472 
amino acid polypeptide, which is found in both the CNS and periphery and in both neural 
and non-neural tissues.  CB1 is coupled to  inhibitory Gi/o  proteins24 which bind to its 
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third intracellular loop and its C-terminus.25  The amino acid residues in transmembrane 
regions 3, 5, and 6 of the CB1 receptor are believed to be involved in binding with 
cannabinergic ligands.26  Activation of CB1 causes inhibition of adenylate cyclase and a 
reduction in cAMP levels.  Reduction of cAMP affects phosphorylation by protein kinase 
A which causes modulation of ion channels and other second messengers.  Activation of 
voltage-sensitive outwardly rectifying K+ channels,27 inwardly rectifying K+ channels28 
and inhibition of voltage gated N, L, P, and Q-type Ca2+ channels29 are observed in 
response to CB1 receptor activation.  
The CB1 receptor is also known to regulate different members of the mitogen-
activated protein kinase (MAP kinase) family of enzymes such as: 
a. extracellular signal-regulated kinase (ERK)30 
b. c-Jun N-terminal kinase31 
c. p38.31b,32 
Activation of MAP kinases is associated with: 
a. activation of immediate early genes like c-Fos and Egr1 (Krox-24)30a  
b. activation of focal adhesion kinase (important for integrating cytoskeletal changes 
associated with signal transduction events) 
c. activation of phospholipases (PL), PLA, PLC, and PLD33 
d. activation of the Na+/H+ exchanger34 
e. activation of phospholipase A2, which in turn causes release of arachidonic acid 
leading to the synthesis of prostaglandins.35 
 
There is also evidence of a second pathway initiated by CB1 receptor stimulation 
which is coupled with sphingomyelinase activation and subsequent release of 
ceramide.30c  Ceramide then causes activation of the Raf-1/MAP kinase cascade36 and 
also carnitine palmitoyltransferase I in mitochondrial membranes to stimulate ketogenesis 
and fatty acid oxidation.37  This elevation in levels of intracellular ceramide have also 
been suggested to be one of the possible factors responsible for the apoptotic effects of 
cannabinoids seen on glioblastoma cells.38  
The CB2 cannabinoid receptor, also referred to as the peripheral cannabinoid 
receptor, is a 41 kDa, 360 amino acid polypeptide that is predominantly expressed in the 
immune system.39  Its amino acid sequence is quite different from that of CB1, especially 
in the amino terminal domain where there is no significant conservation and which is 
significantly shorter in the CB2 receptor when compared to the CB1 receptor.  The amino 
acid residues involved in ligand recognition are also found in the transmembrane domains 
3, 5, and 6 for the CB2 receptor. 
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Like the CB1 receptor, CB2 is also coupled to the inhibitory Gi/o proteins that bind 
to its third intracellular loop and C-terminus.  Activation of the CB2 receptor also causes 
inhibition of adenylate cyclase and therefore a similar reduction in cAMP levels.  Most of 
the known signaling pathways of CB2 are identical to those observed with CB1.  
However, unlike the CB1 receptor, the CB2 receptor has no effect on ion channels.28  
After the discovery of the CB2 receptor it was believed that it was found only in 
the immune system and was completely absent from the CNS.40  Recently, however, CB2 
expression has been confirmed in the brain on microglia,41 blood vessels,41 and on some 
neurons.42  CB2 is, however, expressed in much higher densities than CB1 in the immune 
system.  The expression level of the CB2 gene in immune tissues is 10-100 times that of 
the CB1 gene.43  In fact, the CB2 mRNA content of the spleen and tonsils is almost 
equivalent to the CB1 mRNA content in the CNS.43  This first led researchers to suggest 
that CB2 receptor might play an important role in immune function.  It is no surprise then 
that many reports have been made over the years regarding the deleterious effects of 
marijuana smoking on host defense mechanisms where marijuana smokers were found to 
be more susceptible to bacterial and viral infections.44  Between transmembrane domains 
1 and 7, including the loop regions, the CB2 receptor is only 44% identical to the CB1 
receptor, making it is possible to develop selective CB2 ligands to specifically target the 
immune system.  
GPR55 was first identified and cloned by O’Dowd in 1999.45  It was later 
identified by an in silico screen as a putative cannabinoid receptor due to an amino acid 
sequence in the binding region that is similar.  Research groups at the pharmaceutical 
companies Glaxo Smith Kline and Astra Zeneca then extensively characterized the 
receptor in the hope that it would be responsible for the blood pressure lowering effects 
of cannabinoids.  GPR55 is indeed activated by endogenous, phyto-, and synthetic 
cannabinoids but GPR55 knockout mice generated at Glaxo Smith Kline showed no 
alteration in the cannabinoid induced blood pressure regulation after administration of the 
GPR55 agonist abnormal cannabidiol. 
Many of the known CB1 and CB2 ligands also bind to GPR55.  The receptor is 
activated by phytocannabinoids such as ∆9–THC and cannabidiol,22c synthetic 
cannabinoids such as CP-55,940, and the endocannabinoids anandamide, 2-
arachidonoylglycerol, and nolandin ether.22c  Recent research suggests that 
lysophosphatidylinositol and its 2-arachidonoyl derivative may be the endogenous 
ligands for GPR5546 and the receptor appears likely to be a possible target for treatment 
of inflammation and pain as with the other cannabinoid receptors.47     
While the CB1 and CB2 receptors couple to Gαi/o proteins, GPR55 is coupled to 
Gα13 and activation of the receptor leads to stimulation of a number of GTPases such as 
Ras homolog gene family, member A (RhoA), cell division control protein 42 homolog 
(cdc42) and Ras-related C3 botulinum toxin substrate 1 (rac1).22a  Members of this 
GTPase superfamily appear to regulate a diverse array of cellular events, including the 
control of cell growth, cytoskeletal reorganization, and the activation of protein kinases.48  
Stimulation of GPR55 induces F-actin formation under the control of Gα13, RhoA and 
Rho-associated, coiled-coil containing protein kinase (ROCK).46b  GPR55 activation also 
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induces intracellular calcium release and activation of the transcription factors nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB), nuclear factor of 
activated T-cells (NFAT) and cAMP response element-binding (CREB).46b  
The physiological role of GPR55 remains unclear.  Mice with a target deletion of 
the GPR55 gene show no specific phenotype.49  GPR55 is has been found to be widely 
expressed in the brain, especially in the cerebellum.  It is found in the gastrointestinal 
tract in the jejunum and ileum and also in the adrenal glands but is apparently not highly 
expressed elsewhere in the periphery.22c  Osteoblasts and osteoclasts have also been 
shown to express GPR55 and this has been shown to regulate bone cell function.50 
 
 
1.3 Cannabinoids as Anti-Glioma Agents 
 
 Brain tumors are the second and fifth leading causes of cancer-related deaths in 
males and females ages 20 to 39, respectively.51  The most prevalent form of adult 
primary CNS tumors is collectively referred to as glioma, and the most common, 
devastating, and high-grade glioma is glioblastoma multiforme (GBM).51-52  These 
tumors are classically thought to originate from supporting or glial cells of the CNS, and 
represent roughly fifty percent of all adult primary CNS tumors.  Long term survival of 
patients with a GBM diagnosis with the best radiological, surgical, and anti-tumor drug 
therapy available is extremely rare.  The historical median survival for GBM patients is 3 
to 12 months depending on age and other prognostic factors.53 
 
 
1.3.1 Current Standard of Care for Glioblastoma 
 
CNS tumors in general are difficult to treat because of the complexities 
associated with removing cancerous cells from a background of normal brain tissue 
without introducing considerable neurological damage.  Conventional therapy for 
malignant glioma consists of complete gross resection followed by radiation, either with 
or without chemotherapy.  Radiation is indicated because surgical resection misses 
micro populations of cells that have migrated from the primary tumor site.  However, 
currently accepted therapeutic adjuvants to surgery such as radiotherapy and 
chemotherapy provide only a minor improvement in the disease course and life 
expectancy of patients diagnosed with malignant glioma.54  The blood-brain-barrier 
(BBB) prevents the use of most chemotherapeutic agents; those that are available do not 
significantly impact the course of disease and often have unacceptable side effect 
profiles.55  Therefore, new drugs that adequately treat high-grade glioma of the brain and 
spinal cord are desperately needed if these tumors are going to be treated adequately in 
the future.   
 
 
1.3.1.1 Surgical Intervention 
 
 Therapeutic treatment patterns for GBM have produced limited increases in 
overall survival over the last few decades.  The advent of microneurosurgical techniques 
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along with improvements in neuroanesthesia and perioperative care has resulted in 
remarkable advancement in the management of benign tumors of the brain.  However, 
current surgical technique cannot adequately rid the surrounding brain tissue of 
microscopic foci of high-grade glioma cells that are not visible on the post-operative MRI 
scan.  Although surgery is not sufficient for cure of glioma, it is a necessary component 
of a multi modality approach that includes radiation and chemotherapy in some instances. 
Goals of surgery for malignant glioma include: (1) establishment of a histological 
diagnosis; (2) reduction in tumor cell load leading to reduced intracranial pressure; and 
(3) possibly changing tumor kinetics. 
 
 
1.3.1.2 Radiotherapy 
 
 Surgery alone has fallen short in providing any appreciable long-term increase in 
life expectancy for patients with high-grade gliomas.  Radiotherapy directed at the 
gliomatous area around the surgical cavity is considered beneficial to survival outcome, 
and indeed postsurgical radiation has proven to be the most effective treatment currently 
available for improving survival. There is also mounting evidence to suggest that 
additional radiation, given in the form of brachytherapy or radiosurgery, at initial 
diagnosis as a "boost" to standard radiation or at tumor recurrence, may provide added 
improvement in survival outcome.56  With advancements in radiotherapy tools and 
techniques the practice of whole brain irradiation has somewhat fallen from favor as 
radiation therapy results in radionecrosis not only of rapidly dividing tumor cells, but also 
of surrounding healthy brain tissue.  There are now two main radiotherapy delivery 
techniques: (1) external stereotactic radiotherapy (SRT) boost, administered either in one 
session or in fractions; and (2) brachytherapy boost by peri- or post-operative 
implantation of temporary catheters or permanent isotope seeds. 
 
 
1.3.1.3 Chemotherapy 
 
 At present, most centers in the United States also employ adjuvant chemotherapy 
as part of a patient’s initial treatment.  Current conventional chemotherapy regimens for 
newly diagnosed malignant glioma include single-agent intravenous bis-chloroethyl-
nitrosurea (BCNU; carmustine), single-agent oral procarbazine, or the PCV combination 
of procarbazine, chloroethyl-cyclohexylnitrosourea (CCNU) (lomustine), and vincristine. 
Since the 1980s, some but not all randomized studies have shown a small survival 
advantage for patients receiving one of these chemotherapy regimens in addition to 
surgery and RT.54a,b,57  A meta-analysis of published phase III randomized prospective 
studies showed a modest overall survival benefit and a higher proportion of long-term (> 
24 months in some studies) survivors for patients with GBM who received adjuvant 
chemotherapy.58  The toxicity profile varies among these treatments, with 
myelosuppression being the most frequent dose-limiting effect.55a,57  Factors limiting the 
use of chemotherapy are that there are no strong predictors of chemosensitivity among 
individual patients and the proper timing of upfront chemotherapy in relation to SRT for 
newly diagnosed tumors has never been studied rigorously.  Empirically administered 
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adjuvant chemotherapy generally is begun during or shortly after completion of SRT.  
Despite a variety of drugs and treatment schedules, the median time to tumor progression 
for patients with GBM is 6 to 8 months, and the overall survival remains around 12 
months.  To date there has been no proven prolongation of time to progression or survival 
for patients with malignant glioma when other drugs are added to the "standard" BCNU 
or PCV chemotherapeutic regimens, including cisplatin,59 carboplatin,60  
dibromodulcitol,61  mercaptopurine,62 or 6-thioguanine.63 
 
 
1.3.2 Cannabinoids as Chemotherapeutic Agents for the Treatment of High-
 Grade Gliomas 
 
 Investigational research related to the use of cannabinoids in oncology was 
primarily restricted to anti-emesis prior to the late 1980s.  Although limited studies on 
Lewis lung cancer and leukemia predate this time, active research on the antineoplastic 
potential of cannabinoids gained increased attention following the discovery of the CB1 
and CB2 receptors.  Cannabinoids have now been shown to induce apoptosis in 
rhabdomyosarcoma,64 colon,65 prostate66 and skin carcinomas,67 glioma,32,68 
neuroblastoma,68b and lymphoma/leukemia.69  Furthermore, a decrease in tumor size 
and/or cell growth inhibition has been reported in breast,66b,70 uterus,71 and lung 
cancers,72 and in thyroid epithelioma.73  The ability of cannabinoids to modulate the cell 
survival and death pathways in neoplasia is extremely significant from a drug 
development perspective.  Specifically, clinically investigated cannabinoids, in contrast 
to conventional cancer chemotherapies, do not exhibit the generalized toxic effects, are 
well tolerated by patients, and have the ability to penetrate the blood brain barrier.  This 
fledgling strategy of cancer treatment has the potential of decreasing the often severe side 
effects associated with most antineoplastic agents.  The future development of 
cannabinoids as peripheral antineoplastic agents holds great promise, however possibly 
the greatest impact in cancer therapy is the unprecedented opportunity for the 
development of antineoplastic agents capable of treating malignancies in the CNS. 
 The CNS and associated BBB is arguably the most difficult target organ for 
which drugs are developed.   Despite the development of an arsenal of clinically utilized 
CNS drugs, e.g. anti-depressants and anti-psychotics, highly effective chemotherapeutics 
for the treatment of brain cancers such as glioblastoma remain elusive.  One of the 
principle factors hindering this field of drug development is the fact that many of the 
otherwise efficacious natural product related antineoplastic agents are substrates for the 
anti-porter proteins that are abundant in the CNS microvasculature.  The established 
permeability of classical cannabinoids (CCBs) through the BBB combined with the 
demonstrated in vitro anti-glioma activity of several cannabinoid ligands offers an 
unprecedented opportunity for drug development.  Often such in vitro data does not 
translate to in vivo efficacy; however our lab and others have demonstrated the 
therapeutic potential of CCBs.  Specifically, KM-233 and JWH-133 were highly effective 
in halting the progression of human brain tumors in mice.68a,74  This is significant in that 
JWH-133 and, to a lesser extent KM-233, are selective CB2 receptor ligands and a recent 
report shows that primary human glioblastomas express significant levels of CB2 
receptors.75  This study was conducted prior to the emergence of GPR55 in the CB field 
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and as such expression levels of GPR55 were not evaluated.  As stated earlier, GPR55 is 
widely expressed in the CNS and increased GPR55 expression is consistent with our 
Western blot analysis of GBM cell lines (see Chapter 2, Figure 2.8).  Validation of 
GPR55 as a target for CB based anti-neoplastic agents offers a significant advancement 
in therapies targeted at GBM. 
 Further support for targeting the cannabinoid system comes from a pilot clinical 
study using THC, a non-selective partial agonist of the CB receptors; there was a slight 
improvement in survival in patients with recurrent brain cancers.76  In this study THC 
was administered intratumorally which may have, in part, reduced the overall efficacy of 
the treatment.  Specifically, in our side flank model, administration of KM-233 
intraperitoneally (i.p.) resulted in a greater reduction of tumor load compared to 
intratumor injection.74b  The development of cannabinoids as anti-glioma agents 
represents a promising field of research into the treatment of one of the most malignant 
forms of cancer whose current treatment is either ineffective or only palliative. 
 
 
1.4 Cannabinoids as Anti-Inflammatory Agents 
 
 It has been shown over the last forty years, initially by examining marijuana 
users, then in animal studies, and finally in cell culture, that cannabinoids are proven 
immunomodulators.77   It has been known for a much longer period of time, however, 
that marijuana does possess anti-inflammatory properties.  In what is perhaps the earliest 
literature reference to Cannabis, it is described as an anti-inflammatory agent.  The 
Chinese emperor Shen-nung (ca. 2000 B.C.), in a work called Pen-ts’ao Ching, noted 
many of the effects of Cannabis in humans.  Among other properties, he claimed that 
Cannabis “undoes rheumatism”, suggesting possible anti-inflammatory effects.78 
 
 
1.4.1 Cannabinoid Receptors in the Immune System 
 
 The presence of a cannabinoid receptor in cells of the immune system was known 
before the discovery of CB2.  In 1992, Kaminsky et al. reported the presence of the 
putative cannabinoid receptor on mouse splenic cells.79  This report was supported by the 
evidence of stereoselective immunomodulatory effects of cannabinoids on the splenic 
cells, specific binding of tritiated CP-55,940, and by the identification of mRNA for the 
receptor in the cells.  Shortly after this discovery, the peripheral expression and 
distribution of CB1 was examined in human tissues.  Messenger RNA for the receptor 
was identified in human spleen, tonsil, and peripheral blood leukocytes,80 although at 
much lower levels than in the brain.  The expression patterns found in the human blood 
cells varied significantly by type.  The order of expression level was found to be B cells > 
natural killer (NK) cells > polymorphonuclear neutrophils > CD8+ T lymphocytes > 
monocytes > CD4+ T lymphocytes.  CB1 mRNA at varying levels was also found in a 
number of monocytic and T and B leukemia cell lines, with the exception of Jurkat cells.  
On average, the B cell lines were found to have higher expression levels than the T cells. 
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After the discovery of the CB2 receptor in 1993, it was shown to be the dominant 
cannabinoid receptor in the immune system with (at that time) no quantifiable expression 
in the brain.17,39b  Human tissues were examined for expression levels of CB2 and it was 
found that levels of CB2 are 10-100X that of CB1 in human immune tissues.42a,81  It was 
shown by Galiegue and coworkers that the level of expression of CB2 in the spleen and 
tonsils was equivalent to the CB1 expression levels in the brain.43  Knowing the 
physiologic function of CB1 in the CNS, the researchers drew the conclusion that the 
CB2 receptor must be the major subtype responsible for the immunomodulatory effects 
of cannabinoids.  The order of expression of CB2 in human blood cells was reported to 
be B cells > NK cells > monocytes > polymorphonuclear neutrophils > CD8+ T 
lymphocytes > CD4+ T lymphocytes.  Human cell lines derived from myeloid, 
monocytic, and lymphoid lineages were shown to have the same rank order of CB2 
density as determined by mRNA levels.  The high level of mRNA in the B lymphocytes 
also correlates with receptor expression on the cell surface.  This was confirmed by Lynn 
and Herkenham using tritiated CP-55,940.82  The CB2 receptor has also been verified to 
be present on dendritic cells.83  Its presence on these potent antigen-presenting cells 
suggests a possible role for cannabinoids to modulate antigen presentation.  More 
recently, the presence of CB2 has been reported in the CNS.  Here, the CB2 receptor 
plays a possible role in inflammation due to the high expression levels found in the 
macrophage-like cell type microglia.84 
 With the recent identification of GPR55 as a putative cannabinoid receptor, its 
role in cannabinoid mediated immunomodulatory effects has not been as well established 
as with CB1 and CB2.  While GPR55 has not been shown to be present in peripheral 
blood leukocytes, it has been identified in the spleen.22c  One possibly significant role for 
GPR55 in immune modulation is in the CNS.  In a recent report by Pietr et al., the 
authors claim to have discovered the presence of mRNA for GPR55 in a primary culture 
of mouse microglia and also in the mouse microglial cell line BV-2.47d,85  The possible 
role of this receptor in inflammation in this cell type is supported by the observation of 
altered levels of mRNA for the GPR55 receptor upon exposure to various inflammatory 
stimuli.  Pietr and coworkers reported that stimulation of primary microglia or BV-2 with 
lipopolysaccharide (LPS) caused a concentration-dependent decrease in mRNA levels.  
Differing results were seen, however, utilizing stimulation with interferon gamma (IFN-
γ) which caused a slight decrease in GPR55 mRNA levels in primary culture but an 
increase in the BV-2 cell line.47d  This observation is similar to the reported variation in 
CB2 expression on microglia based on activation state.86 
 
 
1.4.2 Cannabinoid Effects on Immunity 
 
 The effects elicited by cannabinoids on the immune system are mediated by the 
downstream signaling cascades of the cannabinoid receptors.  This is achieved mainly by 
the down-regulation of cAMP formation by inhibition of adenylate cyclase (AC) 
activity.87  It has been shown that lymphocyte activation and cytokine transcription in 
macrophages is regulated by AC activity and the cAMP cascade.88  This is supported by 
the fact that cAMP analogs can stimulate or inhibit the immune response and can also 
antagonize the anti-inflammatory effects of cannabinoids.87 
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 The signaling cascade involved in the anti-inflammatory effects of cannabinoids 
is probably not simply due to regulation of AC.  This would explain why endogenous and 
exogenous cannabinoids can elicit different immunomodulatory effects.  
Endocannabinoids seem to have effects that are very localized, short lived, and are 
stimulatory in nature.89  The endocannabinoid 2-arachidonylglycerol (2-AG), for 
example, has been shown to have immunostimulatory actions such as serving as a 
chemoattractant to myeloid leukemia cells, splenocytes, and microglia90 and has also 
been shown to induce both chemotaxis and chemokinesis on microglia.91  There is some 
evidence, however, that certain metabolically stable analogs of endocannabinoids can be 
immunosuppressive.  An example of this is the anandamide analog 2-methylarachidonyl-
(2′-fluoroethyl) amide that has been shown to suppress immune response in a model of T 
lymphocyte function.92 
 Exogenous cannabinoids, on the other hand, have effects on the immune system 
that are more generalized in nature, persist for longer periods of time, and tend to be 
immunosuppressive.93  Both phytocannabinoids and synthetic cannabinoids have been 
shown to have immunosuppressive effects.  THC, CP-55,940, and the classical 
cannabinoid analog HU-210 have all been shown to inhibit cell contact-dependent lysis 
of tumor cells by macrophages, to inhibit the ability of macrophages to process antigens, 
and to suppress the proliferation of both B and T lymphocytes.94  THC has also been 
shown to attenuate the proliferation and maturation of cytotoxic T lymphocytes and to 
suppress the activity of NK cells.94a  Exogenous cannabinoids have also been reported to 
cause a switch in the T helper (Th) cell profile from the Th1 phenotype to the Th2 
phenotype by alteration of the cytokine / chemokine network.95  This switching of T 
helper function to the anti-inflammatory Th2 phenotype is of particular interest due to the 
possible therapeutic implications in autoimmune diseases.  For example, blocking the Th1 
cytokines and enhancing the Th2 pathways has shown promise in several animal models 
of inflammatory diseases such as experimental autoimmune encephalomyelitis,81,96 
experimental arthritis,97 and experimental autoimmune hepatitis.98  Exogenous 
cannabinoids have also been shown to inhibit immune cell migration and recruitment,99 
in contrast to the effects of endocannabinoids such as 2-AG. 
 The indirect effects that cannabinoids exert on immune function through 
alterations in the cytokine / chemokine network have been extensively studied.77  
Cytokines and chemokines are a large family of proteins that are produced by various 
cells of the immune system.  Their function is to alter the state or the activity of other 
cells in the immune system or to direct the movement of immune cells to sites where they 
are needed.  Cytokines and chemokines can be broadly classified as proinflammatory or 
anti-inflammatory depending upon whether their overall effect on the immune response is 
stimulatory or suppressive, respectively.  Much of the original work in this field was with 
the classical cannabinoid THC and many results were confounding.  For example, THC 
has been shown to increase the processing and release of the proinflammatory cytokine 
interleukin-1 (IL-1) in vitro100 and IL-1 along with proinflammatory tumor necrosis 
factor-alpha (TNF-α) and IL-6 in vivo.101  On the other hand, THC has also been shown 
to suppress the acute phase proinflammatory cytokines such as TNF-α, for example, in 
both human and mouse macrophage cultures.77   
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 With the nearly ubiquitous expression of the cannabinoid receptors (especially 
CB2) in the immune system it is clear why they are ever increasing targets for the 
treatment of inflammatory disorders.  Along with the previously mentioned cells, 
cannabinoids have also been shown to have immunomodulatory effects on other cell 
types such as mast cells,5,102 neutrophils,103 astrocytes,104 glia,95c,105 and neurons.95d,106  
Levels of many other cytokines have been reported to be effected by cannabinoids such 
as decreases in the proinflammatory proteins IFN-γ, IL-2, and IL-125 and increases in the 
anti-inflammatory factors IL-4 and IL-10.107  Much of the current work with 
cannabinoids in this field is focused on CB2 selective compounds which are void of the 
psychotropic effects mediated by the CB1 receptor which could limit their usefulness.  
Current studies on CB2 selective ligands as anti-inflammatory agents will be covered in 
Chapter 5. 
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Chapter 2: Anti-Glioma Activity of KM-233 and Analogs 
 
 
2.1 Introduction 
 
Due to the increasing attention given to the endocannabinoid system as a target 
for the development of antineoplastic agents, we began to evaluate the anti-cancer 
potential of our novel cannabinoid ligands.  The initial antineoplastic work performed in 
our laboratory was by Dr. Mathangi Krishnamurthy for her doctoral dissertation.  She 
prepared a novel series of C1'-dimethyl-aryl Δ8-tetrahydrocannabinol analogs and 
evaluated the compounds for CB1 and CB2 binding.108  The compound which exhibited 
the highest degree of CB2 selectivity was (6aR,10aR)-6,6,9-trimethyl-3-(2-phenylpropan-
2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol; designated KM-233 1 (Figure 
2.1).  This classical cannabinoid exhibited high affinity for the CB1 and CB2 receptors 
with binding affinity constants of 12.3nM and 0.91nM, respectively.  This corresponds to 
a CB1/CB2 ratio of 13.5.  KM-233 showed higher affinities for both the CB1 and CB2 
receptors compared to Δ8-THC (Ki (CB1) = 28.5nM, Ki (CB2) = 25.0nM) with 13-fold 
higher selectivity for the CB2 receptor. Introduction of a phenyl ring in the classical 
cannabinoid side chain also resulted in an increase in logP from 6.08 for Δ8-THC to 6.27 
for KM-233, which suggests improved blood-brain-barrier (BBB) penetrating ability.  
Hence, this combination of lipophilicity and high CB2 affinity indicates that this 
compound would possess significant permeation through the blood-brain-barrier as well 
as good activity at the CB2 receptor and would be a viable candidate to screen for anti-
glioma activity. 
The cytotoxic effects of KM-233 were evaluated against the human glioblastoma 
multiforme cell line U-87 MG.109  Cell death was analyzed after 24, 48 and 72 hours of 
exposure to the drug.  KM-233 effectively killed glioma cells over a 3-day incubation 
period with maximum cytotoxic effects occurring at 5µM (concentrations above 5µM not 
shown) (Figure 2.2) and with the EC50 at 3.1µM.  The cytotoxic effect produced by KM-
233 was compared with that produced by Δ8-THC (Figure 2.3) using a 5µM dose of each 
drug.  Although both drugs showed similar cytotoxic effects at the end of 3 days, KM-
233 was more effective than Δ8-THC over the first 48 hours (data not shown here).  In 
summary, KM-233 was shown to be as efficacious as Δ8-THC as a chemotherapeutic 
agent and may have a more rapid onset of action than Δ8-THC.  
Next, the cytotoxic effect of KM-233 was compared with that produced by 
BCNU, a standard glioblastoma chemotherapeutic agent. For these experiments, a 5µM 
dose of KM-233 was compared with escalating doses of BCNU.  A 5µM dose of KM-
233 was far more cytotoxic than the highest dose of BCNU tested which was 300µM 
(well above the typical 5µM blood level following i.v. administration in humans) (Figure 
2.4).  This led to the conclusion that KM-233 is superior to BCNU as a chemotherapeutic 
agent for the treatment of glioblastoma in terms of its in vitro cytotoxic activity. 
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Figure 2.1:  The structure of KM-233 1 
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Figure 2.2:  Dose response curve for KM-233 on U-87 MG  
C represents untreated control, D represents untreated control with 0.5% DMSO, E 
represents drug treatment at concentration 0.1μM, F represents drug treatment at 1μM 
concentration, G represents drug treatment at 2μM concentration, H represents drug 
treatment at 3μM concentration and I represents drug treatment at 5μM concentration. 
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Figure 2.3:  Comparison of efficacies of KM-233 and Δ8-THC   
B represents untreated control, C represents untreated control with 0.5% DMSO, D 
represents effect after 1 day treatment with KM-233, E represents effect after 2 days 
treatment with KM-233, F represents effect after 3 days treatment with KM-233 and G 
represents effect after 3 days treatment with Δ8-THC.  
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Figure 2.4:  Comparison of efficacies of KM-233 and BCNU   
B represents untreated control, C represents untreated control with 0.5% DMSO, D 
represents treatment with 5μM KM-233, E represents treatment with 100μM BCNU, F 
represents treatment with 200μM BCNU and G represents treatment with 300μM BCNU. 
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2.2 Murine Flank Model 
 
The in vitro efficacy of KM-233 was then translated into an animal model of 
glioblastoma to further evaluate its potential as a chemotherapeutic agent.  The first in 
vivo model performed was a mouse flank model.  The flank model was performed by the 
Duntsch group in the Department of Neurosurgery at the University of Tennessee Health 
Science Center.109  The mouse xenograft subcutaneous model was created by suspending 
2 x 106 glioblastoma multiforme cells in PBS and injecting them subcutaneously into the 
flank of adult SCID mice.  The cell line used was U-87 MG which had been previously 
transduced to express green fluorescent protein to aid in imaging of the tumor.  After 
seeding, the tumors were allowed to develop for 5 days and the mice were then treated 
with KM-233 at a dose of 2mg/kg either intratumorally or intraperitoneally every 12 
hours for 15 days.  Control groups were treated with vehicle at the same frequencies and 
routes of administration.  The animals were sacrificed after 15 days of treatment and the 
tumors removed with the aid of epifluorescence microscopy. 
Once the tumors were removed, they were weighed and the weights compared 
between the vehicle treated and the KM-233 treated groups.  The groups treated with 
KM-233, both intratumorally and intraperitoneally, showed a reduction in tumor size 
when compared to the vehicle treated control groups (Figure 2.5).  The group treated by 
the intraperitoneal route exhibited a greater reduction in tumor size from control when 
compared to the intratumorally treated group.  Clinical monitoring and daily weights 
were similar between groups indicating no gross deleterious effects of KM-233 when 
administered locally or systemically.  These results, while very promising, did not answer 
the question of whether or not KM-233 could cross the BBB and be a viable candidate for 
GBM therapy. 
To further assess the ability of KM-233 to cross the BBB, intracranial model 
studies were carried out, also by the Duntsch group.  The development of a 
chemotherapeutic agent against GBM that crosses the BBB provides distinct advantages 
to existing agents; 1) most existing agents used against GBM do not cross the BBB, and 
to achieve therapeutic levels they are generally administered directly into the tumor; and 
2) direct administration may not target distant GBM foci whereas a systematically active 
agent should “bathe” the brain in drug thus targeting distant foci.  Therefore, the ability 
of KM-233 to cross the blood brain barrier and affect a reduction in tumor load was 
studied in the orthotopic U87 model of GBM.   
Tumors were induced in SCID mice by direct intracranial inoculation of human 
GFP-expressing U87 glioma cells.  Five days following tumor cell inoculation, animals 
were assigned randomly to treatment groups and injected intraperitoneally twice a day for 
20 subsequent days with vehicle, 2, 4, 8, or 12 mg/kg of KM-233 formulated in 100 µl of 
saline containing 3% of Cremophor and 3% of ethanol.  The animals were then sacrificed 
on the 25th day (20th day of treatment) and the brains prepared for confocal laser scanning 
microscopy to measure tumor surface area using imaging software.  As shown in Figures 
2.6 and 2.7, treatment of KM-233 significantly reduced the average tumor load of each 
treatment group in a dose-dependent manner as compared to untreated and vehicle treated 
controls.  Clinical monitoring and daily weights were similar between all controls and  
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Figure 2.5:  In vivo efficacy of KM-233 against human U87 glioma in the murine side-
pocket model 
Human glioma cells were inoculated into the flanks of nude mice (n = 4 per group). After 
5 days of tumor cell incubation, groups were treated either by i.p. injection (a) or direct 
injection into the tumor (b) every 12 h for 15 subsequent days with vehicle or 2 mg/kg of 
KM-233.  Panel c depicts an epifluorescence photomicrograph of the average size of 
tumors dissected from control animals vs. animals treated with i.p. injection KM-233 and 
panel d represents vehicle control vs. treated with intertumoral injection of KM-233. 
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Figure 2.6:  Tumor load in the U87 glioma model 
Adult SCID mice bearing intracranial human U87 glioma were treated with KM-233 for 
20 days.  A one-way ANOVA of the untreated control vs. all treatments (symbols without 
parenthesis) and vehicle control vs. drug treatment (symbols with parenthesis) was 
conducted. * = p < 0.05 and # = p < 0.001. 
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Figure 2.7:  Dose-dependent reduction of U87 glioma after KM-233 treatment 
Adult SCID mice bearing orthotopic human U87 glioma were treated with KM-233 for 
20 days. Representative fluorescence micrographs showing tumor sizes in mouse brains 
where: (A) untreated control (B) vehicle control; (C) 2 mg/kg KM-233; (D) 4 mg/kg KM-
233; (E) 8 mg/kg KM-233; and (F) 12 mg/kg KM-233.  Brains were serial sectioned 
(asterisks indicate areas where tumor separated from normal brain tissue) and the region 
of the needle track identified.  Pictures represent the largest fluorescent section within an 
animal brain where measurements were taken.  
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treated groups.  These studies in conjunction with the flank model described above 
suggest that KM-233 is safe and effective in reducing tumor load, even in the context of 
the BBB, and even when given systemically.  Pathology on the organs of the study 
animals showed that there was no evidence of toxicity-related tissue damage due to KM-
233 administration.  The results of this study demonstrated that KM-233 is a viable 
candidate for further development as an anti-glioma agent. 
 
 
2.3 Efficacy of KM-233 and Analogs against Multiple Glioma Lines 
 
To further evaluate the potential of KM-233 as a chemotherapeutic for the 
treatment of GBM, the drug was screened against four other human glioblastoma cell 
lines: LN-229, T98G, DBTRG-05MG, and MT-310 (a primary GBM cell line provided 
by the Department of Neurosurgery at the University of Tennessee Health Science 
Center).  We hypothesized that KM-233 initiated GBM cell death by ligation to one or 
more of the CB receptors CB1, CB2, and/or GPR55.  The first step in this study was to 
determine the relative expression levels of these receptors in these cell lines along with 
U-87 MG.  Western blot analysis of the particulate fraction, membrane bound proteins, 
and cytosolic fraction of cell lysates is shown in Figure 2.8.  Consistent with earlier 
reports,110 both CB1 and CB2 receptors are present in all the human GBM cell lines with 
CB1 showing a lower immunohistochemical staining relative to CB2.  Interestingly, the 
GPR55 receptor exhibited a relative increased blotting in both the particulate and 
cytosolic fractions.  The presence of GPR55 in the cytosolic fraction may indicate active 
synthesis of the protein or compartmental localization in the cytosol.  The qualitative 
analysis of the Western data was not interpreted in terms of absolute expression levels but 
was used to verify the presence or absence of each receptor type. 
The similarities in receptor expression patterns found in each GBM cell line may 
account for the comparable efficacies of KM-233 in cytotoxicity assays against the 
human GBM cell lines U-87 MG, T98G, LN-229, DBTRG-O5MG, and MT310 (Table 
2.1).  The EC50 values were determined using escalating doses of KM-233 and cell 
viability assayed 18 hours post treatment using the CCK-8 assay which utilizes the 
tetrazolium salt, WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt), which produces a water-soluble 
formazan dye upon bioreduction in the presence of an electron carrier, 1-Methoxy PMS. 
WST-8 is bioreduced by cellular dehydrogenases to an orange formazan product that is 
soluble in tissue culture medium. The amount of formazan produced is directly 
proportional to the number of living cells.  The EC50 for KM-233 was comparable 
between the cell lines with a mean EC50 of 3.44 μM.  In comparison, the clinically 
relevant anti-GBM agents BCNU and temozolomide were either ineffective or 
manifested high micromolar EC50s (Table 2.1).  Specifically, U87 and LN-229 were 
sensitive to BCNU after 18 hours of exposure with EC50s of 223 and 178 μM, 
respectively.  All cell lines responded to BCNU following 48 hours of exposure 
manifesting EC50s ranging from 119 to 305 μM.  In contrast, the EC50s of KM-233 
ranged from 2.3 to 4.9 μM and were effective in the 18 hour assay window.  
Temozolomide was inactive against the cell lines following 18 and 48 hours exposure  
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Figure 2.8:  Western blots for cannabinoid receptors in human glioma cell lines 
Western blots of the particulate (P) and cytosolic (C) fractions of whole cell lysates of U-
87 MG, T98G, LN-229, and DBTRG-O5MG.  All blots are indexed to the structural 
protein α-tubulin, cell lysates were divided into 3 aliquots and run on separate gels for 
each receptor.  
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Table 2.1:  EC50 values for KM-233 and BCNU against human GBM cell lines 
 
 KM-233 18 hrs BCNU 18 hrs BCNU 48 hrs 
 
Cell line 
EC50 (μM) ± 
S.D. 
EC50 (μM) ± 
S.D. 
EC50 (μM) ± 
S.D. 
U-87 MG 3.08 ± 0.30 233 ± 5.1 156.0 ± 2.4 
T98G 4.68 ± 0.45 > 1000 305 ± 1.2 
LN-229 2.26 ± 0.32 178 ± 2.3 119 ± 4.2 
DBTRG-
O5MG 2.27 ± 0.19 > 1000 124 ± 3.0 
MT310 4.92 ± 1.08 n.d. n.d. 
Note: The EC50 values were obtained from three independent experiments run in 
triplicate.  Abreviations: n.d. = not determined. 
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(data not shown).  Temozolomide is pH activated in vivo and the concentration of the 
active compound was not assessed and therefore these results are viewed with caution. 
To further evaluate the KM-233 scaffold as an anti-GBM agent we screened a 
series of substituted aryl analogs (Figure 2.9) that displayed a broad range of binding 
affinities for the CB1 and CB2 receptors.111  The CB1 binding affinities ranged from 1.08 
nM to 142.2 nM while the CB2 affinities ranged from 0.27 nM to 134.5 nM.  The 
CB1/CB2 affinity ratios ranged from 0.23 to 13.5 yielding compounds with modest 
selectivity for the CB1 or CB2 receptor.  To assess if receptor subtype selectively 
affected cytotoxicity in the GBM cell lines, the EC50s for the 4-ethylphenyl 2, 4-
propylphenyl 3, 4-fluorophenyl 4, 4-chlorophenyl 5, 2-thiophenyl 6, and KM-233 were 
determined (Figure 2.10).  This study indicates that receptor subtype selectivity does not 
affect cytotoxicity; however, due to the modest selectivity range it is not possible to 
identify a specific target, i.e. CB1, CB2, or GPR55 receptor, for KM-233 or the analogs. 
 
 
2.4 Receptors Involved in the Anti-Glioma Activity of KM-233 
 
To study the contribution(s) of the CB1, CB2, and/or GPR55 receptors to the 
cytotoxic effect of KM-233 we utilized pharmacological probes.  The CB1 and CB2 
receptors couple through Gαi whereas GPR55 couples via Gα12/13.  To assess the possible 
contribution of CB1 and/or CB2 to the mechanism of action of KM-233, cytotoxicity 
assays were carried out using U87 cells pre-treated 18 hours before the assay with 100, 
200, and 300 ng/ml of pertussis toxin (Ptx).  The Ptx inactivates Gαi via catalytic ADP-
ribosylation thus blocking G-protein-receptor interactions, whereas the Gα12/13 proteins 
are Ptx-resistant.  Increasing concentrations of Ptx caused a 0.75 fold average decrease in 
the EC50 of KM-233 against human U87 cells (Figure 2.11).  We have determined that 
KM-233 is an agonist of the CB1 and an antagonist of the CB2 receptor (Figure 2.12), 
both of which signal through Gαi.  If KM-233 acted only through CB1 or CB2 it would, 
therefore, be predicted that Ptx would block the affects of KM-233 thus the results 
indicate that CB1 and CB2 do not initiate KM-233 anti-cancer activity.  
The compound SR141716A is reported to be an antagonist of GPR55 that has 
antagonist/inverse agonist activity (depending on the type of assay) at the CB1 
receptor.11,112  The dose response curve of KM-233 in the presence of 10 μM SR141716A 
(Figure 2.11) shifted the curve to the right increasing the EC50 7 fold.  The shift in the 
dose response curve suggests that GPR55 is a target of KM-233; however, additional 
pharmacological probes need to be employeed such as cholera toxin (Ctx, constitutively 
activates Gs), inhibition of the Gα12/13-RhoA-ROCK pathway (possible GPR55 mediated 
pathway) with Y-27632, or decoupling Gαi with Ptx and screening GPR55 selective 
ligands such as O-1602 or lysophosphatidylinsoitol (LPI).  These studies are ongoing but 
may not conclusively identify the mechanism(s) of KM-233 action.  We have also begun 
to utilize shRNA to knock-down each of these receptors to compliment the 
pharmacological studies.  Additionally, we are in the process of developing functional 
assays for the GPR55 receptor to aid in studying the pharmacology of KM-233 and 
related analogs. 
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Figure 2.9:  C1'-dimethyl-aryl Δ8-tetrahydrocannabinol analogs screened against human 
glioblastoma cell lines 
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Figure 2.10:  EC50 values of KM-233 and analogs  
Comparison of the EC50 values of KM-233 and analogs as a function of the CB1/CB2 Ki 
ratio in five human glioma cell lines. 
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Figure 2.11:  Effects of KM-233 on U-87 MG in the presence or absence of Ptx and 
SR141716A 
Dose response curves for U-87 MG cells treated with KM-233 in the presence or absence 
of 100, 200, or 300 ng/ml Ptx or 10 μM SR141716A.  Data is derived from 3 independent 
experiments conducted in triplicate. 
 
  
30 
 
 
 
Figure 2.12:  Functional activity of KM-233 at the CB1 and CB2 receptors 
KM-233 does not reverse cAMP production in the CB2 assay and abolishes the activity 
of CP-55,940 identifying KM-233 as an antagonist at CB2.  
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2.5 Mechanistic Studies to Determine the Anti-Glioma Activity of KM-233 
 
The second component of the mechanism(s) of human GBM cytotoxicity of KM-
233 is the downstream pathway(s) resulting in cell death.  This is where I took over the 
study of the anti-glioma activity of KM-233.  In order to elucidate the mechanism(s) by 
which KM-233 elicits anti-glioblastoma activity, we employed a number of techniques 
including epifluorescence microscopy and protein quantification using Meso Scale 
Discovery (MSD) MULTI-ARRAY® microplate technology.  The MSD technology 
platform consists of 96- and 384-well microplates in which there are 1, 4, 7, or 10 
electrodes coated with capture antibodies.  Cell lysates are added to the wells of the plate 
and analytes are captured on the appropriate electrodes.  The plates are then incubated 
with a secondary antibody that is conjugated to ruthenium (II) tris-bipyridine-(4-
methylsulfonate) NHS ester that luminesces when an electrical current is applied to each 
electrode within the well.  The plates are imaged optically and the relative luminescent 
intensity of each sample is compared.  We first conducted a preliminary screen of the 
effect(s) of KM-233 on pathways known to be over active in many cancers.  Initially we 
examined total and phosphorylated ERK1/2, JNK, p38, and, Akt using MSD plates.  The 
screen utilized U-87 MG cells treated with KM-233 at the EC50 (8.7 μM) to evaluate 
signal cascade modulation over a 24 hour time course.  It should be noted that the change 
in the EC50 from the previous experiments is due to modifications made in our 
cytotoxicity protocol which will be discussed in chapter 3.  The preliminary screen 
showed that ERK1/2 and Akt, but not JNK or p38, are downstream signals in U-87 MG 
cells following KM-233 exposure (data not shown).  Based on these results we analyzed 
the kinetic profile of phosphorylation of MEK-ERK-STAT pathway using the MSD 
triplex plate for pMEK1/2, pERK1/2, and pSTAT3.  A significant increase in pSTAT3 
occurred 1 hour post drug treatment (Figure 2.13) which continued thru 18 hours 
followed by a rapid decline at 24 hours post drug treatment.  The level of pERK1/2 
(Figure 2.13) significantly decreased in 1 hour and increased from 12 to 18 hours then 
declined 24 hours post treatment.  The decline in pSTAT3 is of particular interest due to 
its role in tumorigenesis, i.e. proliferation, angiogenesis, and inhibition of apoptosis,113 
and its proposed role in immune tolerance in GBM patients,114 thus it provides a novel 
target in cancer therapy.113,115  This suggest that CBs may be a novel target for the 
regulation of STAT3 function via CB1 or CB2 regulation of Gαo- c-Src116 or via a GPR55 
regulated Gα12/13-RhoA-ERK-STAT3 pathway.117  The level of pMEK (Ser 217, 221) 
showed a significant decline at 6 hours (Figure 2.14), rebounded at 18 hours (though still 
lower than control), and then significantly decreased at 24 hours.  The increases in 
pMEK, pERK (Thr 202, Tyr 204, Thr 185, Tyr 187), and pSTAT3 (Tyr705) in the 6 to 18 
hours time interval may represent a pro-survival response to changes in pAkt and pBAD 
levels.  The temporal increases in pMEK and pERK from 1 to 18 hours are generally 
consistent with the reported effects of HU-210 against U373MG and Neuro2a cell lines118 
while the overall decrease is consistent with studies in C6 glioma cell lines.119  The 
activation is reported to originate from CB1 activation based on the inhibition of 
cytotoxicity by SR141716A; however, decoupling of the signal cascade by Ptx was not 
studied with HU-210 thus leaving open the question of GPR55 participation.  Regardless 
of the molecular mechanism, the Ras-Raf-MEK-ERK pathway is a potential target for the 
development of anti-cancer agents.120 
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Figure 2.13: pERK and pSTAT3 profiles of U-87 MG cells treated with KM-233  
U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals.  
Cells were scraped from the culture dishes, collected by centrifugation, lysed, and the 
protein concentration per lysate was determined.  Total protein added to each well of the 
MSD plate was 20μg.  Aliquots from this experiment were used in all the following 
assays.  All data points represent 3 independent determinations analyzed in duplicate.  * = 
p < 0.02, ** = p < 0.01, and *** = p < 0.001. 
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Figure 2.14: pMEK profile of U-87 MG cells treated with KM-233 
U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals 
and treated as defined in Figure 2.13.  All data points represent 3 independent 
determinations analyzed in duplicate.  * = p < 0.02, ** = p < 0.01, and *** = p < 0.001. 
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Interplay between the ERK1/2 and Akt pathways in C6 glioma cells was 
previously reported by Ellert-Miklaszewska et al.119  To assess the contribution of Akt to 
the signal cascade associated with KM-233 we utilized the pAkt-pGSK-3β-pP70S6K 
MSD assay plate.  Treatment of U87 cells with KM-233 triggers a significant and rapid 
decrease in pAkt beginning at 6 hours and continuing through 24 hours (Figure 2.15).   
Within this time interval a significant increase in glycogen synthase kinase 3 β (pGSK-
3β, Ser9) and a decrease in 70-kDa ribosomal protein S6 kinase (pP70S6K, Ser 217/221) 
were manifested (Figure 2.16).  The reduction in pAkt and pP70S6K are consistent with 
the recent report by Salazar et al. wherein U-87 MG cells were treated with THC.121  The 
inhibition of Akt in cancer therapy is well established; however, it has recently been 
shown that knock-down of p70S6K with siRNA inhibited U-251MG glioma cells by 
greater than 50 percent.  The observed increase in pGSK-3β is consistent with the 
reported increase in apoptosis observed with GSK-3β activation122 although Kotliarova et 
al. reports that inhibition of GSK-3β induces cell death.123  In GBM cell lines it is 
generally reported that regulation of Akt pathways, as well as ERK signaling, is mediated 
through a Gαi/o and/or Gβ/γ pathways; however, it is possible that a Gα12/13-RhoA pathway, 
and by extension GPR55, may regulate the downstream activation/inactivation of the Akt 
and/or the ERK pathways.  For example, Gα12/13 activation of the PI3K-Akt axis has been 
proposed in neuroblastoma cells124 and a pathway involving Rho-ROCK signaling and 
ERK activation has been proposed in the human GBM line LN-19.125 
The down-regulation of the pro-survival kinase cascades ERK1/2 and Akt raised 
the possibility that one downstream mediator may be the Bcl-2 family protein BAD.  
Specifically, phosphorylation of BAD by Akt and ERK has been previously reported;126 
therefore, KM-233 may suppress phosphorylation of BAD resulting in heterodimerization 
with Bcl-2 death suppressors.   To evaluate the effect of KM-233 on BAD 
phosphorylation status we utilized the MSD pBAD (Ser 112) plate.  Treatment of U-87 
MG cells with KM-233 caused a significant decrease in total pBAD (Figure 2.17), 
therefore it was expected that the decrease in pBAD would correlate with mitochondrial 
dysfunction.  One manifestation would be cytochrome C release and activation of caspase 
3.  To evaluate this component we employed the MSD apoptosis plate to screen cleaved 
caspase 3, cleaved PARP, and total- and phospho-p53.  A significant increase in cleaved 
caspase 3 began at 12 hours with a rapid elevation at 18 hours post drug treatment 
(Figure 2.18).  There were no changes in the levels of cleaved PARP or total/phospho-
p53 (data not shown).   
The possible contribution of mitochondrial dysfunction to the mechanism of 
action of KM-233 was further evaluated using DePsipher® (Trevigen; Gaithersburg, 
MD) to evaluate the collapse of the mitochondrial membrane potential (Figure 2.19).  
Treatment of U87 cells with 3μM KM-233 resulted in a significant increase in 
mitochondrial membrane depolarization, as indicated by the inability of the fluorescent 
stain, DePsipher to form red fluorescent eximers inside mitochondria with an almost 
complete depolarization a 6 hours.  Mitochondrial involvement was further verified by 
the observation of cytochrome C release in U-87 MG after 18 hours of exposure to KM-
233 at the EC50 (Figure 2.20). 
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Figure 2.15: pAKT profile of U-87 MG cells treated with KM-233  
U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals 
and treated as defined in Figure 2.13.   All data points represent 3 independent 
determinations analyzed in duplicate. *** = p < 0.001. 
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Figure 2.16: pGSK-3β and pP70S6K profiles of U-87 MG cells treated with KM-233  
U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals 
and treated as defined in Figure 2.13.  All data points represent 3 independent 
determinations analyzed in duplicate. * = p < 0.01, ** = p < 0.005, *** = p < 0.001, **** 
= p < 0.0005, and ***** = p < 0.00001. 
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Figure 2.17: pBAD profile of U-87 MG cells treated with KM-233  
U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals 
and treated as defined in Figure 2.13.  All data points represent 3 independent 
determinations analyzed in duplicate. * = p < 0.05, ** = p < 0.01, and *** = p < 0.001.
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Figure 2.18: Cleaved caspase 3 profile of U-87 MG cells treated with KM-233  
U-87 MG cells were treated with KM-233 at the EC50 for the designated time intervals 
and treated as defined in Figure 2.13.  All data points represent 3 independent 
determinations analyzed in duplicate.  * = p < 0.05, ** = p < 0.005, and *** = p < 0.001.
39 
 
 
 
Figure 2.19: Effects on membrane polarization in U-87 MG cells treated with KM-233 
Change in mitochondrial membrane polarization (Δψm) with DePsipher® -  U-87 MG 
cells were treated with KM-233 at the EC50 for 6 hours then stained with dual fluorescent 
stain; Green fluorescence shifts to red emission following the formation of eximers 
within mitochondria as stain crosses polarized outer mitochondrial membrane.  
Mitochondrial depolarization by KM-233 inhibits DePsipher® permeability and 
subsequent red fluorescence.  Images of U-87 MG cells were collected using 568 nm 
(Red) and 458 (Green) lines of a CLSM.  Control (vehicle treated) cells are shown in the 
A panels and 6 hours post drug treatment is shown in the B panels. 
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Figure 2.20: Effects on cytochrome C release in U-87 MG cells treated with KM-233 
U-87 MG cells were treated with KM-233 at the EC50 for 18 hours and evaluated for 
changes in localization of cytochrome C (red); nuclei are shown in blue.  Control (vehicle 
treated) cells are shown in panel A and 18 hour drug treated cells are shown in panel B.  
Control cells exhibit localization of cytochrome C in the mitochondria (arrows) along the 
cytoskeletal network.  KM-233 treated cells show a diffuse pattern of labeling (arrows) 
indicating that cytochrome C has been released from the mitochondria into the cytosol. 
A
B 
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We also conducted a microscopic study to assess the effects of KM-233 on 
cytoskeleton structure based on the known activity of RhoA and the possibility of a 
GPR55 initiated mechanism.  At 18 hours post KM-233 treatment the cytoskeleton 
manifests profound contraction of F-actin and α-tubulin (Figure 2.21).  Though it is not 
possible to conclude a specific mechanism, the results provide a basis for further 
evaluating RhoA-ROCK contributions to cell death. 
While many of the downstream signaling pathways have been identified, the 
receptor or receptors responsible for initiating the cascades are yet to be elucidated.  We 
have utilized pharmacological knockouts in an effort to identify the target of KM-233 
action.  Pharmacological intervention has distinct limitations due to overlap in activity of 
known agonists and antagonists of the CB1, CB2, and GPR55 receptors.  Our preliminary 
data suggest that GPR55 is the target of KM-233 however this cannot be confirmed 
without the selective knock-down of each CB receptor subtype.  Knowledge of the target 
is critical for the development of a complete mechanism of action for the anti-
glioblastoma activity of KM-233.  The contributions of each cannabinoid receptor are 
currently under investigation using shRNA stably transfected cell lines. 
 
 
2.6 Experimental Methods 
 
 
2.6.1 Cytotoxicity Assays 
 
Human glioblastoma cells U-87MG, T98G, LN-229, DBTRG-O5MG (American 
Type Culture Collection), and MT310 (primary GBM cell line, grade IV, a gift from Dr. 
Valery Kukekov, University of Tennessee Health Science Center, Department of 
Neurosurgery) were cultured in supplemented media according to the recommendations 
of the supplier at 37°C in an atmosphere of 5% CO2 and 95% air. Cell lines were plated 
in 96-well polystyrene flat-bottom plates (7,500 cells/well) at 70% confluency in a 100 µl 
total volume of supplemented media as indicated, and incubated overnight at 37°C to 
allow for adherence.  The media was then replaced with media containing 1% FBS and 
the cultures were inoculated with escalating amounts of drug; cell death was analyzed at 
18h using the BioTek Synergy 2 Multidetection Microplate Reader (BioTek Instruments, 
Inc.).  The percentage of viable cells present in the culture at each time point was 
calculated by comparing the absorbance value at 450nm from the CCK-8 assay (Dojindo 
Molecular Technologies) for each condition with untreated control cells.  All assays were 
conducted per manufacturer’s protocol.  All described values represent the average of 
three data points per determination and three independent determinations. 
 
 
2.6.2 Cytotoxicity Assays with Pertussis Toxin 
 
U-87 MG cells were seeded in 96-well polystyrene flat-bottom plates (7,500 
cells/well) at 70% confluency in a 100 µl total volume of complete growth media and 
incubated overnight at 37°C in an atmosphere of 5% CO2 and 95% air to allow for  
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Figure 2.21: Effects on cytoskeleton structure in U-87 MG cells treated with KM-233 
U-87 MG cells were treated with KM-233 at the EC50 and evaluated for changes in F-
actin (green) and α-tubulin (red), nuclei are shown in blue.  Control (vehicle treated) cells 
are shown in panel A and 18 hour drug treated cells are shown in panel B.  KM-233 
causes significant contraction of the cytoskeleton network as evidenced by the compact 
F-actin around the nucleus. 
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adherence.  The media was then replaced with complete growth media containing 0, 100, 
200, or 300 ng/ml pertussis toxin and the plates returned to the incubator for 18 hours.  
Drug solutions were prepared in DMSO at 100X concentration, and mixed 1:100 in 
media containing 1% FBS to yield the desired concentration.  After 18 hour incubation 
with or without Ptx, full serum media was removed and replaced with drug-media 
mixtures and incubated for an additional 18 hours.  10μl of CCK-8 reagent was added to 
each well to colorimetrically assess viability.  After 2-4 hours of incubation with the 
CCK-8 dye, absorbance was read at 450nm using a BioTek Synergy 2 plate reader. 
 
 
2.6.3 CB1/CB2 Functional Assays 
 
HEK-293 cell lines stably transfected with a cyclic nucleotide-gated channel and 
either human CB1 or CB2 receptors (BD Biosciences,  San Jose, CA USA) were seeded 
in poly-D-lysine coated 96-well plates at a density of 70,000 cells per well.   Plates were 
incubated at 37°C in 5% CO2 overnight prior to assay.  Plates were then removed from 
the incubator and the complete growth medium (DMEM, 10% FBS, 250µg/ml G418 and 
1µg/ml puromycin) was replaced with 100µl DMEM containing 0.25% BSA.  Next, 
100µl membrane potential dye loading buffer (Molecular Devices) was added to each 
well.  The plates were placed back into the incubator for 30 minutes and then the baseline 
fluorescence was read on a BioTek Synergy 2 multi-mode microplate reader with 540nm 
excitation and 590nm emission filters prior to drug addition.   Drugs were added in 50µl 
DPBS containing 2.5% DMSO, 1.25µM 5’-(N-ethylcarboxamido) adenosine and 125µM 
Ro 20-1724.  Plates were then incubated at room temperature for 25 minutes and 
fluorescence measured again at 540nm excitation and 590nm emission. 
 
 
2.6.4 MSD Protein Quantification 
 
U-87 MG cells were plated in poly-D-lysine coated 10cm Petri dishes at a density 
of 4 x 105 cells/ml with 12ml of cell suspension added to each plate.  The cells were 
grown overnight in EMEM media containing 10% FBS.  The following day the media 
was changed to EMEM media containing 1% FBS and allowed to equilibrate for 24 
hours.  This step is essential to allow basal levels of signaling protein to re-equilibrate 
due to changes in the serum concentration.  The media was then replaced at the 
appropriate time points with media containing 1% serum and KM-233 at the EC50 or 
media containing 1% serum and vehicle (DMSO).  After the incubation period with KM-
233 or vehicle, the media was removed from the dishes and transferred to a 15ml 
centrifuge tube to collect any cells that were in suspension.  Cells were then scraped from 
the surface of the dish and transferred into the same 15ml centrifuge tubes and pelleted at 
1000rpm, 4oC for 5min. Supernatant was removed and 0.5ml lysis buffer was added to 
each pellet.  The cells were suspended in the buffer and transferred to 1.5ml 
microcentrifuge tubes.  These were incubated on ice for 30 minutes, being vortexed every 
5 minutes.  The lysates were then centrifuged at 10,000 x g, 4oC for 10 minutes to clear 
cellular debris from the lysate.  The supernatant was removed and assayed for protein 
concentration using a Pierce BCA Protein Assay Kit (Thermo Scientific).  The lysates 
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were then diluted with complete lysis buffer to a concentration of 20μg of protein in 25μl 
volume.  Signaling proteins were then analyzed using MSD phosphoprotein and 
intracellular marker multiplex kits which were imaged on a SECTOR Imager 2400 (Meso 
Scale Discovery) according to the manufacturer’s instructions. 
 
 
2.6.5 Mitochondrial Membrane Potential Assay 
 
U-87 MG cells were grown in 75cm2 flasks in complete growth medium until 
80% confluent.  At the appropriate time points, the media was removed and replaced with 
media containing 1% FBS and either KM-233 at the EC50 or vehicle (DMSO).  After 
incubation with drug or vehicle, cells were harvested by trypsonization and pelleted by 
centrifugation.  The cells were then dyed in suspension using DePsipher membrane 
potential dye according to the manufacturer’s instructions.  The cells were then placed on 
glass slides and covered with glass cover slips.  The cells were then imaged using an 
Olympus BX50 microscope (Olympus America) fitted with a Bio-Rad MRC1024 
confocal laser scanning system (Bio-Rad Laboratories). 
 
 
2.6.6 Microscopic Analysis of Cytoskeleton and Cytochrome C Release 
 
U-87 MG cells were plated in complete growth medium at a density of 15,000 
cells/well in poly-D-lysine coated 96-well polystyrene tissue culture plates and allowed 
to attach over night at 37°C in an atmosphere of 5% CO2 / 95% air.  The media was then 
replaced with media containing 1% FBS and either KM-233 at the EC50 or vehicle 
(DMSO).  The cells were returned to the incubator and after 18 hours exposure to the 
drug or vehicle, media was aspirated and the cells fixed using 4% paraformaldehyde.  
Cells were then stained by immunohistochemical methods using either a Cellomics 
Multiparameter Cell Death Detection Kit or a Cellomics Cytoskeletal Rearrangement Kit 
(Thermo Scientific) according to the manufacturer’s instructions.  Plates were then 
imaged using an Olympus IX71 inverted fluorescence microscope (Olympus America) 
fitted with a Retiga-SRV camera (QImaging). 
 
 
2.6.7 Synthesis of Compounds 1 – 6 
 
 All chemicals and reagents were purchased from Sigma–Aldrich or Thermo 
Fisher Scientific Inc.  Anhydrous solvents were prepared by distillation over sodium 
metal or calcium hydride prior to use.  Reactions were carried out under dry conditions 
under an argon atmosphere. A Biotage SP1 system was used for flash chromatography 
purification.  Routine NMR spectra were obtained on a Varian Inova 500 MHz NMR and 
were consistent with the assigned structures.  Routine mass spectra were determined on a 
Bruker ESQUIRE Ion Trap LC/MS system.  Compounds 1 through 6 were prepared 
according to the methods reported by Krishnamurthy et al.108,111 and all spectral analyses 
of said compounds were in agreement with published data. 
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Chapter 3: Anti-Glioma Activity of HB-I-172 and Analogs 
 
 
3.1 Introduction 
 
We have previously reported the synthesis of a small series of CB2 selective 
triaryl cannabinoids.127  These compounds were designed with the goal of producing 
cannabinoid ligands that would still elicit the desired physiological effects seen with 
other cannabinoids (antineoplastic activity, anti-inflammatory activity, etc.) but which 
would be void of the unwanted CNS side effects mediated by the CB1 receptor.  These 
triaryl compounds were developed by merging structural aspects of two previously 
reported classes of cannabinoids.  The design utilizes the C1’ aryl substitution of the 
classical cannabinoid core previously reported by our laboratory with compounds such as 
KM-233 and the introduction of an aryl ring in place of the terpene C ring in a series of 
biaryl compounds reported by Makriyannis and co-workers as represented by the gem-
dimethyheptyl side chain analog compound 7128 (Figure 3.1).  The design was developed 
with the hypothesis that the A ring of compounds 1 and 7 occupy the same region in the 
CB1 and CB2 ligand binding pockets.   
In an effort to improve CB2 receptor affinity, the C ring of our triaryl cannabinoid 
core possesses a 3,5-dichloro substitution.  This modification was based on the 
observation of Makriyannis that the 3,5-dichlo substitution pattern improves CB2 
receptor affinity in the biaryl cannabinoids.128  In addition to the abovementioned 
structural modifications, three types of side chain linkers: hydroxyl, carbonyl, and gem 
dimethyl were utilized in the design and four compounds were synthesized and assayed 
for CB1 and CB2 receptor binding affinity (Figure 3.2). 
The compounds designed were hypothesized to be selective at the CB2 receptor 
sub-type.  This was based not only on the contribution of the 3,5-dichlorophenyl C ring 
but also on the fact that the compounds comprising the phenyl series, represented by KM-
233, were predominantly CB2 selective.  We believed that the combined increase in 
electronic interactions of the substituents at both the C3 position of the phenolic A ring 
and the aryl C ring in the novel core would enhance the affinity and selectivity of these 
compounds to the cannabinoid receptor sub-type 2. 
The four compounds initially synthesized with the novel triaryl core show 
significant binding affinity to the CB2 cannabinoid receptor subtype (Table 3.1). The 
receptor subtype affinity Ki values ranged from 1.07 to 4.77 nM at the CB2 receptor with 
9–600 fold selectivity towards the CB2 receptor subtype.  Although omission of the B 
ring from the C10 phenyl substituted classical core does not seem to affect the binding 
affinity to the CB2 cannabinoid receptor, there is a pronounced effect on the affinity for 
the CB1 receptor as evidenced by the new analogs 8-11.  The extent to which the 
compounds show selectivity towards the CB2 receptor appears to depend on the 
substitution pattern on ring A and the type of side chain linker at the C10 position.  Our 
binding affinity data show that compounds with a hydroxyl 8 and carbonyl linker 
(compounds 9 and 10) retain affinity for the CB2 receptor when compared to the gem 
dimethyl analog 11.  The presence of the gem dimethyl group as a linker in compound 11  
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Figure 3.1: Design of the novel triaryl cannabinoid core 
The design utilized elements from our C1’ aryl Δ8 classical cannabinoid analogs 1 and 
the biaryl cannabinoids 7 reported by Makriyannis. 
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Figure 3.2: Initial triaryl cannabinoids 
Initial novel triaryl cannabinoids synthesized and screened for receptor binding affinity. 
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Table 3.1: Binding affinity (Ki) of compounds 8-11 for the CB1 and CB2 receptors 
compared to KM-233 1 and Δ8-THC 
 
Compound CB1 Ki (nM) CB2 Ki (nM) CB1/CB2 Ratio 
Δ8-THC 28.5 (± 3.3) 25.0 (± 4.8) 1.1 
KM-233 1 12.3 (± 0.61) 0.91 (± 0.08) 13.5 
8 > 1000 1.66 (± 0.38) > 602.4 
9 > 1000 4.77 (± 0.57) > 209.6 
10 27.0 (± 2.30) 2.94 (± 1.69) 9.2 
11 93.66 (± 2.33) 1.07 (± 0.05) 87.5 
Notes: Values are the mean of three experiments run in triplicate; standard deviation is 
given in parentheses.  CB1/CB2 ratio is expressed as Ki for CB1 / Ki for CB2. 
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results in a CB2 selective compound with a Ki value of 1.07 nM at the CB2 receptor 
compared to 93.66 nM at the CB1 receptor subtype (CB1/CB2 = 87.5).  Compound 8, 
which was initially viewed as a synthetic intermediate, gave perhaps the most significant 
finding.  This compound showed high binding affinity for the CB2 receptor with a Ki of 
1.66 nM and exhibited a high 600-fold selectivity for the CB2 receptor.  The introduction 
of a C10 hydroxyl or carbonyl group in classical cannabinoids has not been extensively 
investigated; however, previous findings by our group108,129 and by Papahatjis and 
coworkers130 indicate that these C10 substituents reduce cannabinoid receptor affinity.  
Interestingly, binding affinity data for these first four compounds show that the carbonyl 
and hydroxyl substituents at the C10 position selectively decrease CB1 receptor affinity 
without altering CB2 receptor binding.  The beneficial effect of the C10 equivalent 
hydroxyl, as well as the carbonyl, in CB2 receptor affinity may reflect that the removal of 
the pyran ring provides greater conformational flexibility thus allowing for more 
favorable receptor interactions at CB2, or that the triaryl compounds possess a different 
binding orientation relative to classical cannabinoids.  
 
 
3.2 SAR of Triaryl Cannabinoids 
 
To begin to develop an SAR (structure activity relationship) of this new triaryl 
class of cannabinoids, five more compounds were synthesized.  Compounds 12-16 
(Figure 3.3) completed the possible permutations of the three types of side chain linkers: 
hydroxyl, carbonyl, and gem-dimethyl, combined with the three substitution patterns on 
the A ring: dimethoxy, methoxy-hydroxy, and dihydroxy.  These compounds were then 
screened for receptor binding affinity and functional activity at the CB1 and CB2 
receptors.   
After the remaining compounds were synthesized and evaluation of their affinity 
to the CB1 and CB2 receptors had begun, compound 10 was screened again.  The results 
were contradictory to the previously published values.  The Ki values for both CB1 and 
CB2 increased significantly from 27.0 (± 2.30)nM to 6040 (± 1477)nM and from 2.94 (± 
1.69)nM to 487 (± 101)nM, respectively.  At first, it was suspected that there was some 
error in the more current assay technique or analysis.  However, after performing several 
Scatchard analyses on the membrane preparations and screening several well 
characterized cannabinoids such as Δ8-THC and CP-55,940, the current analytical 
techniques were validated.  The remaining three original compounds (8, 9, and 11) were 
reevaluated for their receptor binding affinities and these values (along with compounds 
12-16) are summarized in Table 3.2.  There has been, as yet, no sufficient explanation as 
to the differences between the current Ki values and those previously reported. 
A general SAR concerning the side chain linker and the substitutions on the A 
ring for this class of compounds can be easily developed from the binding data.  First, the 
A ring must possess at least one hydroxyl group with two being ideal for maximum 
affinity at both the CB1 and CB2 receptors.  The three dimethoxy analogs 8, 14, and 15 
showed very little binding at either receptor with Ki values above 10,000nM while the 
methoxy-hydroxy analogs 9 and 16 possessed detectable binding at the CB1 receptor 
with Ki values of 7235 (± 3056)nM and 206 (± 130)nM and at CB2 with values of 2439 
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Figure 3.3: Nine triaryls used to develop SAR of this new class of cannabinoids 
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Table 3.2: Binding affinity (Ki) of compounds 8-16 for the CB1 and CB2 receptors 
compared to KM-233 1 and Δ8-THC 
 
Compound CB1 Ki (nM) CB2 Ki (nM) CB1/CB2 Ratio 
Δ8-THC 28.5 (± 3.3) 25.0 (± 4.8) 1.1 
KM-233 1 12.3 (± 0.61) 0.91 (± 0.08) 13.5 
8 > 10,000 > 10,000 n.d. 
9 7235 (± 3056) 2439 (± 639) 3.0 
10 6040 (± 1477) 487 (± 101) 12.4 
11 250 (± 49) 7.67 (± 3.14) 32.6 
12 > 10,000 > 10,000 n.d. 
13 > 10,000 3382 (± 1389) > 3.0 
14 > 10,000 > 10,000 n.d. 
15 > 10,000 > 10,000 n.d. 
16 206 (± 130) 66.0 (± 17.2) 3.1 
Notes: Values are the mean of three experiments run in triplicate; standard deviation is 
given in parentheses.  CB1/CB2 ratio is expressed as Ki for CB1 / Ki for CB2.  n.d. = not 
determined when there is no specific Ki that can be determined for either CB1 or CB2. 
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(± 639)nM and 66.0 (± 17.2)nM, respectively.  The methoxy-hydroxy compound 12 
which has a hydroxyl side chain linker, on the other hand, still possesses very low affinity 
for each receptor with Ki values above 10,000nM.  The three compounds possessing the 
dihydroxy substituted A ring were the best binders at each receptor subtype.  Compound 
11 which has the gem-dimethyl linker displayed the highest affinity for CB1 (Ki = 250 (± 
49)nM) and for CB2 (Ki = 7.67 (± 3.14)nM) while the hydroxyl side chain compound 13 
possessed very low affinity for CB1 (Ki > 10,000nM) and only very modest affinity for 
CB2 (Ki = 3382 (± 1389)nM).  Examining within each set of three compounds that have 
the same substitution pattern on the A ring: the dimethoxy (8, 14, and 15), the methoxy-
hydroxy (12, 9, 16), and the dihydroxy (13, 10, and 11), it becomes clear that the side 
chain linker has a very profound effect on the binding affinity of the triaryl cannabinoids.  
The rank order for the highest affinity to both CB1 and CB2 is gem-dimethyl > ketone > 
hydroxyl.  The negative effects on binding contributed by the hydroxyl linker is perhaps 
the most significant deviation from the originally reported data which showed that 
compound 8 retained high affinity for CB2 (Ki = 1.66 (± 0.38)nM).  It is also worth 
noting that while all of the compounds with detectable affinity were CB2 selective, none 
were as selective as the previously reported values for compounds 8 and 9 (> 602.4 and > 
209.6, respectively).  Compound 11 which showed the highest affinity for each receptor 
also has the highest level of CB2 selectivity with a Ki (CB1) / Ki (CB2) ratio of 32.6.  The 
next most CB2 selective compound was 10 with a ratio of 12.4. 
 
 
3.3 Antineoplastic Activity of Triaryl Cannabinoids and Selection of HB-I-172 
 
 Due to reported efficacy of cannabinoids against a wide range of cancers,72a,131 it 
was decided to screen the nine triaryl analogs against a panel of varied human neoplastic 
cell lines.  The compounds were tested against human lung (H69AR), prostate (DU-145 
and PC-3), colorectal (HCT-15), glioma (U-87 MG, LN-229, T98G, and DBTRG-05MG) 
and pancreatic (BxPC-3) cancer cell lines (Tables 3.3 and 3.4).  The dimethoxy-ketone 
14 and dimethoxy-dimethyl 15 analogs were quickly eliminated due to a lack of 
solubility in the cytotoxicity assay conditions.  All but one of the remaining seven triaryls 
exhibited broad spectrum antineoplastic activity against all cell lines tested.  Compound 
13, the dihydroxy-hydroxy analog, was efficacious only against the PC-3 prostate 
carcinoma line and two glioblastoma lines: U-87 MG and LN-229.  Even though 
compound 13 lacked broad spectrum activity, it proved to be potent against the 
susceptible cancers with EC50s ranging from 4.63 to 5.10µM.  Compounds 8, 9, 10, 11, 
12, and 16 were active against all cancers screened with EC50s ranging from 0.30 to 
6.34µM.  These results were unexpected considering the vast range in binding affinity of 
these compounds for the CB1 and CB2 receptors.  This finding is evidence for the 
possibility that the antineoplastic activity of the triaryls is mediated through a receptor 
other than the cannabinoid receptor subtypes 1 and 2. 
 To begin to elucidate the antineoplastic mechanism of action of this new class of 
cannabinoids we needed to pick one lead compound for the studies.  We decided to 
evaluate their metabolic stability in order to select a compound that could potentially be 
evaluated in vivo.  Phase I metabolism studies were performed in the lab of Dr. Bernd 
Meibohm at the University of Tennessee Health Science Center with an in vitro method 
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Table 3.3: Efficacy of three triaryl cannabinoids against a variety of human cancer cell 
lines 
 
 
 
Compound 
8 
Compound 
12 
Compound 
13 
 
Cell Line 
EC50 (µM) ± 
S.D. 
EC50 (µM) ± 
S.D. 
EC50 (µM) ± 
S.D. 
 
DU-145 
prostate 
5.07 (± 0.30) 3.72 (± 0.83) n.a. 
 
PC-3 
prostate 
3.47 (± 1.36) 4.08 (± 0.82) 4.63 (± 0.63) 
 
H69AR 
lung 
6.30 (± 0.19) 5.16 (± 0.53) n.a. 
 
HCT-15 
colorectal 
5.43 (± 0.73) 3.74 (± 0.57) n.a. 
 
BxPC-3 
pancreatic 
3.28 (± 1.21) 2.49 (± 0.28) n.a. 
 
U-87 MG 
glioma 
4.67 (± 0.23) 3.13 (± 0.31) 4.94 (± 0.11) 
 
LN-229 
glioma 
2.57 (± 0.19) 1.93 (± 0.09) 5.10 (± 0.18) 
 
T98G 
glioma 
5.20 (± 0.69) 5.29 (± 2.39) n.a. 
 
DBTRG-05MG 
glioma 
 
n.a. 5.03 (± 1.10) n.a. 
Note: The EC50 values were obtained from three independent experiments run in 
triplicate; standard deviation is given in parentheses.  Compounds 14 and 15 were not 
screened due to insolubility in assay conditions.  Abreviations: n.a. = not active. 
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Table 3.4: Efficacy of four triaryl cannabinoids against a variety of human cancer cell 
lines 
 
Note: The EC50 values were obtained from three independent experiments run in 
triplicate; standard deviation is given in parentheses.  Compounds 14 and 15 were not 
screened due to insolubility in assay conditions. 
 
 
 
Compound 
9 
Compound 
10 
Compound 
16 
Compound 
11 
 
Cell Line 
EC50 (µM) ± 
S.D. 
EC50 (µM) ± 
S.D. 
EC50 (µM) ± 
S.D. 
EC50 (µM) ± 
S.D. 
 
DU-145 
prostate 
4.45 (± 0.35) 2.38 (± 0.75) 2.56 (± 0.63) 2.46 (± 0.46) 
 
PC-3 
prostate 
1.96 (± 0.32) 3.83 (± 0.62) 2.90 (± 0.55) 1.83 (± 0.24) 
 
H69AR 
lung 
3.49 (± 0.66) 5.22 (± 1.12) 3.34 (± 0.39) 1.73 (± 0.13) 
 
HCT-15 
colorectal 
2.23 (± 0.07) 4.40 (± 1.03) 2.42 (± 0.37) 2.09 (± 0.46) 
 
BxPC-3 
pancreatic 
2.47 (± 0.20) 4.60 (± 0.11) 4.32 (± 0.74) 2.18 (± 0.39) 
 
U-87 MG 
glioma 
2.01 (± 0.27) 2.90 (± 0.27) 2.68 (± 0.74) 1.20 (± 0.58) 
 
LN-229 
glioma 
1.29 (± 0.40) 4.63 (± 1.10) 1.14 (± 0.08) 0.30 (± 0.06) 
 
T98G 
glioma 
3.15 (± 0.75) 4.25 (± 0.26) 2.34 (± 0.49) 3.69 (± 0.74) 
 
DBTRG-05MG 
glioma 
 
6.20 (± 3.33) 6.34 (± 4.10) 4.73 (± 1.94) 2.18 (± 1.92) 
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utilizing rat liver microsomal preparations.  The criteria used for selecting acceptable 
compounds would be that at least 30% of the parent drug must remain after a 90 minute 
incubation with the microsomes.  The results of that study narrowed the compounds to 
three potential candidates: 10, 12, and 13 with 45.3, 38.7, and 42.1% remaining, 
respectively.  Compound 13 was eliminated due to the previously mentioned lack of 
broad spectrum activity and compound 12 was dropped from consideration because of the 
presence of a chiral center in this molecule.  The development of an asymmetric ligand 
with therapeutic potential requires efficacy and toxicology studies on each isomer along 
with the racemic mixture.  The synthesis of each chirally pure isomer can be expensive or 
the attempted separation of the isomers from the mixture can be very difficult and time 
consuming.  Therefore, compound 10 (henceforth named HB-I-172) was selected to 
proceed into studies to determine the mechanism of action of these compounds and to 
determine the receptor responsible for the antineoplastic efficacy. 
 
 
3.4 Receptors Involved in the Anti-Glioma Activity of HB-I-172 
 
Based on our previous experience with both in vitro and in vivo models of 
glioblastoma multiforme,109,111 it was decided to focus on this particular type of neoplasm 
for our further studies.  We hypothesized that HB-I-172 initiated GBM cell death by 
ligation to one or more of the CB receptors CB1, CB2, and/or GPR55.  The first step in 
our target receptor studies was to determine the relative expression levels of the receptors 
in the human GBM lines U-87 MG, T98G, LN-229, and DBTRG-O5MG.  Western blot 
analysis of the particulate fraction (membrane bound proteins) and cytosolic fraction of 
cell lysates is shown in Figure 3.4.  Consistent with earlier reports,110b,132 both CB1 and 
CB2 receptors are present in all the human GBM cell lines with the CB1 showing a lower 
immunohistochemical staining relative to CB2.  Interestingly, the GPR55 receptor 
exhibited a relative increased blotting in both the particulate and cytosolic fractions.  The 
presence of GPR55 in the cytosolic fraction may indicate active synthesis of the protein 
or compartmental localization in the cytosol.  The qualitative analysis of the Western data 
is not interpreted in terms of absolute expression levels but is used to verify the presence 
or absence of each receptor type.  The similarities in receptor expression patterns found 
in each GBM cell line may account for the comparable efficacies of HB-I-172 against the 
four human GBM cell lines screened.  
 To study the contribution(s) of the CB1, CB2, and/or GPR55 receptors to the 
cytotoxic effect of HB-I-172 we utilized pharmacological probes.  The CB1 and CB2 
receptors couple through Gαi whereas GPR55 couples via Gα12/13.  To assess the possible 
contribution of CB1 and/or CB2 to the mechanism of action of HB-I-172, cytotoxicity 
assays were carried out using U87 cells pre-treated 8 hours before the assay with 
100ng/ml of pertussis toxin (Ptx).  The Ptx inactivates Gαi via catalytic ADP-ribosylation 
thus blocking G-protein-receptor interactions, the Gα12/13 proteins are Ptx-resistant.  The 
decoupling of CB1 and CB2 from Gαi using Ptx caused an insignificant increase in EC50 
of HB-I-172 against human U87 cells (Figure 3.5).  We have determined that HB-I-172 
is an antagonist of the CB1 receptor (binding affinity Ki = 6040 (± 1477)nM) and an 
inverse agonist (EC50 = 361nM) of the CB2 receptor (binding affinity Ki = 487 
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Figure 3.4:  Western blots for cannabinoid receptors in human glioma cell lines 
Western blots of the particulate (P) and cytosolic (C) fractions of whole cell lysates of U-
87 MG, T98G, LN-229, and DBTRG-O5MG.  All blots are indexed to the structural 
protein α-tubulin; cell lysates were divided into 3 aliquots and run on separate gels for 
each receptor.  
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Figure 3.5:  Effects of HB-I-172 on U-87 MG in the presence or absence of Ptx 
Dose response curves for U-87 MG cells treated with HB-I-172 in the presence or 
absence of 100 ng/ml Ptx.  The EC50 manifested a slight shift from 13.4 to 17.6µM in the 
presence of Ptx.  Data is derived from 3 independent experiments conducted in triplicate.
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(± 101)nM) coupling through Gαi (Figure 3.6).  If the antineoplastic activity is initiated 
by CB1 or CB2 it would be predicted that Ptx would block the effects of HB-I-172 thus 
the results indicate that CB1 and CB2 do not play a role in HB-I-172 anti-cancer activity.   
Selective pharmacological inhibition of the three receptors is not a viable 
approach to identifying the target receptors.  Specifically, the CB1 antagonist AM-251 is 
an agonist of GPR55, and SR141716A is reported to be either an agonist or antagonist of 
GPR55, depending on assay conditions.85  The selective CB2 antagonist/inverse agonist 
SR144528 to our knowledge has not been tested against GPR55; however, the inverse 
agonist activity at CB2 is the same as HB-I-172 and as such would not unambiguously 
help in identifying the target receptor.  We are currently developing lines of U-87 MG 
that are stably expressing shRNA to knock-down each of the three receptors in an effort 
to overcome the limitations of pharmacological knock-downs. 
 
 
3.5 Comparison of HB-I-172 to Standard GBM Treatments 
 
During the course of a study utilizing immunohistochemical staining techniques 
to microscopically analyze the cytotoxic activities of other compounds prepared in our 
laboratory, it was discovered that the previously utilized method for determining 
cytotoxicity possessed an inherent error.  In this method, cells were plated in 96-well 
polystyrene plates and allowed to attach overnight in an incubator.  The complete growth 
media was then replaced with serum-free media (100µl) before drug addition.  Small 
volumes of drug solutions (1µl) prepared in DMSO were then pipetted into the 
appropriate wells.  The small ratio of drug solution to media did not allow for proper 
mixing and dilution of the drug and allowed for a much higher localized concentration of 
the test compounds in certain areas of the well.  Figure 3.7 illustrates this finding.  This 
micrograph is of LN-229 that has been treated with KM-233 at the EC50.  It is evident 
that there is a disparity in the effects that the drug has on cells within this one field of 
view.  In another set of experiments designed to evaluate the activity of caspase 3 in 
glioma cells treated with KM-233, we found that exposure to serum-free media during 
the drug incubation period increases the activity of caspase 3 separate and apart from any 
effect of the drug. 
 With the knowledge obtained from these two experiments, we developed a 
revised method for determining cytotoxicity of our compounds.  The drug solutions are 
premixed in media containing 1% serum and added after the removal of the complete 
growth media.  This allows for thorough mixing of the test compounds with the media 
and the small amount of serum reduces the interference with the basal metabolic activity 
observed in serum-free conditions. 
 We then screened HB-I-172 against U-87 MG and LN-229 utilizing the new 
method.  We also tested two clinically relevant compounds, BCNU and temozolomide, 
under these conditions for comparison.  We observed a 4.6 and 2.1 fold increase in the 
EC50 of HB-I-172 against U-87 MG and LN-229, respectively.  In comparison, BCNU 
and temozolomide were either ineffective or manifested high micromolar EC50s (Table 
3.5).  Specifically, U87 and LN-229 were sensitive to BCNU after 18 hours of exposure 
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Figure 3.6:  Functional activity of HB-I-172 at the CB1 and CB2 receptors 
HB-I-172 does not reverse cAMP production in the CB1 ActOne© assay and shifts the 
response curve of CP-55,940 to the right identifying HB-I-172 as an antagonist at CB1.  
The increase in response in the CB2 assays is indicative of inverse agonist activity. 
60 
 
 
 
Figure 3.7: Inefficient mixing of drug solutions with media in cytotoxicity assays 
Representative immunofluorescence micrograph of LN-229 GBM cells treated with KM-
233 at the EC50 imaged using a 10X objective.  The labels are: cytochrome C (red), DAPI 
nuclear stain (blue), and whole cell stain (green).  Cells with dysfunctional cell 
membranes show increased permeability so that the double stained nucleus appears cyan 
color (white arrows).  The effects due to localized concentration of KM-233 can be easily 
observed in the upper right hand corner of the micrograph while the cells in the 
remainder of the image are relatively unaffected. 
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Table 3.5: Efficacy of HB-I-172 against U-87 MG and LN-229 
 
 HB-I-172  18 hrs BCNU 18 hrs BCNU 48 hrs 
 
Cell Line 
EC50 (μM) ±  
S.D. 
EC50 (μM) ± 
S.D. 
EC50 (μM) ± 
S.D. 
U-87 MG 13.4 (± 0.98) 233 (± 5.1) 156.0 (± 2.4) 
LN-229 9.74 (± 0.56) 178 (± 2.3) 119 (± 4.2) 
Note: The EC50 values were obtained from three independent experiments run in 
triplicate; standard deviation is given in parentheses.  
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with EC50s of 223 and 178 μM, respectively.  Following 48 hours of exposure to BCNU 
the EC50s decreased to 156 and 119µM.  In contrast, the EC50s of HB-I-172 were found 
to be 13.4 and 9.74µM for U-87 MG and LN-229, respectively, and were effective in the 
18 hour assay window.  Temozolomide was inactive against the cell lines following 18 
and 48 hours exposure (data not shown).  Although temozolomide is pH activated, the 
concentration of the active compound was not assessed and therefore these results are 
viewed with caution. 
 
 
3.6 Mechanistic Studies to Determine the Anti-Glioma Activity of HB-I-172 
 
 
3.6.1 Methods and Results 
 
 The second component of the mechanism(s) of human GBM cytotoxicity of HB-
I-172 is the downstream pathway resulting in cell death.  To evaluate the downstream 
signal cascade(s) we utilized a combination of fluorescence microscopy and protein 
quantification using Meso Scale Discovery (MSD) MULTI-ARRAY® microplate 
technology.  We first conducted a preliminary screen of the effect(s) of HB-I-172 on total 
and phosphorylated ERK1/2, JNK, p38, and, Akt using MSD plates.  The screen utilized 
U-87 MG cells treated with HB-I-172 at the EC50 (13.4μM) to evaluate signal cascade 
modulation over a 24 hour time course.  The preliminary screen showed that ERK1/2 and 
Akt, but not JNK or p38, are downstream signals in U-87 MG cells following HB-I-172 
exposure (data not shown).  Based on these results we analyzed the kinetic profile of 
phosphorylation of the MEK-ERK-STAT pathway using the MSD triplex plate for 
pMEK1/2 (Ser217/221), pERK1/2 (Thr202/Tyr204 and Thr185/Tyr187), and pSTAT3 
(Tyr705).  Cells were cultured in 10cm Petri dishes using media containing 1% serum for 
24 hours to equilibrate intracellular signaling cascades.  The media was replaced after 
equilibration with either media containing 1% serum and vehicle alone (DMSO) or media 
containing 1% serum and HB-I-172.  The level of pMEK1/2 showed a significant decline 
in relative intensity 1 hour after the change in media in both control and drug treated cells 
(Figure 3.8).  The control cells manifested a return to basal levels at 6 hours; however, 
HB-I-172 significantly reduced pMEK1/2 levels throughout the remainder of the 
experiment.   
 The levels of pERK1/2 exhibited a similar decline 1 hour post media change in 
both groups (Figure 3.9).  Unlike pMEK1/2, the control group exhibited a significant 
increase in pERK1/2 at 6 hours that continued the remainder of the experiment.  The 
effect of HB-I-172 on pERK1/2 however caused a significant and lasting decrease in 
relative levels.  The Ras-Raf-MEK-ERK pathway is a potential target for the 
development of anti-cancer agents.120  The precise mechanism whereby HB-I-172 
inhibits ERK phosphorylation remains to be determined.  Due to the observed decrease in 
activated MEK, it must be further upstream in the signaling cascade.  We do not believe 
that the response is due to Ras-Raf since we would predict an increase in pERK1/2 with 
decreased pAkt (see below), i.e. pAkt negatively regulates Raf thus an increase in 
pERK1/2 is predicted.133 
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Figure 3.8: pMEK1/2 profile of U-87 MG cells treated with HB-I-172 
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
Cell cultures were plated for 24 hours; the media changed to 1% serum for 24 hours to 
equilibrate intracellular pathways, then media was changed to either media containing 1% 
serum or media containing 1% serum plus HB-I-172.  At the designated time intervals 
cells were scraped from the dishes, collected by centrifugation, the pellet lysed, and the 
protein concentration per lysate was determined.  Total protein added to each well of the 
MSD plate was 20μg.  Aliquots from this experiment were used in all the following 
pathway assays.  All data points represent 3 independent determinations analyzed in 
duplicate.  Dashed lines indicate comparisons between control samples and solid lines 
between control and drug treated samples.  * = p < 0.001.  
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Figure 3.9: pERK1/2 profile of U-87 MG cells treated with HB-I-172 
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Dashed lines indicate comparisons 
between control samples and solid lines between control and drug treated samples.  * = p 
< 0.001.  
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Interplay between the ERK1/2 and Akt pathways in C6 glioma cells was 
previously reported by Ellert-Miklaszewska et al.119  To assess the contribution of Akt to 
the signal cascade associated with HB-I-172 we utilized the MSD Akt Signaling Panel 
which measures pAkt, pGSK-3β, and p-p70S6K.  Treatment of U-87 MG cells with HB-
I-172 triggers a significant and rapid decrease in pAkt (Ser 473) beginning at 1 hour and 
continuing through 24 hours (Figure 3.10).  Within this time interval a decrease in 
phosphorylated 70-kDa ribosomal protein S6 kinase (p-p70S6K, Ser 217/221) (Figure 
3.11) was observed along with a significant decrease in the Akt target glycogen synthase 
kinase 3 beta (pGSK-3β, Ser 9) (Figure 3.12) at 1 and 6 hours followed by a highly 
significant increase in GSK-3β phosphorylation beginning at 18 hours post treatment.   
The reductions in pAkt and p-p70S6K are consistent with the recent report by 
Salazar et al. wherein U-87 MG cells were treated with THC.134  The inhibition of Akt in 
cancer therapy is well established; however, it has recently been shown that knock-down 
of p70S6K with siRNA inhibited U-251 MG glioma cells by greater than 50 percent.  The 
observed increase in pGSK-3β is consistent with the reported increase in apoptosis 
observed with GSK-3β activation122 although Kotliarova et al. report that inhibition of 
GSK-3β induces cell death.123  In GBM cell lines it is generally reported that regulation 
of Akt pathways, as well as ERK signaling, is mediated through a Gαi/o and/or Gβ/γ 
pathway; however, it is possible that a Gα12/13-RhoA pathway, and by extension GPR55, 
may regulate the downstream activation/inactivation of the Akt and/or the ERK 
pathways.  For example, Gα12/13 activation of the PI3K-Akt axis has been proposed in 
neuroblastoma cells124 and a pathway involving Rho-ROCK signaling and ERK 
activation in the human GBM line LN-19.125   
 The reduction in pERK1/2 could significantly impact the activity of cancer 
survival and gene expression pathways, for example p90RSK-BAD, p53, NF-κB, 
STAT1/3, Elk-1, and/or c-fos.  Three of these pathways, p53, BAD, and STAT1/3 were 
evaluated using MSD technology.  A significant decrease in pSTAT3 occurred at 1 hour 
in both treatment groups (Figure 3.13).  The levels of pSTAT3 recovered by 12 hours; 
however, thereafter HB-I-172 caused a significant decrease in pSTAT3 levels relative to 
controls.  The decline in pSTAT3 is of particular interest due its role in tumorigenesis, 
i.e. proliferation, angiogenesis, and inhibition of apoptosis,113 the proposed role in 
immune tolerance in glioblastoma patients,114 and provides a novel target in cancer 
therapy.113,115  This suggests that cannabinoid receptors may be a novel target for the 
regulation of STAT3 function via CB1 or CB2 regulation of Gαo- c-Src116 or via a GPR55 
regulated Gα12/13-RhoA-ERK-STAT3 pathway.117 
 The effect of HB-I-172 on the tumor suppressor protein p53 was determined using 
the MSD Multiplex Apoptosis Panel which measures levels of p53, p-p53 (Ser 15), 
cleaved PARP and cleaved caspase-3.  Treatment of U-87 MG cells with HB-I-172 
caused a significant increase in levels of both total p53 (Figure 3.14) and phospho-p53 
(Figure 3.15) beginning 1 hour post treatment and continuing for the duration of the 24 
hour experiment.  This increase is probably a result of the decrease in ERK1/2 which 
suggests a negative regulation of p53 by ERK.  This agrees with previous reports that 
also observed increases in p53 following suppression of ERK.135  This increase in p53 is 
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Figure 3.10: pAkt profile of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Dashed lines indicate comparisons 
between control samples and solid lines between control and drug treated samples.  * = p 
< 0.005, ** = p < 0.0005, *** = p < 0.00001. 
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Figure 3.11: Phospho-p70S6K profile of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Dashed lines indicate comparisons 
between control samples and solid lines between control and drug treated samples.  * = p 
< 0.05, ** = p < 0.005, *** = p < 0.001, **** = p < 0.00001. 
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Figure 3.12: pGSK-3β profile of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Solid lines indicate comparisons 
between control and drug treated samples.  * = p < 0.01, ** = p < 0.001, *** = p < 
0.0005. 
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Figure 3.13: pSTAT3 profile of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Dashed lines indicate comparisons 
between control samples and solid lines between control and drug treated samples.  * = p 
< 0.0005, ** = p < 0.000005, *** = p < 0.00000005. 
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Figure 3.14: p53 profile of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Solid lines indicate comparisons 
between control and drug treated samples.  * = p < 0.005, ** = p < 0.0001, *** = p < 
0.000001. 
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Figure 3.15: Phospho-p53 profile of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Solid lines indicate comparisons 
between control and drug treated samples.  * = p < 0.005, ** = p < 0.001, *** = p < 
0.0001. 
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of interest due to its role in suppression of tumor proliferation by initiating cellular 
senescence136 and its ability to initiate apoptosis.137 
The down-regulation of the pro-survival kinase cascades ERK1/2 and Akt raised 
the possibility that one downstream mediator of glioblastoma cytotoxicity due to HB-I-
172 may be the Bcl-2 family protein BAD.  Specifically, phosphorylation of BAD by Akt 
and ERK has been previously reported;126 therefore, HB-I-172 may suppress 
phosphorylation of BAD resulting in heterodimerization with Bcl-2 death suppressors.   
To evaluate the effect of HB-I-172 on BAD phosphorylation status we utilized the MSD 
Phospho (Ser 112)/Total BAD assay.  Treatment of U-87 MG cells with HB-I-172 caused 
a significant decrease in BAD phosphorylation at 6 hours post-exposure (Figure 3.16).   
 It was expected that the decrease in pBAD would correlate with mitochondrial 
dysfunction.  One manifestation would be cytochrome C (cytC) release and activation of 
caspase 3.  To evaluate this component we employed the previously mentioned MSD 
Apoptosis Panel.  A rapid and significant increase in cleaved caspase 3 began at 6 hours 
post-drug treatment and persisted until the end of the experiment (Figure 3.17).  The 
increase in caspase 3 activity is followed downstream by activation of caspase 9 twelve 
hours later at the 18 hour time point as determined by the Caspase-Glo® 9 Assay System 
from Promega (Figure 3.18).  This probably accounts for the further increase in cleaved 
caspase 3 at the 24 hour time point as caspase 9 cleaves procaspase 3 into the active 
enzyme.   
Coinciding with the increase in caspase 3 activity, the same rapid increase at 6 
hours was observed in the level of cleaved PARP (Figure 3.19).  The increase in cleaved 
PARP is of interest due to its ability to potentiate apoptosis by depleting the intracellular 
supply of ATP and also to independently initiate apoptosis by production of poly(ADP-
ribose) which stimulates mitochondria to release apoptosis inducing factor.138   
 The possible contribution of mitochondrial dysfunction to the mechanism of 
action of HB-I-172 was further evaluated using DePsipher® (Trevigen; Gaithersburg, 
MD) to evaluate the collapse of the mitochondrial membrane potential (Figure 3.20).  
Treatment of LN-229 glioblastoma cells with HB-I-172 at the EC50 resulted in a 
significant increase in mitochondrial membrane depolarization, as indicated by the 
inability of the fluorescent stain DePsipher to form red fluorescent eximers inside 
mitochondria with a marked effect at 6 hours and an almost complete depolarization at 18 
hours post-drug treatment.  Mitochondrial involvement was further verified by the 
observation of cytochrome C release in U-87 MG after 6 hours of exposure to HB-I-172 
at the EC50 as determined by immunohistochemical staining techniques (Figure 3.21).  
This same fluorescence photomicrograph also depicts cells with nuclei in which DNA has 
become fragmented and has begun to condense which is further evidence for an apoptotic 
mechanism of cell death. 
The increased activity of PARP which was observed in the MSD assay was also 
confirmed by immunohistochemistry.  In U-87 MG cells treated with HB-I-172 at the 
EC50, the presence of PARP can be seen in the nuclei 6 hours after drug exposure (Figure 
3.22).  The presence of PARP in the nuclei further confirms that there has been DNA 
fragmentation as one of its major roles is to repair DNA breaks. 
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Figure 3.16: BAD phosphorylation of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for 6 hours.  See legend of Figure 
3.8 for experimental details.  Solid line indicates comparison between control and drug 
treated samples.  * = p < 0.00005. 
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Figure 3.17: Caspase 3 activity profile of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Solid lines indicate comparisons 
between control and drug treated samples.  * = p < 0.000005, ** = p < 0.000000005. 
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Figure 3.18: Caspase 9 activity of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for 18 and 24 hours.  Cells were 
seeded in white, opaque 96-well culture plates at a density of 10,000 cells/well in a 
volume of 100µl media.  The cells were allowed to attach overnight and the complete 
growth media was changed to media containing 1% serum for 24 hours to equilibrate 
intracellular signaling pathways, then media was changed to either media containing 1% 
serum or media containing 1% serum plus HB-I-172.  At the designated time intervals 
100µl of Caspase-Glo® 9 Assay Reagent (Promega) was added to each well and the plate 
mixed on a rotary shaker for 30 seconds.  After incubation at room temperature for 90 
minutes the luminescence was read on a Biotek Synergy 2 plate reader.  The luminescent 
signal is proportional to the amount of caspase 9 activity present.  All data points 
represent 6 independent determinations.  Solid lines indicate comparisons between 
control and drug treated samples.  * = p < 0.01, ** = p < 0.005. 
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Figure 3.19: Cleaved PARP profile of U-87 MG cells treated with HB-I-172  
U-87 MG cells were treated with HB-I-172 at the EC50 for the designated time intervals.  
See legend of Figure 3.8 for experimental details.  Solid lines indicate comparisons 
between control and drug treated samples.  * = p < 0.000001, ** = p < 0.0000005, *** = 
p < 0.00000005. 
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Figure 3.20: Effects on membrane polarization in U-87 MG cells treated with HB-I-172 
Change in mitochondrial membrane polarization (Δψm) with DePsipher® -  U-87 MG 
cells were treated with HB-I-172 at the EC50 for 6 and 18 hours, and then stained with 
dual fluorescent stain; green fluorescence shifts to red emission following the formation 
of eximers within mitochondria as stain crosses polarized outer mitochondrial membrane.  
Mitochondrial depolarization by HB-I-172 inhibits DePsipher permeability and 
subsequent red fluorescence.  U-87 MG cells were imaged using an Olympus IX71 
inverted fluorescence microscope fitted with a Retiga-SRV camera.  Control (vehicle 
treated) cells are shown in panel A, 6 hours post drug treatment in panel B, and 18 hours 
post drug treatment in panel C. 
 
 
78 
 
 
 
Figure 3.21: Effects on cytochrome C release in U-87 MG cells treated with HB-I-172 
U-87 MG cells were treated with HB-I-172 at the EC50 for 18 hours and evaluated for 
changes in localization of cytochrome C (red); nuclei are shown in blue.  Control (vehicle 
treated) cells are shown in panel A and 18 hour drug treated cells are shown in panel B.  
Control cells exhibit localization of cytochrome C in the mitochondria (white arrow) 
along the cytoskeletal network.  HB-I-172 treated cells show a diffuse pattern of labeling 
(green arrow) indicating that cytochrome C has been released from the mitochondria into 
the cytosol.  Some of the drug treated cells show a much fainter red labeling (yellow 
arrow, approximate cell outline represented by dashed white line) indicating depletion of 
cytochrome C.  Some drug treated cells also show DNA fragmentation and condensation 
(red arrow).  U-87 MG cells were imaged using an Olympus IX71 inverted fluorescence 
microscope fitted with a Retiga-SRV camera. 
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Figure 3.22: Activity of PARP in U-87 MG cells treated with HB-I-172 
U-87 MG cells were treated with HB-I-172 at the EC50 and evaluated for activity of 
PARP (red) in the nuclei (blue).  Control (vehicle treated) cells are shown in panel A and 
6 hour drug treated cells are shown in panel B.  HB-I-172 causes activation of PARP as 
seen by the red staining in the nuclei (white arrows).  U-87 MG cells were imaged using 
an Olympus IX71 inverted fluorescence microscope fitted with a Retiga-SRV camera.  
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We also conducted a microscopic study to assess the effects of HB-I-172 on 
cytoskeleton structure based on the known activity of RhoA and the possibility of a 
GPR55 initiated mechanism.  At 18 hours post HB-I-172 treatment the cytoskeleton 
manifests profound contraction of F-actin and α-tubulin (Figure 3.23).  Though it is not 
possible to conclude a specific mechanism, this result provides a basis for further 
evaluating the possibility of RhoA-ROCK contributions to cell death. 
 
 
3.6.2 Proposed Mechanism of the Anti-Glioma Activity of HB-I-172 
 
 The ability of HB-I-172 (and possibly the other triaryl cannabinoids) to block two 
major pro-survival signaling pathways, namely Raf1/MEK/ERK and PI3K/Akt, may 
account for its broad spectrum antineoplastic activity.  Activation of these pathways is 
essential for cell survival and over-activation of each has been shown to be common in 
many forms of cancer.119  Constitutive Akt over-activation can many times be attributed 
to amplification of the Akt gene or mutations in components of the upstream signaling 
pathway.139  Akt plays a critical role in the regulation of cell survival and apoptosis by 
phosphorylation and inhibition of a number of proteins including GSK-3β140 and caspase-
9.141  The Raf1/MEK/ERK pathway has been shown to be over-active in nearly one-third 
of all human cancers.  This pathway appears to play a large role in cell survival and 
transduction of differentiation and mitogenic signals.142  Both of these pro-survival 
pathways converge on the pro-apoptotic Bcl-2 protein BAD.  Each pathway (Akt directly 
and ERK1/2 through p90 ribosomal S6 kinase (p90RSK)) phosphorylates and inhibits 
BAD which allows the pro-survival members of the Bcl-2 family to remain active and 
prevent apoptosis.  Since each pathway is capable of inhibiting BAD, it would be 
predicted that inhibition of a single pathway would not be sufficient to bring about 
apoptosis.  This has, in fact, been demonstrated in a recent report by Ellert-
Miklaszewska, Kaminska, and Konarska in which specific inhibition of each pathway in 
the C6 glioma cell line did not bring about any significant cell death.119  These two 
pathways share another common signaling protein, namely GSK-3β.  Akt and p90RSK 
both inhibit GSK-3β by phosphorylation.  Inhibition of the two pathways leads to 
increases in the activity of GSK-3β which, in turn, activates the pro-apoptotic Bcl-2–
associated X protein (BAX) which leads to loss of mitochondrial membrane potential.143  
GSK-3β also up-regulates the transcription factor protein 53 (p53) which leads to further 
up-regulation of BAX and also the pro-apoptotic Bcl-2 homologous antagonist/killer 
(BAK).144  By down-regulation of both the PI3K/Akt and Raf1/MEK/ERK pathways, 
HB-I-172 decreases the downstream phosphorylation of BAD and allows it to dimerize 
with Bcl-2 in the mitochondrial membrane leading to loss of membrane potential, release 
of cytochrome C and activation of the caspase cascade beginning with caspase 9 (Figure 
3.24). 
 The down regulation of the two pro-survival pathways in glioblastoma by HB-I-
172 does not give clear evidence for the molecular target of the drug.  We know that HB- 
I-172 is an inverse agonist at the CB2 receptor.  Since CB2 signals through Gαi, the 
effects of an agonist would lead to decreases in cAMP which would decrease the activity 
of protein kinase A (PKA) and up-regulate the Raf1/MEK/ERK pathway.  An inverse 
agonist, on the other hand, would cause increases in cAMP which would increase the 
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Figure 3.23: Effects on cytoskeleton structure in U-87 MG cells treated with HB-I-172 
U-87 MG cells were treated with HB-I-172 and evaluated for changes in F-actin (yellow) 
and α-tubulin (red), nuclei are shown in blue.  Control (vehicle treated) cells are shown in 
panel A and 12 hour drug treated cells are shown in panel B.  HB-I-172 causes significant 
contraction of the cytoskeleton network as evidenced by the compact F-actin (yellow 
arrows) and α-tubulin (white arrows) around the nuclei.  U-87 MG cells were imaged 
using an Olympus IX71 inverted fluorescence microscope fitted with a Retiga-SRV 
camera.   
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Figure 3.24: Proposed induction of apoptosis by HB-I-172 mediated through CB2 
See text for definitions of abbreviations.  
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activity of PKA and down-regulate Raf1/MEK/ERK.  This correlates with our observed 
decreases in phosphorylated MEK1/2 and ERK1/2.  The inhibition of the PI3K/Akt 
pathway can also be explained by a CB2 mediated mechanism.  Ligation of the CB2 
receptor can cause an intracelleular buildup of ceramide produced from sphingomyelin 
by the action of sphingomyelinase which is activated by factor associated with neutral 
sphingomyelinase (FAN) (Figure 3.24).  The increase in ceramide inhibits the activation 
of both PI3K and Akt145 which, again, agrees with our data. 
 HB-I-172 acting through CB2 alone would however not account for the observed 
effects on the cytoskeleton of U-87 MG cells.  The formation of stress fibers following 
treatment with HB-I-172 is better explained through a GPR55 mediated mechanism.  
GPR55 signals through Gα12/13 which activates the Rho family of GTPases through the 
activity of guanine nucleotide exchange factors (GEFs).  One of these GTPases, Rho A, 
then activates focal adhesion kinase (FAK) and Rho-associated, coiled-coil containing 
protein kinase (ROCK) which lead to cytoskeleton rearrangement and formation of stress 
fibers.146  GPR55 can also affect both the PI3K/Akt and Raf1/MEK/ERK pathways 
through the action of Ras on PI3K and Raf1.  For this to be a viable explanation, HB-I-
172 would have to be an antagonist or an inverse agonist at GPR55 also.  This would lead 
to decreases in the activities of Ras-related C3 botulinum toxin substrate 1 (Rac1) and 
cell division control protein 42 homolog (cdc42) and downstream decreases in p21-
activated kinase (PAK) and Ras which would lead to decreases in the activity of PI3K 
and Raf1 (Figure 3.25). 
 The effects of either CB2 or GPR55 (or possibly both) on the two pro-survival 
pathways would be sufficient to initiate apoptosis in glioma cells via activation of BAD 
and GSK-3β by each pathway, the activation of caspase 9 by Akt, and the activation of 
p53 by both GSK-3β and ERK1/2.  There, however, seems to be more to the puzzle than 
the inhibition of these two pathways.  Our observation that caspase 3 is active 
approximately 12 hours before caspase 9 led us to look for alternative mechanisms for the 
activation of caspase 3.  One such possibility is through endoplasmic reticulum (ER) 
stress caused by the unfolded protein response (UPR).  ER stress has been shown to 
initiate apoptosis in a mitochondria independent manner by activation of caspase 3 via 
caspase 12147 (Figure 3.26).  ER stress can also initiate apoptosis via a mitochondria 
dependent pathway involving the release of calcium from the ER into the cytosol which 
causes the collapse of the mitochondrial membrane potential and leads to the release of 
cytochrome C.148  ER stress can play further roles in the initiation of apoptosis also.  The 
UPR can lead to activation of the transcription factor C/EBP homologous protein 
(CHOP) which inhibits the pro-survival Bcl-2 at the transcription level.149  We observed 
increased translocation of active CHOP to the nuclei of HB-I-172 treated U-87 MG cells 
in as little as 3 hours.  At the 3 hour time point, the percent of drug treated cells showing 
positive immunohistochemical staining for CHOP in the nucleus was nearly 8-fold higher 
than in control cells (data not shown).  The number of CHOP positive cells in the drug 
treated group continued to grow throughout the length of the experiment and was 40-fold 
higher than control at the 18 hour terminal time point.  ER stress has also been shown to 
inhibit Akt by activation of the tribbles homolog 3 (TRIB3) pseudo-kinase by the 
transcriptional co-activator p8.134  Much like ERK1/2, ER stress can increase the activity 
of the tumor suppressor p53 which leads to the transcription of p53-up-regulated 
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Figure 3.25: Proposed induction of apoptosis by HB-I-172 mediated through GPR55 
See text for definitions of abbreviations.  
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Figure 3.26: Proposed induction of apoptosis by HB-I-172 initiated by ER stress 
mediated through CB2 
See text for definitions of abbreviations.  
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modulator of apoptosis (PUMA) and Noxa which cause cytochrome C release from 
mitochondria through activation of BAX and BAK.150 
 ER stress has been shown to be caused by the accumulation of de novo 
synthesized ceramide in the ER.151  Considering the increase in ceramide synthesis 
caused by ligation of the CB2 receptor, this seems a reasonable pathway to consider.  In 
the recent report by Salazar et al., THC was shown to induce ER stress in human glioma 
cells which led to autophagy preceding apoptosis.121  They determined that autophagy 
was initiated by the inhibition of Akt by TRIB3 which leads to the down-regulation of the 
autophagy inhibitor mammalian target of rapamycin complex 1 (mTORC1) (Figure 3.27) 
which consists of mTOR, regulatory associated protein of mTOR (Raptor), and 
mammalian LST8/G-protein β-subunit like protein (GβL).  Though the authors were not 
able to determine the exact manner in which autophagy leads to apoptosis, they did 
determine that it is a necessary precursor to cannabinoid induced apoptotic cell death in 
glioblastoma.  This, in fact, does fit with our data.  The human glioblastoma cell line LN-
229 was treated with HB-I-172 at the cytotoxic EC50 and the cells were 
immunohistochemically stained for the microtubule associated protein 1 light chain 3 
(LC3B) which associates into membranes of autophagosomes during autophagy.  The 
number of cells positive for LC3B increased 6-fold over control in just 3 hours with a 20-
fold increase at the 18 hour terminal time point (data not shown).  This corroborates the 
autophagy component of cannabinoid mediated glioma toxicity as reported by Salazar et 
al.  The authors of the study however attributed the process to activation of the CB1 
receptor.  We do not believe that the CB1 receptor plays a role in the activity of HB-I-172 
due to the previously mentioned finding that it is an antagonist at CB1.  This same 
experiment needs to be repeated using U-87 MG to strengthen the evidence for 
autophagy in this mechanism of cell death. 
 I believe that there is clear evidence to support a mechanism of cell death in U-87 
MG cells following HB-I-172 exposure that involves multiple targets such as CB2 and 
GPR55.  The early intracellular events following drug exposure are most likely due to 
inverse agonism at the CB2 receptor.  The increases in cAMP and ceramide following the 
ligation of CB2 by HB-I-172 would clearly lead to the down-regulation of the PI3K/Akt 
and Raf1/MEK/ERK pathways which is seen beginning at one hour post exposure.  ER 
stress, as a result of ceramide production, is responsible for the activation of caspase 3 six 
hours before the observed activation of caspase 9.  The case for ER stress is further 
supported by other events at earlier time points such as the activity of CHOP and the 
observance of autophagy as determined by LC3B staining at 3 hours.  We believe that the 
observed changes in the cytoskeleton are due to GTPase activity resulting from ligation 
of the GPR55 receptor.  The role that GPR55 plays in the down regulation of the 
PI3K/Akt and Raf1/MEK/ERK pathways remains to be determined.  As previously 
stated, HB-I-172 could perhaps be an antagonist/inverse agonist at GPR55 which would 
lead to the down-regulation of Ras and the inhibition of the two pro-survival pathways.  
If HB-I-172 were a GPR55 agonist, an increase in the signaling of these two pathways 
would be expected.  Cross talk and inhibition of signaling between the two receptors has 
been demonstrated following anandamide ligation.152  The complete proposed signaling 
pathway is shown in Figure 3.28. 
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Figure 3.27: Proposed induction of autophagy followed by apoptosis by HB-I-172 
initiated by ER stress mediated through CB2 
See text for definitions of abbreviations. 
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Figure 3.28: Entire proposed mechanism of glioma cell death by HB-I-172 mediated by 
CB2 and GPR55 
See text for definitions of abbreviations.  
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 Much remains unanswered about the signaling cascade initiated by HB-I-172 in 
glioblastoma.  We are currently in the process of preparing for a series of assays that will 
evaluate the activation of the GTPases RhoA and Rac1.  This will give a clearer picture 
of the activity, or lack thereof, of GPR55 following exposure to HB-I-172.  Selective 
inhibition of any of a number of signaling proteins in the proposed pathways either 
pharmacologically or by shRNA knock-down would give further insight into the 
importance of each segment of the cascade initiated by HB-I-172. 
While many of the downstream signaling pathways have been identified, the 
receptor or receptors responsible for initiating the cascades are yet to be elucidated.  We 
have utilized pharmacological knockouts in an effort to identify the target of HB-I-172 
action.  Pharmacological intervention has distinct limitations due to overlap in activity of 
known agonists and antagonists of the CB1, CB2, and GPR55 receptors.  Our preliminary 
data suggests that both CB2 and GPR55 are both targets of HB-I-172 however this cannot 
be confirmed without the selective knock-down of each CB receptor subtype.  
Knowledge of the target is critical for the development of a complete mechanism of 
action for the anti-glioblastoma activity of HB-I-172.  The contributions of each 
cannabinoid receptor are currently under investigation using shRNA stably transfected 
cell lines. 
 
 
3.7 Chemical Synthesis 
 
 
3.7.1 General 
 
 In order to synthesize the core of the triaryl compounds 8-16, and provide a route 
for future functionalization of this series, an efficient synthetic route was designed.  
Commercially available syringaldehyde 17 was selected to form the A ring in the triaryl 
series.  The phenolic hydroxyl was activated for a Suzuki coupling by reaction with 
trifluoromethanesulfonic anhydride to yield intermediate 18 (Scheme 3.1).  Formation of 
the biaryl ring system was carried out via a Suzuki coupling reaction with 3,5-
dichlorophenyl boronic acid 19 in the presence of tetrakis(triphenylphosphine) palladium, 
and potassium carbonate in toluene and water to yield the aldehyde intermediate 20 
(Scheme 3.1).  The resulting aldehyde was reacted with phenyl magnesium bromide 21 
to obtain the racemic alcohol 8, which was oxidized using PCC, to yield the ketone 14.  
The ketone 14 was dimethylated using dimethylzinc and titanium (IV) chloride to yield 
compound 15 (Scheme 3.2).  The mono- and di-deprotected analogs of 14 and 15 were 
prepared by reaction with BBr3 (Scheme 3.3).  To prepare the equivalent analogs 
possessing the hydroxyl linker compounds 9 and 10 were reduced with sodium 
borohydride to give analogs 12 and 13 (Scheme 3.4). 
  All chemicals were obtained from Sigma Aldrich or Fisher Scientific Inc. 
Anhydrous solvents were obtained by distillation over either calcium hydride or metallic 
sodium and benzophenone.  Final compounds and intermediates were purified using 
column chromatography on the Biotage SP1 system employing Flash column cartridges 
or by crystallization.  NMR spectra were obtained on a Bruker 300MHz or Varian 
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Scheme 3.1: Synthesis of aldehyde intermediate 20 
(a) Triflic anhydride, 2,3,5 collidine, DCM, -20°C, 2hr; (b) (PPh3)4Pd, K2CO3, toluene / 
water, reflux, 18hr.  
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Scheme 3.2: Synthesis of compounds 8, 14, and 15 
(a) THF, 0°C, 4hr – RT overnight; (b) PCC, DCM, RT, 18 h; (c) TiCl4, Zn(CH3)2, DCM, 
-40°C, 2hr – RT overnight.  
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Scheme 3.3: Synthesis of compounds 9, 10, 16, and 11 
(a) BBr3, DCM, -78°C, 3hr – RT overnight.  
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Scheme 3.4: Synthesis of compounds 12 and 13 
(a) NaBH4, MeOH, 0°C - RT, 2hr.  
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500MHz Inova NMR.  HPLC analysis of final products was carried out by gradient 
elution using water/acetonitrile (0.1% TFA) with a gradient of 70% (3min), 50% (2min), 
and 10% (15min).  A reverse-phase ODS Hypersil column, manufactured by Thermo 
Scientific, of dimensions 4.6 x 150mm with 5µm particle size was used for HPLC 
analyses. 
 
 
3.7.2 Synthesis of 4-formyl-2,6-dimethoxyphenyl trifluoromethanesulfonate 
(18) 
 
Syringaldehyde 17 (10g, 55mmol) and 2,3,5 collidine (26.7g, 28.7ml, 220mmol) 
were dissolved in anhydrous DCM (250ml) under an atmosphere of argon,stirred, and 
cooled to -20°C followed by the dropwise addition of triflic anhydride (23.4g, 14ml, 
83mmol). The reaction was maintained at this temperature, with stirring, for 2 hours.  The 
reaction was stopped by the addition of saturated aqueous NaHCO3.  The layers were 
separated and the aqueous layer was extracted with DCM.  The organic fractions were 
combined and washed with saturated aqueous CuSO4, water, and brine and dried over 
Na2SO4.  The organic phase was concentrated and the product purified by column 
chromatography using 100% DCM as the mobile phase to yield a white to off-white 
solid.  Yield: 14.14g (82%) (Rf = 0.648; 100% DCM).   MS: m/z (ESI, pos.) = 315.1 [M + 
H]+.  1H NMR (300 MHz, CDCl3): δ 9.93 (s, 1H), 7.18 (s, 2H), 3.99 (s, 6H), 13C NMR 
(300MHz, CDCl3): δ 190.52, 153.48, 136.15, 121.00, 116.52, 106.18, 56.88.   
 
 
3.7.3 Synthesis of 3',5'-dichloro-2,6-dimethoxybiphenyl-4-carbaldehyde (20) 
 
Triflate 18 (8g, 25.5mmol) along with 3,5 dichloro phenyl boronic acid (7.25g, 
38mmol), Tetrakis(triphenylphosphine)palladium (1.18g, 1.02mmol), and K2CO3 (7.05g, 
51mmol) were added to toluene (100ml) and water (33ml) in a round bottom flask fitted 
with a condenser.  The reaction was heated to reflux for 18 hours.  The reaction was then 
allowed to cool to room temperature and diluted with diethyl ether.  The organic layer 
was separated and washed with saturated aqueous NaHCO3, water, and brine and then 
dried over Na2SO4.  The organic phase was concentrated and the product was purified by 
column chromatography using an EtOAc / hexanes gradient to yield a white solid.  Yield: 
4.97g (63%) (Rf = 0.402; 15% EtOAc / hexanes).  MS: m/z (ESI, pos.) = 333.1 [M + 
Na]+.  1H NMR (500 MHz, CDCl3): δ (ppm) 9.98 (s, 1H), 7.34 (t, 1H), 7.21 (d, 2H), 7.15 
(s, 2H), 3.83 (s, 6H).  13C NMR (500MHz, CDCl3): δ (ppm) 191.70, 158.17, 137.66, 
136.21, 134.44, 129.27, 127.73, 122.95, 105.34, 56.37. 
 
 
3.7.4 Synthesis of (3',5'-dichloro-2,6-dimethoxybiphenyl-4-
yl)(phenyl)methanol (8) 
 
Aldehyde 20 (4.94g, 15.9mmol) was dissolved in anhydrous THF (100ml), stirred 
under argon, and cooled to 0°C.  Phenyl MgBr (21) (3M solution, 1.67ml, 5mmol) was 
then added by syringe and the reaction maintained with stirring at 0°C for 4 hours and 
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then allowed to warm to room temperature overnight.  The reaction mixture was then 
diluted with diethyl ether, washed with water and brine, and dried over Na2SO4.  The 
organic phase was concentrated and the product was crystallized from EtOAc / hexanes 
to yield a white solid.  Yield: 2.1g (79%) (Rf = 0.341; 20% EtOAc / hexanes). MS: m/z 
(ESI, pos.) = 411.1 [M + Na]+.  1H NMR (500 MHz, CDCl3): δ (ppm) 7.43 (d, 2H, J = 
7Hz), 7.38 (t, 2H, J = 7.5Hz), 7.31 (t, 1H, J = 7Hz), 7.28 (t, 1H, J = 2Hz), 7.20 (d, 2H, J = 
1.5Hz), 6.67 (s, 2H), 5.85 (d, 1H, J = 3Hz), 3.72 (s, 6H), 2.26 (d, 1H, J = 3Hz), 13C NMR 
(500MHz, CDCl3): δ (ppm) 157.63, 145.94, 143.60, 137.24, 134.15, 129.73, 128.88, 
128.15, 127.02, 126.82, 102.44, 76.65, 56.12.  HPLC retention time: 10.612min; purity 
98.92%. 
 
 
3.7.5 Synthesis of (3',5'-dichloro-2,6-dimethoxybiphenyl-4-
yl)(phenyl)methanone (14) 
 
Alcohol 8 (2.1g, 5.4mmol), pyridinium chlorochromate (2.33g, 10.8mmol) and 
Celite® (2.33g) were added to anhydrous CH2Cl2 and stirred under argon at room 
temperature for 18 hours.  The reaction mixture was then filtered over a plug of silica gel 
and the filtrate was washed with saturated aqueous NaHCO3, water, and brine and then 
dried over Na2SO4.  The organic phase was concentrated and the product was purified by 
column chromatography using an EtOAc / hexanes gradient to yield an off-white solid.  
Yield: 1.77g (85%) (Rf = 0.448; 15% EtOAc / hexanes). MS: m/z (ESI, pos.) = 409.1 [M 
+ Na]+.  1H NMR (300 MHz, CDCl3): δ (ppm) 7.86 (m, 2H), 7.56 (m, 4H), 7.34 (t, 1H, J 
= 1.8Hz), 7.25 (t, 1H, J = 2.4Hz), 7.05 (s, 2H), 3.75 (s, 6H).  13C NMR (300MHz, 
CDCl3): δ 196.18, 157.64, 139.26, 137.44, 135.62, 135.30, 132.93, 130.28, 129.26, 
128.63, 128.59, 118.91, 111.49, 104.61, 56.34.  HPLC retention time: 12.051min; purity 
98.37%. 
 
 
3.7.6 Synthesis of 3',5'-dichloro-2,6-dimethoxy-4-(2-phenylpropan-2-
yl)biphenyl (15) 
 
Anhydrous CH2Cl2 was added to a round bottom flask, stirred under argon and 
cooled to -40°C using a dry ice / acetonitrile bath.  Titanium chloride (1M, 30ml, 
30mmol) was added by syringe followed by dimethyl zinc (2M, 15ml, 30mmol).  This 
mixture was allowed to stir at -40°C for 15 minutes.  Ketone (14) (1.95g, 5mmol) 
dissolved in anhydrous CH2Cl2 (100ml) was then added by syringe and the reaction 
stirred at -40°C for 2 hours and was then allowed to warm to room temperature 
overnight.  The reaction was then quenched by the addition of ice.  The organic layer was 
separated and washed with saturated aqueous NaHCO3, water, and brine and then dried 
over Na2SO4.  The organic phase was concentrated and the product was purified by 
column chromatography using an EtOAc / hexanes gradient to yield a white solid.  Yield: 
1.9g (95%) (Rf = 0.750; 15% EtOAc / hexanes). MS: m/z (ESI, pos.) = 423.1 [M + Na]+.  
1H NMR (500 MHz, CDCl3): δ 7.43 (m, 1H), 7.30 (m, 3H), 7.27 (t, 1H, J = 1.5Hz), 7.24 
(d, 1H, J = 2Hz), 7.20 (m, 2H), 6.48 (s, 2H), 3.65 (s, 6H), 1.72 (s, 6H).  13C NMR 
(500MHz, CDCl3): δ 157.04, 153.70, 150.12, 136.27, 135.36, 129.69, 129.54, 128.02, 
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126.84, 125.99, 112.49, 107.64, 102.75, 55.91, 43.50, 30.85, 30.73.  HPLC retention 
time: 13.909min; purity 96.42%. 
 
 
3.7.7 Synthesis of (3',5'-dichloro-2-hydroxy-6-methoxybiphenyl-4-
yl)(phenyl)methanone (9) and (3',5'-dichloro-2,6-dihydroxybiphenyl-4-
yl)(phenyl)methanone (10) 
 
Ketone 14 was dissolved in anhydrous CH2Cl2 (120ml), stirred under argon, and 
cooled to -78°C in a dry ice / acetone bath.  Boron tribromide (1M, 9ml, 9mmol) was 
slowly added by syringe and the reaction was allowed to stir at -78°C for 3 hours and 
then allowed to warm to room temperature and stirred an additional 16 hours.  The 
reaction was then quenched by the addition of methanol and washed with saturated 
aqueous NaHCO3, water, and brine and then dried over Na2SO4.  The organic phase was 
concentrated and the products were purified by column chromatography using an EtOAc 
/ hexanes gradient to yield an off-white solid 9 and a reddish solid 10.   
9 Yield: 314mg (21%) (Rf = 0.390; 20% EtOAc / hexanes). MS: m/z (ESI, neg.) = 
370.9 [M - H]-.  1H NMR (500 MHz, CDCl3): δ 7.84 (d, 2H, J = 8Hz), 7.61 (t, 1H, J = 
8Hz), 7.51 (t, 2H, J = 7.5Hz), 7.42 (d, 1H, J = 1.5Hz), 7.30 (d, 2H, J = 1.5Hz), 7.04 (s, 
1H), 7.00 (d, 1H, J = 1.5Hz), 5.19 (d, 1H, J = 16Hz), 3.79 (s, 3H),  13C NMR (500MHz, 
CDCl3): δ 196.18, 157.64, 153.36, 139.26, 137.44, 135.62, 135.30, 132.93, 130.28, 
129.26, 128.63, 128.59, 118.91, 111.49, 104.61, 56.34.  HPLC retention time: 10.780min; 
purity 99.03%. 
10 Yield: 106mg (7%) (Rf = 0.235; 20% EtOAc / hexanes). MS: m/z (ESI, neg.) = 
356.9 [M - H]-.  1H NMR (500 MHz, CDCl3): δ 7.84 (d, 2H, J = 7.5Hz), 7.61 (t, 1H, J = 
7.5Hz), 7.48 (m, 3H), 7.37 (d, 2H, J = 1.5Hz), 7.02 (s, 2H), 5.42 (s, 2H), 13C NMR 
(500MHz, CDCl3): δ 196.24, 153.77, 139.32, 137.18, 136.29, 134.46, 133.08, 130.34, 
129.25, 129.18, 128.61, 117.63, 110.18.  HPLC retention time: 9.618min; purity 100%. 
 
 
3.7.8 Synthesis of 3',5'-dichloro-6-methoxy-4-(2-phenylpropan-2-yl)biphenyl-
2-ol (16) and 3',5'-dichloro-4-(2-phenylpropan-2-yl)biphenyl-2,6-diol (11) 
 
Dimethyl compound 15 was reacted with boron tribromide (1M, 9ml, 9mmol) in 
anhydrous CH2Cl2 (120ml) in a manner similar to the synthesis of compounds 9 and 10.  
The products were purified by column chromatography using an EtOAc / hexanes 
gradient to yield a yellow resin 16 and a golden foam 11. 
16 Yield: 290mg (17%) (Rf = 0.317; 10% EtOAc / hexanes). MS: m/z (ESI, pos.) 
= 409.2 [M + Na]+.  1H NMR (500 MHz, CDCl3): δ 7.35 (t, 1H, J = 1.5Hz), 7.29 (m, 6H), 
7.20 (m, 1H), 6.51 (d, 1H, J = 1.5Hz), 6.37 (d, 1H, J = 1.5Hz), 4.73 (s, 1H), 3.63 (s, 3H), 
1.69 (s, 6H), 13C NMR (500MHz, CDCl3): δ 157.04, 153.70, 153.01, 150.12, 136.27, 
135.36, 129.69, 129.54, 128.02, 126.84, 125.99, 112.49, 107.64, 102.75, 55.91, 43.50, 
30.85, 30.73.  HPLC retention time: 11.716min; purity 99.48%. 
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11 Yield: 950mg (57%) (Rf = 0.167; 10% EtOAc / hexanes). MS: m/z (ESI, pos.) 
= 395.2 [M + Na]+.  1H NMR (500 MHz, CDCl3): δ 7.40 (t, 1H, J = 2Hz), 7.29 (m, 
6H),7.19 (m, 1H), 6.40 (s, 2H), 4.81 (s, 2H), 1.65 (s, 6H), 13C NMR (500MHz, CDCl3): δ 
154.07, 153.11, 149.97, 136.07, 135.34, 129.58, 129.43, 128.68, 128.58, 128.23, 111.10, 
107.27, 43.16, 30.58.  HPLC retention time: 10.271min; purity 96.81%. 
 
 
3.7.9 Synthesis of 3',5'-dichloro-4-(hydroxy(phenyl)methyl)-6-
methoxybiphenyl-2-ol (12) 
 
Ketone 9 (75mg, 0.2mmol) was dissolved in MeOH (5ml) and cooled to 0°C.  
NaBH4 (9.5mg, 0.25mmol) was slowly added with stirring.  The reaction was then 
allowed to warm to room temperature and stirred for 2 hours.  The solvent was then 
removed by rotary evaporation and the product was purified by column chromatography 
using an EtOAc / hexanes gradient to yield a white foam.   Yield: 63mg (84%) (Rf = 
0.361; 30% EtOAc / hexanes). MS: m/z (ESI, neg.) = 372.8 [M - H]-.  1H NMR (300 
MHz, MeOD): δ 7.37 (m, 6H), 7.25 (m, 2H), 6.65 (s, 1H), 6.62 (s, 1H), 5.80 (d, 1H, J = 
5Hz), 4.83 (s, 1H), 3.73 (s, 3H), 2.25 (d, 1H, J = 5.5Hz).  13C NMR (500MHz, MeOD): δ 
152.65, 153.77, 146.12, 143.03, 135.90, 135.23, 129.45, 129.40, 128.87, 128.21, 126.81, 
112.96, 106.47, 105.62, 76.09, 56.54.  HPLC retention time: 9.989min; purity 94.88%. 
 
 
3.7.10 Synthesis of 3',5'-dichloro-4-(hydroxy(phenyl)methyl)biphenyl-2,6-diol 
(13) 
 
Ketone 10 (33mg, 0.092mmol) was reacted with NaBH4 (4.8mg, 0.129mmol) in 
MeOH (4ml) in a manner similar to compound 12.  The product was purified by column 
chromatography using an EtOAc / hexanes gradient to yield a white solid.   Yield: 18mg 
(54%) (Rf = 0.441; 40% EtOAc / hexanes). MS: m/z (ESI, neg.) = 358.9 [M - H]-.  1H 
NMR (500 MHz, CDCl3): δ 7.37 (t, 1H, J = 1.5Hz), 7.33 (m, 4H), 7.29 (m, 1H), 7.25 (d, 
2H, J = 1Hz), 6.52 (s, 2H), 5.67 (s, 1H), 5.38 (s, 2H), 2.71 (s, 1H), 13C NMR (500MHz, 
CDCl3): δ 153.77, 146.12, 143.03, 135.90, 135.23, 129.45, 129.40, 128.87, 128.21, 
126.81, 112.96, 106.47, 76.09.  HPLC retention time: 9.046min; purity 96.05%. 
 
 
3.8 Experimental Methods 
 
 
3.8.1 Radioligand Binding Assays 
 
Binding affinity studies were carried out using cell membranes from HEK293 
cells transfected with the human CB1 receptor (Kd for tritiated CP-55,940 binding: 1.0 
nM) and membranes from HEK293 cells transfected with the human CB2 receptor (Kd 
for tritiated CP-55,940 binding: 1.0 nM).  Non-specific binding was determined using 10 
µM WIN55, 212-2.  Increasing concentrations of compounds to be tested were made 
ranging from 10-12 M to 10-4 M and were added in triplicate for each experiment and the 
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individual molar IC50 values were determined using GraphPad Prism software.  The 
corresponding Ki values for each drug were determined utilizing the Cheng-Prusoff 
equation and final data are presented as Ki ± standard deviation of n = 3 experiments run 
in triplicate. 
 
 
3.8.2 Cytotoxicity Assays 
 
Human glioblastoma cells U-87MG, T98G, LN-229, DBTRG-O5MG (American 
Type Culture Collection) were cultured in supplemented media according to the 
recommendations of the supplier at 37°C in an atmosphere of 5% CO2 and 95% air. Cell 
lines were plated in 96-well polystyrene flat-bottom plates (7,500 cells/well) at 70% 
confluency in a 100 µl total volume of supplemented media as indicated, and incubated 
overnight at 37°C to allow for adherence.  The media was then replaced with serum-free 
media and the cultures were treated with escalating amounts of drug and cell death was 
analyzed at 18h, using the BioTek Synergy 2 Multidetection Microplate Reader (BioTek 
Instruments, Inc.).  The percentage of viable cells present in the culture at each time point 
was calculated by comparing the absorbance value at 450nm from the CCK-8 assay 
(Dojindo Molecular Technologies) for each condition with untreated control cells.  All 
assays were conducted per manufacturer’s protocol.  All described values represent the 
average of three data points per determination and three independent determinations. 
 
 
3.8.3 Cytotoxicity Assays with Pertussis Toxin 
 
U-87 MG cells were seeded in 96-well polystyrene flat-bottom plates (7,500 
cells/well) at 70% confluency in a 100 µl total volume of complete growth media and 
incubated overnight at 37°C in an atmosphere of 5% CO2 and 95% air to allow for 
adherence.  The media was then replaced with complete growth media containing 0 or 
100ng/ml pertussis toxin and the plates returned to the incubator for 18 hours.  Drug 
solutions were prepared in DMSO at 100X concentration, and mixed 1:100 in media 
containing 1% FBS to yield the desired concentration.  After 18 hour incubation with or 
without Ptx, full serum media was removed and replaced with drug-media mixtures and 
incubated for an additional 18 hours.  10μL of CCK-8 reagent was added to each well to 
colorimetrically assess viability.  After 2-4 hours of incubation with the CCK-8 dye, 
absorbance was read at 450nm using a BioTek Synergy 2 plate reader. 
 
 
3.8.4 CB1/CB2 Functional Assays 
 
HEK-293 cell lines stably transfected with a cyclic nucleotide-gated channel and 
either human CB1 or CB2 receptors (BD Biosciences,  San Jose, CA USA) were seeded 
in poly-D-lysine coated 96-well plates at a density of 70,000 cells per well.   Plates were 
incubated at 37°C in 5% CO2 overnight prior to assay.  Plates were then removed from 
the incubator and the complete growth medium (DMEM, 10% FBS, 250µg/ml G418 and 
1µg/ml puromycin) was replaced with 100µL DMEM containing 0.25% BSA.  Next, 
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100µL membrane potential dye loading buffer (Molecular Devices) was added to each 
well.  The plates were placed back into the incubator for 30 minutes and then the baseline 
fluorescence was read on a BioTek Synergy 2 multi-mode microplate reader with 540nm 
excitation and 590nm emission filters prior to drug addition.   Drugs were added in 50µL 
DPBS containing 2.5% DMSO, 1.25µM 5’-(N-ethylcarboxamido) adenosine and 125µM 
Ro 20-1724.  Plates were then incubated at room temperature for 25 minutes and 
fluorescence measured again at 540nm excitation and 590nm emission. 
 
 
3.8.5 MSD Protein Quantification 
 
U-87 MG cells were plated in poly-D-lysine coated 10 cm Petri dishes at a density 
of 4 x 105 cells/ml with 12ml of cell suspension added to each plate.  The cells were 
grown overnight in EMEM media containing 10% FBS.  The following day the media 
was changed to EMEM media containing 1% FBS and allowed to equilibrate for 24 
hours.  This step is essential to allow basal levels of signaling protein to re-equilibrate 
due to changes in the serum concentration.  The media was then replaced at the 
appropriate time points with media containing 1% serum and KM-233 at the EC50 or 
media containing 1% serum and vehicle (DMSO).  After the incubation period with KM-
233 or vehicle, the media was removed from the dishes and transferred to a 15ml 
centrifuge tube to collect any cells that were in suspension.  Cells were then scraped from 
the surface of the dish and transferred into the same 15ml centrifuge tubes and pelleted at 
1000rpm, 4oC for 5min. Supernatant was removed and 0.5ml lysis buffer was added to 
each pellet.  The cells were suspended in the buffer and transferred to 1.5ml 
microcentrifuge tubes.  These were incubated on ice for 30 minutes, being vortexed every 
5 minutes.  The lysates were then centrifuged at 10,000 x g, 4oC for 10 minutes to clear 
cellular debris from the lysate.  The supernatant was removed and assayed for protein 
concentration using a Pierce BCA Protein Assay Kit (Thermo Scientific).  The lysates 
were then diluted with complete lysis buffer to a concentration of 20μg of protein in 25μl 
volume.  Signaling proteins were then analyzed using MSD phosphoprotein and 
intracellular marker multiplex kits which were imaged on a SECTOR Imager 2400 (Meso 
Scale Discovery) according to the manufacturer’s instructions. 
 
 
3.8.6 Caspase 9 Assay 
 
U-87 MG cells were seeded in white, opaque 96-well culture plates at a density of 
10,000 cells/well in a volume of 100µl complete growth media.  The cells were allowed 
to attach overnight and the complete growth media was changed to media containing 1% 
serum for 24 hours to equilibrate intracellular signaling pathways, then media was 
changed to either media containing 1% serum or media containing 1% serum plus HB-I-
172.  At the appropriate time intervals 100µl of Caspase-Glo® 9 Assay Reagent 
(Promega, prepared according to manufacturer’s instructions) was added to each well and 
the plate mixed on a rotary shaker for 30 seconds.  After incubation at room temperature 
for 90 minutes the luminescence was read on a Biotek Synergy 2 plate reader.  The 
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luminescent signal is proportional to the amount of caspase 9 activity present.  All data 
points represent 6 independent determinations.  
 
 
3.8.7 Mitochondrial Membrane Potential Assay 
 
U-87 MG cells were seeded in poly-D-lysine coated 96-well plates at a density of 
10,000 cells per well.  At the appropriate time points, the media was removed and 
replaced with media containing 1% FBS and either HB-I-172 at the EC50 or vehicle 
(DMSO).  After incubation with drug or vehicle, cells were dyed using DePsipher 
membrane potential dye according to the manufacturer’s instructions.  Plates were then 
imaged using an Olympus IX71 inverted fluorescence microscope (Olympus America) 
fitted with a Retiga-SRV camera (QImaging).  
 
 
3.8.8 Microscopic Analysis Using Immunohistochemical Techniques 
 
U-87 MG cells were plated in complete growth medium at a density of 15,000 
cells/well in poly-D-lysine coated 96-well polystyrene tissue culture plates and allowed 
to attach over night at 37°C in an atmosphere of 5% CO2 / 95% air.  The media was then 
replaced with media containing 1% FBS and either HB-I-172 at the EC50 or vehicle 
(DMSO).  The cells were returned to the incubator and after the appropriate periods of 
exposure to the drug or vehicle, media was aspirated and the cells fixed using 4% 
paraformaldehyde.  Cells were then stained by immunohistochemical methods using 
either a Cellomics Multiparameter Cell Death Detection Kit, Cellomics Cytoskeletal 
Rearrangement Kit, or Cellomics Cleaved PARP Activation Kit (Thermo Scientific) 
according to the manufacturer’s instructions.  Plates were then imaged using an Olympus 
IX71 inverted fluorescence microscope (Olympus America) fitted with a Retiga-SRV 
camera (QImaging). 
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Chapter 4: Design, Synthesis, and Testing of Novel Cannabinoid Ligands 
 
 
4.1 Introduction 
 
Classical cannabinoids are tricyclic terpenoid compounds consisting of a 
benzopyran core structure that are either naturally occurring in the hemp plant 
(phytocannabinoids) or are synthetic analogs of naturally occurring compounds.  Δ9-THC 
and its isomer Δ8-THC (Figure 4.1) are the prototypical members of this class of 
cannabinoids.  They bind without selectivity to the CB1 and CB2 cannabinoid receptors 
and act as agonists or partial agonists.11  The classical cannabinoids are by far the most 
well studied of the cannabinoid compounds in terms of pharmacology and structure 
activity relationships (SAR) and have gained considerable attention over the years due to 
their potential indication in the treatment of several pathological conditions from 
inflammation to asthma, inflammatory bowel diseases, multiple sclerosis, Parkinson’s 
disease, epilepsy, glaucoma, septic shock, hemorrhagic shock, and cancer. 
SAR studies have determined that there are three pharmacophoric elements 
(Figure 4.1) in classical cannabinoids that are required for cannabimimetic activity. 
These include: 
a. C-1 phenolic hydroxyl group 
b. lipophilic C-3 alkyl side chain 
c. trans ring junction at the B and C rings. 
Many studies have been performed in an attempt to elucidate the SAR of the classical 
cannabinoids with respect to modifications of the tricyclic ring and side chain 
substituents at the C-3 position.  Some of the different side chain modifications that have 
been reported thus far include the branched chain alkyls,153 unsaturated alkyls,130,154 and 
alkyls that contain a 1',1'-cyclic functionality.155 Each of these modifications has been 
directed at the goal of producing compounds that have higher binding affinities for the 
cannabinoid receptors and also that are selective for one subtype over the other.  
The potential for important therapeutic interventions from this class of 
compounds has provided the impetus to develop ligands that can elicit the desired 
physiological effects of Δ9-THC (mediated through CB2) without producing the 
unwanted CNS side effects.  In the absence of X-ray crystal structures of cannabinoid 
receptors, medicinal chemists have relied on chemical diversifications to develop new 
ligands for CB1 and CB2.  Structurally diverse compounds that probe the available space 
in the ligand binding pocket of the cannabinoid receptors have provided important 
insights into the structural requirements for binding as well as for activity.  
This need for diversity in the cannabinoid chemical arsenal has led to the 
development of compounds belonging to diverse chemical classes, both classical and 
non-classical.  The term “non-classical” was originally used to describe compounds that 
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Figure 4.1: Structure of Δ8-THC with identification of its various structural domains 
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lack the B ring of the classical cannabinoids and possess an alkyl side chain such as the 
compound CP-55,940 (Figure 4.2).  The term is now more widely used to describe any 
compound which is a ligand that binds the cannabinoid receptors which lacks the basic 
tricyclic benzopyran ring system.  An explosion of work into the non-classical arena has 
led to several new structural classes of cannabinoids.  These new compounds can be 
classified broadly into 9 distinct chemical scaffolds (Figures 4.2 and 4.3): 
a. Non-classical cannabinoids – exemplified by the CP-55,940 group of 
compounds.156  
b. Aminoalkyl indoles – exemplified by the WIN 55,212-2 group of 
compounds.157  
c. Biaryl pyrazoles – exemplified by SR14716A group of compounds.158 
d. Biphenyls – exemplified by the biaryl-gem-dimethyl heptyl group of  
 compounds.128  
e. Triaryls – exemplified by HB-I-172.127 
f. N-alkyl isatin acylhydrazones exemplified by MDA77.159 
g. Benzimidazoles as exemplified by PF-03550096.160 
h. N-arylamide oxadiazoles.161 
i. Quinolone-3 carboxamides.162 
j. Triaryl bis-sulfones.163 
These compounds act via the CB1 or CB2 receptors (and possibly GPR55) and are 
agonists, antagonists, inverse agonists, or partial agonist/antagonists.  They are 
collectively known as “cannabimimetic” agents, “cannabinergic” agents, or simply 
“cannabinoids.”  These structural classes of ligands display varying affinities as well as 
selectivity for the cannabinoid receptor subtypes, though most of the recent work has 
been in improving CB2 selectivity.  Although all of these cannabinoids essentially bind to 
the same receptors and activate or deactivate the same downstream signaling cascade, it 
is not surprising that there is increasing evidence to suggest that they display different 
binding modes.  It is believed that each structural class interacts with different critical 
amino acids in the binding pocket of each receptor.  This may explain why the differing 
chemical classes display very different selectivities for CB1/CB2.  This growing volume 
of knowledge can be exploited for the further tailoring of compounds that have specific 
binding affinity profiles. 
 The reported SAR studies of cannabinoid receptor ligands indicate that there are 
important amino acid residues in the transmembrane domains 3, 5, and 6 of the CB1 and 
the CB2 receptors that are involved in the discrimination of the cannabinergic ligands.164 
Molecular modeling studies have also suggested the importance of specific amino acid 
residues in the CB1 receptor binding pocket that play a critical role in binding to classical 
cannabinoids (Figure 4.4).  These residues are as follows: 
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Figure 4.2: Representatives of various classes of non-classical cannabinoids 
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Figure 4.3: Further representatives of various classes of non-classical cannabinoids 
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Figure 4.4: Classical cannabinoid binding interactions 
Interactions between classical cannabinoids and key amino acid residues in the ligand 
binding pocket of the cannabinoid receptors. 
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 a.  Lys 192 is a very important residue required for binding to classical 
 cannabinoids.  Due to the conformational flexibility of this residue, it can  
 adopt an orientation that interacts with the phenolic hydroxyl in the A ring  
 of classical cannabinoids.165  
 b.  A predominantly hydrophobic pocket comprised of residues Tyr 275, Trp 279, 
 Leu 359, Met 363, and Phe 200 is involved in binding to the C-3 side   
 chain.166  
 c.  Phe 189 lies in close proximity to the A ring of classical cannabinoids and may 
 be involved in aromatic stacking interactions with the ring.166  
While there is a sufficient understanding of binding interactions involved between 
ligands and the CB1 receptor, interactions at the CB2 receptor are not as well defined.  It 
has been demonstrated that compounds lacking the phenolic hydroxyl of the A ring or 
having it occupied in an ether linkage, show enhanced affinity for CB2 as well as 
selectivity.167  The observations made with these modifications indicate the involvement 
of additional specific electronic and steric factors in ligand recognition at the CB2 
receptor.  It is also important to note that elimination of the B ring of the classical 
cannabinoid core with the biphenyl or triaryl core has resulted in compounds that are 
more CB2 selective also.127-128  Work in our laboratory has also demonstrated that 
classical cannabinoids with phenyl substitutions at the C3 position have affinities shifted 
toward CB2 selectivity.108 
 
 
4.2 Design and Synthesis of Novel Compounds 
 
 
4.2.1 Rationale 
 
Upon careful review of past and current literature, it became clear that there had 
been one major design possibility that had been overlooked.  In the efforts to design 
compounds that were more CB2 selective, no group had reported heteroaromatic 
modifications to the A ring of classical cannabinoids.  Replacement of the phenyl ring 
with a pyrimidine could take advantage of the additional electronic interactions that are 
involved in ligand recognition at the CB2 receptor.  A logical extension of this design 
was the addition of the heteroaromatic motif to the triaryl scaffold as well (Figure 4.5).  
It was also speculated that the addition of the pyrimidine to these cannabinoid structures 
could increase water solubility thereby making it easier to formulate these compounds 
into dosage forms.  The decrease in lipophilicity could also limit the blood-brain barrier 
penetration of the cannabinoids which would make them ideal candidates as therapies for 
systemic inflammatory conditions. 
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Figure 4.5: General design of pyrimidyl cannabinoids 
Rationale for the pyrimidine heteroaromatic substitution in the classical cannabinoids and 
the triaryls. 
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4.2.2 Synthesis of Hexahydro Pyrimidine Classical Cannabinoids 
 
The hexadydro pyrimidine classical cannabinoids were prepared by reacting an 
intermediate pyrimidine with the appropriate terpene to generate the desired compounds 
according to the Scheme 4.1.  The hexahydro compounds are synthesized utilizing a 
modification of the Diastereoselective Domino Knoevenagel Hetero-Diels-Alder 
Reaction described by Tietz.168  The ring formations are accomplished under microwave 
conditions with the appropriately substituted pyrimidine and citronellal. 
Synthesis of the intermediate substituted pyrimidines proved to be more 
challenging.  The first strategy was to form the hexahydro core with commercially 
available 4,6 dihydroxy pyrimidine which lacked the side chain (Scheme 4.2).  The 
phenolic -OH would then be protected by a tert-butyldimethylsilyl (TBDMS) group.  The 
addition of the side chain could then be accomplished by deprotonation of the 2 position 
of the pyrimidine and then reacting with an appropriate aldehyde to form the intermediate 
alcohol or lithiation of the same position by butyl lithium and N,N-dimethylaminoethanol 
and then reacting with the aldehyde to form the alcohol or a nitrile to form the ketone 
(Scheme 4.3).  Neither of these methods was successful in formation of the side chain.  
An attempt to prime the 2 position of the pyrimidine as a Grignard substrate was also 
performed by reacting the lithiate with dimethylformamide to form an aldehyde in this 
position which could then be reacted with the appropriate magnesium halides (Scheme 
4.3).  This method was also unsuccessful. 
The second strategy involved the synthesis of ethyl 4,6-dimethoxypyrimidine-2-
carboxylate from malononitrile, methanol, and ethyl chloroxoacetate (Scheme 4.4).169  
This intermediate would then serve as the scaffold for building the side chain.  The ester 
was then reduced to the aldehyde using diisobutylaluminum hydride (DIBAL-H) to 
prepare the molecule for the Grignard reaction (Scheme 4.5).  The aldehyde was then 
reacted with an appropriate aldehyde and the resulting alcohol oxidized to the ketone 
using pyridinium chlorochromate (PCC) (Scheme 4.5).  The ketone could then be 
dimethylated using tin chloride and dimethyl zinc according to the method employed by 
Krishnamurthy.108  This method, however led to the monomethyl alcohol as did 
methylation using trimethyl aluminum (Scheme 4.6).  The same product was also formed 
when trimethyl aluminum was paired with trimethylsilyl trifluoromethanesulfonate in an 
attempt to make the alcohol a better leaving group to allow for the formation of the 
dimethyl linker170 (Scheme 4.7).  An attempt to activate the alcohol was also made by 
converting it to the mesylate;171 this however led to the vinyl elimination product 
(Scheme 4.7). 
It became clear that forming the dimethyl linker in the side chain would not be 
feasible using 4,6-dimethoxypyrimidine-2-carboxylate as the starting material.  This 
would work, however, for the hydroxyl and ketone linker.  Unfortunately, another 
problem arose.  In order to form the hexahydro classical cannabinoids, citronellal must be 
reacted with the deprotected pyrimidine, not the dimethoxy intermediate.  The differences 
between dimethoxy phenyl rings and pyrimidine rings caused difficulties here also.  
Previous methods employed by our laboratory to cleave the methyl ethers such as boron 
tribromide108,129 were unsuccessful in the deprotection of the dimethoxy pyrimidines.   
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Scheme 4.1: Synthesis of hexahydro pyrimidine classical cannabinoids  
Hexahydro pyrimidine classical cannabinoids are synthesized from R-citronellal and a 
substituted dihydroxy pyrimidine.  (a) piperidine, pyrimidine, EtOH, µwave, 200 watts, 
130°C, 1hr. 
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Scheme 4.2: Synthesis of TBDMS protected hexahydro pyrimidine classical 
cannabinoids  
TBDMS protected hexahydro pyrimidine classical cannabinoids were synthesized from 
R-citronellal and substituted dihydroxy pyrimidine.  (a) piperidine, pyrimidine, EtOH , 
µwave, 200 watts, 130°C, 1hr.  (b) TBDMS-Cl, imidazole, CH3CN, µwave, 150 watts, 
140°C, 2hr. 
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Scheme 4.3: Attempts at introduction of the hexahydro pyrimidine side chain  
Failed attempts at introduction of the hexahydro pyrimidine side chain to protected 
hexahydro pyrimidine classical cannabinoids.  (a) n-butyllithium, THF, -78°C - RT, 18hr.  
(b) n-butyllithium, N,N dimethylaminoethanol, hexanes, THF, -78°C - RT, 18hr.   
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Scheme 4.4: Synthesis of 4,6-dimethoxypyrimidine-2-carboxylate 
(a) methanol, HCl (gas), methyl acetate, -18°C, 3hr, cooled to 5°C.  (b) DIEA, CH2Cl2, 
40°C - RT, 18hr.   
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Scheme 4.5: Introduction of the side chain to 4,6-dimethoxypyrimidine-2-carboxylate 
 (a) DIBAL-H, toluene, -78°C - 25min, HCl 0°C.  (b) Phenyl MgBr, THF, 0°C – 4hr, RT 
- 18hr.  (c) PCC, Celite, CH2Cl2, RT, 18hr. 
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Scheme 4.6: Attempts at dimethylation of the ketone intermediate 
(a) TiCl4, Zn(CH3)2, CH2Cl2, -40°C – 2hr, RT – 16hr.  (b) Me3Al, CH2Cl2, 0°C – 1hr, RT 
- 16hr. 
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Scheme 4.7: Further attempts at dimethylation of the ketone intermediate 
Me3Al, TMSOSO2CF3, CH2Cl2, 0°C – 1hr, RT – 16hr.  (b) NaH, THF, 0°C – RT, 1hr, 
40°C – 3hr, methane sulfonyl chloride, RT – 1hr, 40°C - 2hr. 
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Other methods were also employed: KOH, HBr, and methylmagnesium iodide.  None of 
these proved successful (Scheme 4.8). 
This combination of difficulties led to the abandonment of methods that had 
previously been employed successfully in our laboratory for synthesis of classical 
cannabinoid side chains.  It was decided to form the side chain first which would contain 
a cyano group. This cyano group would be converted to the amidine which would be 
reacted with diethyl malonate to form the dihydroxy pyrimidine with the side chain in 
place. 
The nitriles were formed either by reaction of a commercially available aryl or 
alkyl halide with isobutyronitrile in the presence of potassium bis(trimethylsilyl)amide 
(KHMDS) (Scheme 4.9)172 or by dimethylation of a commercially available aryl or alkyl 
nitrile with methyl iodide in the presence of KHMDS (Scheme 4.10).173  The amidines 
are then formed from the nitriles by Garigipati’s reaction utilizing methylchloroaluminum 
amide formed in situ from trimethylaluminum and ammonium chloride (Scheme 4.11).174  
This method, which only provided moderate yields of around 40%, was chosen due to the 
known unreactivity of hindered nitriles in the more common Pinner reaction.  The limited 
availability of anhydrous ammonia at that time also made the Pinner reaction less 
feasible.  One major drawback of this method is that it requires an extensive two day 
purification procedure to separate the amidines from residual ammonium chloride. 
The amidines were to then be cyclized into dihydroxy pyrimidines by reacting 
with diethyl malonate.  This reaction was first attempted in the presence of N,N-
diisopropylethylamine (DIEA).  This method did not lead to formation of the desired 
product and it was speculated that perhaps DIEA was not a strong enough base to drive 
the reaction forward.  Sodium ethoxide was chosen as the base and commercially 
available solid sodium ethoxide was purchased and tried in the reaction.  This also did not 
lead to formation of the product.  The reaction was also attempted under solvent-free 
conditions and also under microwave irradiation.  Each of these efforts remained 
unfruitful.  Successful formation of the pyrimidines was finally achieved by in situ 
formation of fresh sodium ethoxide to deprotonate the amidines (Scheme 4.12).175  
Diethyl malonate was then added and the reactions heated to reflux overnight.  The solid 
sodium chloride was then filtered out and the filtrate was diluted with water and acidified 
to pH 2 causing the dihydroxy pyrimidnes to precipitate.  
The pyrimidine hexahydro classical cannabinoids were then formed by reaction of 
the appropriately substituted dihydroxy pyrimidines with R-citronellal under microwave 
conditions (Scheme 4.13).  This Domino Knoevenagel Hetero-Diels-Alder method uses 
ethanol as the solvent and piperidine and pyridine as co-solvents and as the base to 
catalyze the coupling.  The final compounds are easily purified using flash 
chromatography and are isolated in good yields of ~80%.  The side chains selected for 
these novel structures were the dimethyl heptyl, dimethyl cyclohexyl, dimethyl phenyl, 
and the dimethyl 2-thiophene.  These selections were made based on the known binding 
affinity afforded to classical cannabinoids by the linear dimethyl heptyl and by our 
groups findings that that the cyclohexyl has similar binding affinities to the linear alkyl 
and that aryl groups such as the phenyl and thiophenyl shift selectivity toward the CB2 
receptor.153a 
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Scheme 4.8: Attempts at deprotection of the dimethoxy pyrimidine intermediates 
(a) BBr3, CH2Cl2, -78°C – 3hr, RT – 16hr.  (b) HBr–AcOH (1:3), 80°C, 1h, then 
saturated NaHCO3.  (c) MeMgI, 1,4 dioxane, reflux, 16hr.  (d) KOH, 1,4 dioxane, reflux, 
16hr. 
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Scheme 4.9: Formation of nitrile intermediates from halides and isobutyronitrile 
(a) KHMDS, toluene, 80°C, 24hr. 
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Scheme 4.10: Formation of nitrile intermediates from cyanides 
(a) KHMDS, MeI, THF, 0°C, 10min. 
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Scheme 4.11: Formation of amidines from nitriles 
(a) NH4Cl, Me3Al, toluene, 0°C - RT, 45min, reflux, 18hr, then silica gel, CHCl3, RT, 
10min, then methanolic HCl, diethyl ether, RT, overnight, then isopropanol:acetone 4:1, 
RT, overnight, then diethyl ether, RT. 
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Scheme 4.12: Synthesis of dihydroxy pyrimidine intermediates 
(a) Na metal, diethyl malonate, EtOH, reflux, 18hr. 
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Scheme 4.13: Coupling of pyrimidine hexahydro classical cannabinoids 
(a) piperidine, pyrimidine, EtOH , µwave, 200 watts, 130°C, 1hr. 
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 All chemicals were obtained from Sigma Aldrich or Fisher Scientific Inc. 
Anhydrous solvents were obtained by distillation over either calcium hydride or metallic 
sodium and benzophenone.  Final compounds and intermediates were purified using 
column chromatography on the Biotage SP1 system employing Flash column cartridges 
or by crystallization.  NMR spectra were obtained on a Bruker 300MHz or Varian 
500MHz Inova NMR.  HPLC analysis of final products was carried out by gradient 
elution using water/acetonitrile (0.1% TFA) with a gradient of 70% (3min), 50% (2min), 
and 10% (15min).  A reverse-phase ODS Hypersil column, manufactured by Thermo 
Scientific, of dimensions 4.6 x 150mm with 5µm particle size was used for HPLC 
analyses. 
 
 
4.2.2.1 Synthesis of 2-methyl-2-phenylpropanenitrile (22) 
 
To a solution of fluorobenzene (5.85mL, 62.4mmol) in 100 mL of anhydrous 
toluene was added isobutyronitrile (22.5mL, 250mmol) followed by 200mL (100mmol) 
of a 0.5M solution of KHMDS in toluene.  The reaction was stirred at 80°C for 24 hours.  
The reaction was then allowed to cool to room temperature, diluted with diethyl ether, 
and washed with water and brine.  The organic fraction was then dried over sodium 
sulfate and concentrated under reduced pressure.  The product was purified by flash 
chromatography using an ethyl acetate/hexanes gradient to yield 4.57g (50%) of the 
objective compound as a brown oil.  MS: (ESI, pos.) m/z 168.0 [M + Na]+, I.R. (neat) 
nitrile 2230 cm-1, 1H NMR (500 MHz, CDCl3):  δ (ppm) 7.48 (d, 2H), 7.39 (t, 2H), 7.31 
(t, 1H), 1.73 (s, 6H). 
 
 
4.2.2.2 Synthesis of 2-cyclohexyl-2-methylpropanenitrile (23) 
 
Prepared in a manner similar to compound 22 from bromo cyclohexane (0.8 ml, 
6.4 mmol) and isobutyronitrile (2.34ml, 26mmol) in the presence of KHMDS (20ml, 
10mmol).  Purified via vacuum distillation (Bp 50-55°C at 1.1 torr).  Yield:  84%, MS: 
(ESI, pos.) m/z 174.1 [M + Na]+, I.R. (neat) nitrile 2230 cm-1, 1H NMR (500 MHz, 
CDCl3):  δ (ppm) 1.5 (m, 4H) 1.4-1.3 (m, 12H), 0.9 (s, 3H). 
 
 
4.2.2.3 Synthesis of 2-methyl-2-(thiophen-2-yl)propanenitrile (24) 
 
To a solution of 2-(thiophen-2-yl) acetonitrile (1g, 8.13mmol) in 4ml anhydrous 
THF, KHMDS (24.4mmol, 48.9ml, 0.5M in toluene) was added at 0°C.  The mixture was 
allowed to stir for 3 minutes, after which a solution of 16.26mmol iodomethane (1.13ml 
in 26ml anhydrous THF) was added slowly over a period of 10 minutes.  The mixture 
was stirred for 5 minutes and monitored by TLC.  Upon completion, the reaction was 
quenched with aqueous ammonium chloride.  The organic phase was separated with ethyl 
acetate and dried over sodium sulfate.  The product was purified via vacuum distillation.  
(bp 42°C at 1 torr) Yield:  89%, MS: (ESI, pos.) m/z 174.1 [M + Na]+, I.R. (neat) nitrile 
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2230 cm-1, 1H NMR (500 MHz, CDCl3):  δ (ppm) 7.4 ppm (d, 1H), 7.2 ppm (t, 1H), 
7.0 ppm (d, 1H), 1.9 ppm (s, 6H). 
 
 
4.2.2.4 Synthesis of 2,2-dimethyloctanenitrile (25) 
 
Prepared in a manner similar to compound 24 from octanenitrile and iodomethane 
in the presence of KHMDS.  Purified via vacuum distillation (bp 50-55°C at 1.1 torr).  
Yield:  84%, MS: (ESI, pos.) m/z 176.2 [M + Na]+, I.R. (neat) nitrile 2230 cm-1, 1H NMR 
(500 MHz, CDCl3):  δ (ppm) 1.5 (m, 4H), 1.4-1.3 (m, 12H), 0.9 (s, 3H). 
 
 
4.2.2.5 Synthesis of 2-methyl-2-phenylpropanimidamide 
hydrochloride (26) 
 
Ammonium chloride (1.06 g, 19.8mmol) was suspended in 10 ml of anhydrous 
toluene, stirred under argon, and cooled to 0°C.  To this suspension was added 9.2ml 
(18.4 mmol) of a 2M solution of trimethylaluminum in toluene.  The reaction was 
allowed to warm to room temperature and stirring was continued until the evolution of 
methane ceased (~1 hour).  Then, 1.6g (11mmol) of nitrile 22 in 5ml of anhydrous 
toluene was added and the reaction was heated to 80°C for 18 hours.  The reaction was 
then cooled to room temperature and slowly poured into a slurry of 5.5g of silica gel in 
18ml of chloroform and stirred for 5 minutes.  The silica was filtered and washed with 
methanol.  The filtrate and washings were combined and reduced to a volume of ~5ml 
and refiltered.  Then, 4ml (12mmol) of a 3N solution of methanolic HCl was added to the 
filtrate followed by 300ml of diethyl ether.  After 16 hours of stirring at room 
temperature, a white precipitate formed was subsequently filtered.  This crude solid was 
then added to 150ml of a 4:1 mixture of isopropanol-acetone and stirred for an additional 
16 hours at room temperature.  Undissolved ammonium chloride was then removed by 
filtration and the filtrate reduced to ~5ml.  After the addition of 300ml of diethyl ether the 
mixture was stirred for ~1 hour.  The white precipitate was then filtered and dried to yield 
639mg (29%) of the objective compound as the hydrochloride salt.  MS:  (ESI, pos.) m/z 
163.0 [M + H]+, 1H NMR (500 MHz, DMSO-d6):  δ (ppm) 9.27 (br.s, 2H), 8.71 (br.s, 
2H), 7.41 (m, 2H), 7.36 (m, 2H), 7.32 (m, 1H), 1.60 (s, 6H) 13C NMR (500 MHz, 
DMSO-d6):  δ (ppm) 175.91, 143.27, 128.71, 127.42, 125.65, 44.06, 26.31. 
 
 
4.2.2.6 Synthesis of 2-methyl-2-(thiophen-2-yl)propanimidamide 
hydrochloride (27) 
 
Prepared in a manner similar to compound 26 from nitrile 24 (1.5g, 9.9mmol), 
ammonium chloride (952mg, 17.8mmol), and trimethylaluminum (8.25ml, 16.5mmol).  
Yield:  36% (white solid) MS:  (ESI, pos.) m/z 169.0 [M + H]+, 1H NMR (500 MHz, 
DMSO-d6):  δ (ppm) 8.8 (br.d, 3H), 7.53 (dd, 1H), 7.13 (dd, 1H), 7.04 (dd, 1H), 1.70 (s, 
1H) 13C NMR (500 MHz, DMSO-d6):  δ (ppm) 174.75, 147.04, 127.18, 125.72, 125.48, 
41.92, 27.20. 
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4.2.2.7 Synthesis of 2-cyclohexyl-2-methylpropanimidamide 
hydrochloride (28) 
 
Prepared in a manner similar to compound 26 from nitrile 23 (6g, 40mmol), 
ammonium chloride (3.92g, 72mmol), and trimethylaluminum (33.3ml, 66.6mmol).  An 
exception to the procedure is that after the addition of methanolic HCL and diethyl ether, 
the solid that formed was ammonium chloride and the amidine remained in solution.  The 
solid was removed and the solvent evaporated to yield the product as a highly viscous 
yellow resin.  Yield: 70%.  MS:  (ESI, pos.) m/z 169.1 [M + H]+, 1H NMR (500 MHz, 
DMSO-d6):  δ (ppm) 8.84 (b.d., 3H), 1.78 (m, 3H), 1.57 (m, 3H), 1.25 (s, 2H), 1.19 (t, 
1H), 1.12 (s, 6H), 0.97 (m, 2H).  13C NMR (500 MHz, DMSO-d6):  δ (ppm) 177.11, 
44.74, 42.90, 27.47, 26.73, 26.15, 25.80, 25.73, 23.86, 21.29. 
 
 
4.2.2.8 Synthesis of 2,2-dimethyloctanimidamide hydrochloride (29) 
 
Prepared in a manner similar to compound 28 from nitrile 25 (1.5g, 9.8mmol), 
ammonium chloride (957mg, 17.6mmol), and trimethylaluminum (8.15ml, 16.3mmol).  
Product is a highly viscous yellow resin. Yield: 60.7%.  MS:  (ESI, pos.) m/z 171.1 [M + 
H]+, 1H NMR (500 MHz, DMSO-d6):  δ (ppm) 8.87 (b.d., 4H), 1.56 (t, 2H), 1.3-1.0 (m, 
14H), 0.85 (t, 3H).  13C NMR (500 MHz, DMSO-d6):  δ (ppm) 176.63, 39.97, 39.62, 
31.02, 28.87, 24.80, 23.72, 22.02, 13.92. 
 
 
4.2.2.9 Synthesis of 2-(2-phenylpropan-2-yl)pyrimidine-4,6-diol (30) 
 
Sodium metal (145mg, 6.29mmol) was reacted with 8ml of anhydrous ethanol.  
To this was added 500mg (2.52mmol) of amidines hydrochloride 26 and the reaction was 
allowed to stir at room temperature for 5 minutes.  Diethyl malonate (400mg, 2.5mmol) 
was then added and the reaction was heated to reflux overnight.  The reaction was then 
cooled to room temperature and filtered.  The solid was washed several times with 
absolute ethanol.  The filtrate and washings were combined and diluted with 2 volumes 
of water and acidified with 5N HCl to a pH of ~2 and the product precipitated.  The 
mixture was chilled and then filtered.  The solid was washed several times with diethyl 
ether and then dried to yield 218mg (38%) of an off-white solid.  MS: (ESI, neg.) m/z 
228.9 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.35 (br.s, 2H), 7.33 (t, 2H), 
7.23 (m, 3H), 5.19 (s, 1H), 1.62 (s, 6H) 
 
 
4.2.2.10 Synthesis of 2-(2-(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-
diol (31) 
 
Prepared in a manner similar to compound 30 from sodium metal (140mg, 
6.11mmol), amidine hydrochloride 27 (500mg, 2.44mmol), and diethyl malonate 
(388mg, 2.42mmol).  Product is an off-white solid.  Yield: 185mg (32%).  MS: (ESI, 
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neg.) m/z 235.1 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.39 (br.s, 2H), 7.41 
(d, 1H), 6.99 (d, 1H), 6.97 (t, 1H), 5.2 (s, 1H),1.72 (s, 6H). 
 
 
4.2.2.11 Synthesis of 2-(2-cyclohexylpropan-2-yl)pyrimidine-4,6-diol 
(32) 
 
Prepared in a manner similar to compound 30 from sodium metal (140mg, 
6.11mmol), amidine hydrochloride 28 (500mg, 2.44mmol), and diethyl malonate 
(509mg, 3.18mmol).  Product is an off-white solid.  Yield: 185mg (32%).  MS: (ESI, 
neg.) m/z 235.1 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.41 (br.s, 2H), 5.12 
(s, 1H), 1.80 (t, 1H), 1.69 (d, 2H), 1.38 (s, 1H),1.72 (d, 2H), 1.19 – 1.02 (m, 4H), 1.15 (s, 
6H), 0.94 (dd, 2H). 
 
 
4.2.2.12 Synthesis of 2-(2-methyloctan-2-yl)pyrimidine-4,6-diol (33) 
 
Prepared in a manner similar to compound 30 from sodium metal (111mg, 
4.84mmol), amidine hydrochloride 29 (400mg, 1.93mmol), and diethyl malonate 
(309mg, 1.93mmol). Product is a light peach colored solid.  Yield: 39%  MS: (ESI, neg.) 
m/z 236.8 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.33 (br.s, 2H), 5.13 (s, 
1H), 1.62 (m, 2H), 1.22 (s, 6H), 1.20 (m, 6H),  1.04 (m, 2H), 0.83 (t, 3H). 
 
 
4.2.2.13 Synthesis of (6aS,9R,10aR)-6,6,9-trimethyl-3-(2-
phenylpropan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-
d]pyrimidin-1-ol (34) 
 
Dihydroxy pyrimidine 30 (100 mg, 0.434 mmol) was added to 3ml of absolute 
ethanol in a 10ml microwave reaction vessel.  To this was also added 66µl of pyridine 
and 3µl of piperidine followed by (R)-(+)-citronellal (201mg, 235µl, 1.3mmol).  The 
reaction vessel was then sealed and irradiated at 200 watts to 130°C for 1 hour.  The 
reaction mixture was then concentrated and the product purified by flash chromatography 
using a methanol/methylene chloride gradient to yield 180 mg (69%) of the objective 
product as an off-white solid.  MS: (ESI, neg.) m/z 365.0 [M – H]-, 1H NMR (500 MHz, 
DMSO-d6): δ 11.43 (s, 1H), 7.32 (q, 2H, J = 7.5Hz), 7.21 (m, 3H), 3.06 (d, 1H, J = 
12.5Hz), 2.16 (td, 1H, J = 11Hz and 2.5Hz), 1.76 (m, 2H), 1.56 (m, 11H), 1.37 (s, 3H), 
1.01 (m, 2H), 0.87 (d, 3H, J = 6.5Hz), 0.48 (q, 1H, J = 12Hz).  13C NMR (500 MHz, 
DMSO-d6): δ (ppm) 163.44, 163.23, 145.75, 128.27, 128.23, 126.46, 126.06, 125.86, 
99.47, 79.98, 47.47, 44.48, 36.86, 34.83, 33.44, 31.81, 27.19, 27.05, 26.90, 22.40, 19.46.  
HPLC retention time: 10.631min; purity 100%. 
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4.2.2.14 Synthesis of (6aS,9R,10aR)-6,6,9-trimethyl-3-(2-(thiophen-2-
yl)propan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-
d]pyrimidin-1-ol (35) 
 
Prepared in a manner similar to compound 34 from dihydroxy pyrimidine 31 
(23mg, 0.097mmol) and (R)-(+)-citronellal (45mg, 53µl, 0.292mmol).  Yield: 46% MS: 
(ESI, neg.) m/z 371.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ 11.52 (s, 1H), 7.40 (d, 
1H, J = 4.5Hz), 6.97 (m, 2H), 3.06 (d, 1H, J = 12Hz), 2.16 (td, 1H, J = 11.5Hz and 2Hz), 
1.70 (m, 8H), 1.50 (m, 2H), 1.36 (s, 3H), 1.06 (m, 5H), 0.87 (d, 3H, J = 6.5Hz), 0.47 (q, 
1H, J = 12Hz).  13C NMR (500MHz, DMSO-d6): δ (ppm) 163.46, 163.07, 150.12, 
126.70, 126.64, 124.86, 124.39, 99.63, 80.07, 47.42, 42.72, 36.79, 34.80, 33.42, 31.80, 
28.08, 28.00, 27.02, 26.87, 22.40, 19.43.  HPLC retention time: 10.580min; purity 
98.04%. 
 
 
4.2.2.15 Synthesis of (6aS,9R,10aR)-3-(2-cyclohexylpropan-2-yl)-6,6,9-
trimethyl-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-
d]pyrimidin-1-ol (36) 
 
Prepared in a manner similar to compound 34 from dihydroxy pyrimidine 32 
(100mg, 0.42mmol) and (R)-(+)-citronellal (194mg, 228µl, 1.26mmol).  Yield: 36% MS: 
(ESI, neg.) m/z 371.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ 11.52 (s, 1H), 3.10 (d, 
1H, J = 12.5Hz), 2.16 (td, 1H, J = 11Hz and 2.5Hz), 1.73 (m, 5H), 1.52 (m, 2H), 1.34 (s, 
3H), 1.26 (m, 4), 1.10 (m, 10H), 1.05 (s, 3H), 0.96 (m, 2H), 0.88 (d, 3H, J = 6.5Hz), 0.48 
(q, 1H, J = 12Hz).  13C NMR (500MHz, DMSO-d6): δ (ppm) 165.54, 163.41, 163.34, 
98.96, 79.78, 47.47, 44.61, 43.13, 36.97, 34.83, 33.45, 31.83, 27.17, 27.03, 26.90, 26.39, 
26.06, 22.41, 22.05, 21.99, 19.41.  HPLC retention time: 11.732min; purity 97.65%. 
 
 
4.2.2.16 Synthesis of (6aS,9R,10aR)-6,6,9-trimethyl-3-(2-methyloctan-
2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol 
(37) 
 
Prepared in a manner similar to compound 34 from dihydroxy pyrimidine 33 
(100mg, 0.42mmol) and (R)-(+)-citronellal (194mg, 228µl, 1.26mmol).  Yield: 31% MS: 
(ESI, neg.) m/z 373.1 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ 11.57 (s, 1H), 3.10 (d, 
1H, J = 12.5Hz), 2.16 (td, 1H, J = 11Hz and 2.5Hz), 1.75 (m, 2H), 1.56 (m, 6H), 1.34 (s, 
3H), 1.18 (m, 12H), 1.02 (m, 5H), 0.89 (d, 3H, J = 6.5Hz), 0.82 (t, 3H, J = 7Hz), 0.48 (q, 
1H, J = 12Hz).  13C NMR (500MHz, DMSO-d6): δ (ppm) 163.79, 163.47, 163.14, 99.01, 
79.78, 47.52, 44.58, 40.14, 36.95, 34.85, 33.44, 31.82, 30.98, 29.00, 27.03, 26.89, 25.71, 
25.59, 23.87, 22.42, 22.02, 19.37, 13.91.  HPLC retention time: 12.503min; purity 
95.12%. 
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4.2.3 Synthesis of Pyrimidine Non-Classical Cannabinoids 
 
The first attempts at synthesis of the heteroaromatic triaryl compounds utilized 
reactions that were successfully employed in the creation of the carbocyclic triaryl 
compounds.127  The rationale was that the previously created dihydroxy pyrimidines 
(Compounds 30, 31, 32, and 33) could be activated for Suzuki coupling to introduce the 
aromatic C ring.  This was accomplished by bromination of the dihydroxy pyrimidines in 
the 5 position by N-bromosuccinimide (Scheme 4.14).176  This brominated compound 
would then be a substrate for the palladium catalyzed Suzuki reaction.  This reaction, 
however, was not successful in formation of the triaryl coupled products (Scheme 4.15). 
 With the experience gained from the successful formation of the dihydroxy 
pyrimidines, it was decided to form the final compounds by cyclization of the pyrimidine 
ring with the side chain and the aromatic C ring already in place.  This could be 
accomplished in a reaction similar to the formation of the dihydroxy pyrimidines by 
reaction of an amidine with a substituted diethyl malonate (Scheme 4.16).  The 2-
position substituted diethyl malonates can be formed by copper catalyzed coupling of an 
alkyl or aryl halide and diethyl malonate (Scheme 4.17).177  Six substituted malonates 
were reacted with four amidine hydrochlorides to successfully yield fifteen pyrimidine 
nonclassical cannabinoids (Figure 4.6).  Some of the combinations of synthons would 
not react to yield a substituted pyrimidine product in every permutation .  The 
purification of theses compounds was more involved than the dihydroxy pyrimidines 
which were precipitated by acidification.  The pyrimidine nonclassical cannabinoids 
formed a gummy resin in the aqueous solution upon acidification.  This was extracted 
with ethyl acetate, dried over sodium sulfate, concentrated by rotary evaporation, and 
purified using flash chromatography. 
 All chemicals were obtained from Sigma Aldrich or Fisher Scientific Inc. 
Anhydrous solvents were obtained by distillation over either calcium hydride or metallic 
sodium and benzophenone.  Final compounds and intermediates were purified using 
column chromatography on the Biotage SP1 system employing Flash column cartridges 
or by crystallization.  NMR spectra were obtained on a Bruker 300MHz or Varian 
500MHz Inova NMR.  HPLC analysis of final products was carried out by gradient 
elution using water/acetonitrile (0.1% TFA) with a gradient of 70% (3min), 50% (2min), 
and 10% (15min).  A reverse-phase ODS Hypersil column, manufactured by Thermo 
Scientific, of dimensions 4.6 x 150mm with 5µm particle size was used for HPLC 
analyses. 
 
 
4.2.3.1 Synthesis of diethyl 2-m-tolylmalonate (38) 
 
 A two-necked round-bottomed flask was charged sequentially with CuI (0.114 g, 
0.6 mmol), 2-picolinic acid (0.148 g, 1.2 mmol), and CsCO3 (5.89 g, 18 mmol).  The 
flask was evacuated and back filled with nitrogen 3 times.  Anhydrous 1,4-dioxane 
(10 ml) was added volumetrically followed by distilled diethyl malonate (1.9 ml, 
12 mmol) and 3-iodotoluene (0.8ml, 6 mmol).  The reaction was heated to 70°C for 30 
hours.  After monitoring the progress by TLC, the reaction was cooled to room 
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Scheme 4.14: Synthesis of 5-bromo dihydroxy pyrimidines 
(a) NBS, DMF, RT, 40min. 
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Scheme 4.15: Attempt at synthesis of pyrimidine triaryl compounds 
Failed attempt at synthesis of pyrimidine triaryl compounds using palladium catalyzed 
Suzuki coupling.  (a) (PPh3)4Pd, K2CO3, toluene / water, reflux, 18hr. 
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Scheme 4.16: Synthesis of pyrimidine nonclassical cannabinoids 
(a) Na metal, EtOH, diethyl malonate, reflux, 18hr. 
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Scheme 4.17: Synthesis of 2-position substituted diethyl malonates 
(a) CuI, 2-picolinic acid, CsCO3, aryl or alkyl iodide, diethyl malonate, 1,4-dioxane, 
70°C, 30hr. 
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Figure 4.6: Pyrimidine non-classical cannabinoids 
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temperature, diluted with ethyl acetate and washed with ammonium chloride.  The 
organic phase was dried over sodium sulfate, concentrated, and the product purified by 
column chromatography using a 1:9 ethyl acetate/hexane mixture to yield the product as 
a colorless oil.  Yield:  92%, Rf  = 0.48 (ethyl acetate/hexane = 1:9).  MS: (ESI, pos.) m/z 
273.0 [M + Na]+, 1H NMR (500 MHz, CDCl3): δ (ppm) 7.12-7.3 (m, 4H), 4.62 (s, 1H), 
4.20-4.28 (m, 4H),2.27 (s, 3H), 1.22-1.25 (m, 6H). 
 
 
4.2.3.2 Synthesis of diethyl 2-(3,5-dichlorophenyl)malonate (39) 
 
Compound 39 was prepared in a manner similar to compound 38 from CuI 
(0.17 g, 0.89 mmol), 2-picolinic acid (0.22 g, 1.78 mmol), CsCO3 (8.7 g, 26.7 mmol), 
diethyl malonate (2.9ml, 17.8mmol), and 1,3-dichloro-5-iodobenzene (2.4g, 8.9mmol).  
Rf  =  0.41 (ethyl acetate/hexane = 1:9).  MS: (ESI, pos.) m/z 328 [M + Na]+, 1H NMR 
(500 MHz, CDCl3): δ (ppm) 7.34 (m, 3H), 4.54 (s, 1H), 4.25 (m, 4H), 1.28 (t, 6H). 
 
 
4.2.3.3 Synthesis of diethyl 2-cyclohexylmalonate (40) 
 
Compound 40 was prepared in a manner similar to compound 38 from CuI 
(0.114 g, 0.6 mmol), 2-picolinic acid (0.148 g, 1.2 mmol), CsCO3 (5.89 g, 18 mmol), 
diethyl malonate (1.9ml, 12mmol), and iodocyclohexane (0.8ml, 6mmol).  Yield:  94%, 
Rf  = 0.59 (ethyl acetate/hexane = 1:9).  MS: (ESI, pos.) m/z 265 [M + Na]+, 1H NMR 
(500 MHz, CDCl3): δ (ppm) 4.22-4.14 (m, 4H), 3.12 (d, 1H), 2.14-2.05 (m, 1H), 1.75-
1.63 (m, 5H), 1.34-1.24 (m, 8H), 1.20-1.20 (m, 3H). 
 
 
4.2.3.4 Synthesis of diethyl 2-(pyridin-2-yl)malonate (41) 
 
Compound 41 was prepared in a manner similar to compound 38 from CuI 
(0.114 g, 0.6 mmol), 2-picolinic acid (0.148 g, 1.2 mmol), CsCO3 (5.89 g, 18 mmol), 
diethyl malonate (1.9ml, 12mmol), and 2-bromopyridine (0.59ml, 6mmol).  Yield:  88%, 
Rf  = 0.32 (ethyl acetate/hexane = 3:7).  MS: (ESI, pos.) m/z 260 [M + Na]+, 1H NMR 
(500 MHz, CDCl3): δ (ppm) 8.5 (d, 1H), 7.7 (d, 1H), 7.62-7.58 (m, 1H), 7.18-7.12 (m, 
1H), 4.80 (s, 1H), 4.21-4.15 (m, 4H), 1.21 (t, 6H). 
 
 
4.2.3.5 Synthesis of diethyl 2-benzylmalonate (42) 
 
Compound 42 was prepared in a manner similar to compound 38 from CuI 
(0.114 g, 0.6 mmol), 2-picolinic acid (0.148 g, 1.2 mmol), CsCO3 (5.89 g, 18 mmol), 
diethyl malonate (1.9ml, 12mmol), and benzyl bromide (1.44ml, 6mmol).  Yield:  78%.  
Rf  = 0.52 (ethyl acetate/hexane = 1:9).  MS: (ESI, pos.) m/z 273 [M + Na]+, 1H NMR 
(300 MHz, CDCl3): δ (ppm) 7.24 (m, 5H), 4.15 (q, 4H), 3.66 (t, 1H), 3.22 (d, 2H), 1.18 
(t, 6H). 
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4.2.3.6 Synthesis of diethyl 2-hexylmalonate (43) 
 
Compound 43 was prepared in a manner similar to compound 38 from CuI 
(0.019 g, 0.1mmol), 2-picolinic acid (0.025 g, 0.2 mmol), CsCO3 (0.977g, 3mmol), 
diethyl malonate (0.3ml, 2mmol), and 1-iodohexane (0.15ml, 1mmol).  Yield:  91%, Rf  = 
0.44 (ethyl acetate/hexane = 1:9).  MS: (ESI, pos.) m/z 267 [M + Na]+, 1H NMR (300 
MHz, CDCl3): δ (ppm) 4.11-4.40 (m, 4H), 331 (t, 1H), 1.80 (m, 2H), 1.38 (m, 2H), 1.1-
1.4 (m, 12H), 0.8 (t, 3H).  
 
 
4.2.3.7 Synthesis of 2-(2-phenylpropan-2-yl)-5-m-tolylpyrimidine-4,6-
diol (44) 
 
Sodium metal (115mg, 5mmol) was reacted with 4ml of anhydrous ethanol.  To 
this was added 400 mg (2 mmol) of 2-methyl-2-phenylpropanimidamide hydrochloride 
26 and the reaction was allowed to stir at room temperature for 5 minutes.  Diethyl 2-m-
tolylmalonate 38 (500mg, 2mmol) was then added in 2ml of anhydrous ethanol and the 
reaction was heated to reflux overnight.  The reaction was then cooled to room 
temperature and filtered.  The solid was washed several times with absolute ethanol.  The 
filtrate and washings were combined and diluted with 2 volumes of water and acidified 
with 5N HCl to a pH of ~2 and the product precipitated as a sticky resin.  The product 
was extracted with ethyl acetate and dried over sodium sulfate.  The organic phase was 
concentrated and the product purified on a Biotage SP-1 flash chromatography using a 
MeOH/CH2Cl2 gradient.  Yield: 39% MS: (ESI, neg.) m/z 319.0 [M – H]-, 1H NMR (500 
MHz, DMSO-d6): δ (ppm) 11.50 (br.s, 2H), 7.36 (t, 2H, J = 7Hz), 7.30 (d, 2H, J = 
7.5Hz), 7.25 (m, 3H), 7.19 (t, 1H, J = 7.5Hz), 7.01 (d, 1H, J = 7.5Hz), 2.29 (s, 3H), 1.68 
(s, 6H).  13C NMR (500MHz, DMSO-d6): δ (ppm) 145.79, 135.93, 132.54, 130.96, 
128.31, 127.56, 127.07, 126.75, 126.51, 126.03, 100.61, 44.64, 27.26, 21.08.  HPLC 
retention time: 9.724min; purity 99.65%. 
 
 
4.2.3.8 Synthesis of 2-(2-(thiophen-2-yl)propan-2-yl)-5-m-
tolylpyrimidine-4,6-diol (45) 
 
Compound 45 was prepared in a similar manner to compound 44 from sodium 
metal (140mg, 6.11mmol), EtOH (8ml), 2-methyl-2-(thiophen-2-yl)propanimidamide 
hydrochloride 27 (500mg, 2.44mmol), and diethyl 2-m-tolylmalonate 38 (611mg, 
2.44mmol).  Yield 4.3%, MS:  (ESI, neg.) m/z 324.9 [M – H]-, 1H NMR (500 MHz, 
DMSO-d6):  δ (ppm) 11.51 (br.s, 2H), 7.44 (dd, 1H, J = 5Hz and 1Hz), 7.23 (s, 1H), 7.20 
(q, 2H, J = 8Hz), 7.06 (dd, 1H, J = 3.5Hz and 1.5Hz), 7.00 (m, 2H), 2.28 (s, 3H), 1.70 (s, 
6H).  13C NMR (500MHz, DMSO-d6): δ (ppm) 150.33, 136.00, 132.46, 130.96, 127.57, 
127.14, 126.85, 126.77, 126.46, 124.91, 124.40, 123.41, 100.76, 42.88, 28.14, 21.11.  
HPLC retention time: 8.060min; purity 95.35%. 
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4.2.3.9 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-m-tolylpyrimidine-
4,6-diol (46) 
 
Compound 46 was prepared in a similar manner to compound 44 from sodium 
metal (140mg, 6.11mmol), EtOH (6ml), 2-cyclohexyl-2-methylpropanimidamide 
hydrochloride  28 (500mg, 2.44mmol), and diethyl 2-m-tolylmalonate 38 (796mg, 
3.18mmol).  Yield 21%, MS:  (ESI, neg.) m/z 325 [M – H]-, 1H NMR (500 MHz, DMSO-
d6):  δ (ppm) 11.55(br.s), 7.26 (s, 1H) 7.23 (d, 1H, J = 8Hz), 7.17 (t, 1H, J = 7.5Hz), 6.99 
(d, 1H, J = 7.5Hz), 2.28 (s, 3H), 1.87 (t, 1H, J = 12Hz), 1.72 (d, 2H, J = 12.5Hz), 1.44 (d, 
2H, J = 12Hz), 1.20 (s, 6H), 1.18 to 1.06 (m, 4H), 0.99 (m, 2H).  13C NMR (500MHz, 
DMSO-d6): δ (ppm) 170.36, 165.93, 135.90, 132.80, 131.01, 127.60, 127.07, 126.63, 
100.04, 59.77, 44.84, 43.29, 27.22, 26.41, 26.06, 22.11, 21.13, 20.78, 14.10.  HPLC 
retention time: 10.095min; purity 99.23%. 
 
 
4.2.3.10 Synthesis of 2-(2-methyloctan-2-yl)-5-m-tolylpyrimidine-4,6-
diol (47) 
 
Compound 47 was prepared in a similar manner to compound 44 from sodium 
metal (111mg, 4.83mmol), EtOH (6ml), 2,2-dimethyloctanimidamide hydrochloride 29 
(400mg, 1.93mmol), and diethyl 2-m-tolylmalonate 38 (483mg, 1.93mmol).  Yield 
11.2%, MS:  (ESI, pos.) m/z 351.3 [M + Na]+, 1H NMR (500 MHz, DMSO-d6):  δ (ppm) 
11.58 (br.s, 2H), 7.26 (s, 1H) 7.22 (d, 1H, J = 7.5Hz), 7.19 (t, 1H, J = 7.5Hz), 7.01 (d, 1H, 
J = 7.5Hz), 2.91 (s, 3H), 1.68 (m, 2H), 1.28 (s, 6H), 1.24 to 1.07 (m, 16H), 0.853 (m, 
3H).  13C NMR (500MHz, DMSO-d6): δ (ppm) 179.57, 165.84, 136.39, 133.20, 131.47, 
128.08, 127.55, 127.16, 100.64, 48.48, 40.61, 31.53, 29.57, 26.21, 25.90, 24.48, 22.53, 
21.61, 14.39.  HPLC retention time: 9.685min; purity 91.54%. 
 
 
4.2.3.11 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-phenylpropan-2-
yl)pyrimidine-4,6-diol (48) 
 
Compound 48 was prepared in a similar manner to compound 44 from sodium 
metal (115mg, 5mmol), EtOH (6ml), 2-methyl-2-phenylpropanimidamide hydrochloride 
26 (400mg, 2mmol), and diethyl 2-(3,5-dichlorophenyl)malonate 39 (610mg, 2mmol).  
Yield: 27%; MS:  (ESI, neg.) m/z 372.9 [M – H]-, 1H NMR (500 MHz, DMSO-d6): δ 
(ppm) 12.48 (br.s, 2H), 7.61 (d, 2H, J = 2Hz), 7.49 (s, 1H), 7.31 (m, 2H), 7.27 (m, 3H), 
1.68 (s, 6H).  13C NMR (500MHz, DMSO-d6): δ (ppm) 172.33, 171.56, 141.09, 139.75, 
134.08, 133.23, 129.02, 128.97, 126.78, 126.73, 110.00, 45.28, 32.74.  HPLC retention 
time: 9.335min; purity 92.38%. 
 
 
 
 
 
138 
 
4.2.3.12 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-(thiophen-2-
yl)propan-2-yl)pyrimidine-4,6-diol (49) 
 
Compound 49 was prepared in a similar manner to compound 44 from sodium 
metal (113mg, 4.9mmol), EtOH (6ml), 2-methyl-2-(thiophen-2-yl)propanimidamide 
hydrochloride 27 (400mg, 1.95mmol), and diethyl 2-(3,5-dichlorophenyl)malonate 39 
(595mg, 1.95mmol).  Yield: 32%; MS: (ESI, neg.) m/z 378.8 [M – H]-, 1H NMR (500 
MHz, DMSO-d6): δ (ppm) 7.62 (s, 2H), 7.48 (s, 1H), 7.43 (d, 1H, J = 5.5Hz), 7.06 (d, 
1H, J = 3.5Hz), 6.99 (t, 1H, J = 5Hz), 1.77 (s, 6H).  13C NMR (500MHz, DMSO-d6): δ 
(ppm) 172.39, 171.61, 141.14, 139.83, 134.12, 133.24, 129.13, 128.96, 126.87, 126.71, 
99.19, 39.41, 28.08.  HPLC retention time: 9.335min; purity 90.19%. 
 
 
4.2.3.13 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-(3,5-
dichlorophenyl)pyrimidine-4,6-diol (50) 
 
Compound 50 was prepared in a similar manner to compound 44 from sodium 
metal (140mg, 6.1mmol), EtOH (6ml), 2-cyclohexyl-2-methylpropanimidamide 
hydrochloride 28 (500mg, 2.44mmol), and diethyl 2-(3,5-dichlorophenyl)malonate 39 
(970mg, 3.18mmol).  Yield: 7%; MS: (ESI, neg.) m/z 379.0 [M – H]-, 1H NMR (500 
MHz, DMSO-d6): δ (ppm) 7.69 (s, 2H), 7.38 (s, 1H), 1.87 (m, 1H), 1.68 (m, 3H), 1.44 (d, 
2H, J = 11Hz), 1.21 (s, 6H), 1.12 (m, 3H), 0.98 (m, 2H).  13C NMR (500MHz, DMSO-
d6): δ (ppm) 172.38, 171.61, 140.65, 135.68, 133.24, 128.46, 100.25, 59.77, 44.10, 42.98, 
27.22, 26.49, 26.02, 21.67, 20.34, 14.10.  HPLC retention time: 8.932min; purity 94.24%. 
 
 
4.2.3.14 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-methyloctan-2-
yl)pyrimidine-4,6-diol (51) 
 
Compound 51 was prepared in a similar manner to compound 44 from sodium 
metal (111mg, 4.83mmol), EtOH (8ml), 2,2-dimethyloctanimidamide hydrochloride 29  
(400mg, 1.93mmol), and diethyl 2-(3,5-dichlorophenyl)malonate 39 (589mg, 1.93mmol).  
Yield: 14%; MS: (ESI, neg.) 380.9 m/z [M – H]-, 1H NMR (500 MHz, methanol-d4): δ 
(ppm) 7.57 (s, 2H), 7.24 (s, 1H), 1.71 (m, 2H), 1.34 (m, 5H), 1.28 (s, 6H), 1.20 (m, 3H), 
0.88 (t, 3H, J = 6Hz).  13C NMR (500MHz, DMSO-d6): δ (ppm) 170.98, 169.54, 139.32, 
135.79, 131.05, 129.09, 100.15, 48.48, 40.61, 30.48, 29.79, 26.92, 25.43, 23.76, 22.53, 
14.41.  HPLC retention time: 9.132min; purity 96.84%. 
 
 
4.2.3.15 Synthesis of 5-cyclohexyl-2-(2-phenylpropan-2-yl)pyrimidine-
4,6-diol (52) 
 
Compound 52 was prepared in a similar manner to compound 44 from sodium 
metal (145mg, 6.3mmol), EtOH (6ml), 2-methyl-2-phenylpropanimidamide 
hydrochloride 26 (500mg, 2.5mmol), and diethyl 2-cyclohexylmalonate 40 (606mg, 
2.5mmol).  Yield:  39% (yellow waxy solid) MS:  (ESI, neg.) m/z 311.0 [M – H]-, 1H 
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NMR (500 MHz, DMSO-d6):  δ (ppm) 11.30 (br.s, 1H), 10.93 (br.s., 1H), 7.33 (m, 2H), 
7.23 (m, 3H), 2.72 (tt, 1H, J = 12.5Hz and 3Hz), 1.92 (q, 2H, J = 13Hz), 1.70 (d, 2H, J = 
12.5Hz), 1.62 (s, 7H), 1.38 (d, 2H, J = 12Hz), 1.18 (m, 3H).  13C NMR (500MHz, 
DMSO-d6): δ (ppm) 164.35, 145.90, 128.28, 126.46, 126.02, 104.19, 44.34, 33.28, 28.87, 
27.25, 26.67, 25.75.  HPLC retention time: 8.983min; purity 99.46%. 
 
 
4.2.3.16 Synthesis of 5-cyclohexyl-2-(2-(thiophen-2-yl)propan-2-
yl)pyrimidine-4,6-diol (53) 
 
Compound 53 was prepared in a similar manner to compound 44 from sodium 
metal (140mg, 6.1mmol), EtOH (6ml), 2-methyl-2-(thiophen-2-yl)propanimidamide 
hydrochloride 27 (500mg, 2.44mmol), and diethyl 2-cyclohexylmalonate 40 (591mg, 
2.44mmol).  Yield 8%, MS:  (ESI, neg.) m/z 316.9 [M – H]-, 1H NMR (500 MHz, 
DMSO-d6):  δ (ppm) 11.36 (br.s, 1H), 10.88 (br.s, 1H) 7.39 (d, 1H, J = 5Hz), 7.01 (s, 
1H), 6.96 (t, 1H, J = 3.5Hz), 2.72 (t, 1H, J = 12Hz), 1.91 (q, 2H, J = 12.5Hz), 1.72 (s, 
6H), 1.61 (d, 1H, J = 10.5Hz), 1.36 (d, 2H, J = 12Hz), 1.18 (m, 3H).  13C NMR (500MHz, 
DMSO-d6): δ (ppm) 164.41, 126.72, 124.80, 124.29, 109.53, 104.31, 48.61, 42.60, 33.27, 
28.80, 28.11, 26.63, 25.72.  HPLC retention time: 8.934min; purity 100%. 
 
 
4.2.3.17 Synthesis of 5-cyclohexyl-2-(2-cyclohexylpropan-2-
yl)pyrimidine-4,6-diol (54) 
 
Compound 54 was prepared in a similar manner to compound 44 from sodium 
metal (140mg, 6.1mmol), EtOH (6ml), 2-cyclohexyl-2-methylpropanimidamide 
hydrochloride 28 (500mg, 2.44mmol), and diethyl 2-cyclohexylmalonate 40 (770mg, 
3.18mmol).  Yield 1.3%, MS:  (ESI, neg.) m/z 316.9 [M – H]-, 1H NMR (500 MHz, 
DMSO-d6):  δ (ppm) 11.43 (br.s, 1H), 10.64 (br.s, 1H) 2.72 (tt, 1H, J = 12.5Hz and 
3.5Hz), 1.91 (m, 2H), 1.81 (t, 1H, J = 12Hz), 1.71 (d, 4H, J = 12Hz), 1.61 (m, 2H), 1.37 
(d, 2H, J = 12.5Hz), 1.23 to 0.90 (m, 16H).  13C NMR (500MHz, DMSO-d6): δ (ppm) 
164.44, 164.29, 103.69, 44.73, 42.98, 33.25, 28.94, 27.18, 26.68, 26.38, 26.06, 25.75, 
22.11.  HPLC retention time: 10.273min; purity 98.33%. 
 
 
4.2.3.18 Synthesis of 5-cyclohexyl-2-(2-methyloctan-2-yl)pyrimidine-
4,6-diol (55) 
 
Compound 55 was prepared in a similar manner to compound 44 from sodium 
metal (111mg, 4.84mmol), EtOH (8ml), 2,2-dimethyloctanimidamide hydrochloride 29 
(400mg, 1.93mmol), and diethyl 2-cyclohexylmalonate 40 (468mg, 1.93mmol).  Yield 
4.5%, MS:  (ESI, neg.) m/z 319.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6): 2.72 (tt, 1H, 
J = 12Hz and 3Hz), 1.92 (m, 2H), 1.70 (d, 2H, J = 12.5Hz), 1.61 (t, 4H, J = 8.5Hz), 1.37 
(d, 2H, J = 12Hz), 1.23 to 1.16 (m, 16H), 1.04 (m, 2H), 0.83 (m, 4H).  13C NMR 
(500MHz, DMSO-d6): δ (ppm) 164.35, 163.82, 103.74, 40.26, 33.23, 31.03, 29.04, 28.90, 
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26.67, 25.75, 25.71, 23.95, 22.04, 13.91.  HPLC retention time: 10.304min; purity 
99.06%. 
 
 
4.2.3.19 Synthesis of 5-(pyridin-2-yl)-2-(2-(thiophen-2-yl)propan-2-
yl)pyrimidine-4,6-diol (56) 
 
Compound 56 was prepared in a similar manner to compound 44 from sodium 
metal (112mg, 4.88mmol), EtOH (6ml), 2-methyl-2-(thiophen-2-yl)propanimidamide 
hydrochloride 27 (400mg, 1.95mmol), and diethyl 2-(pyridin-2-yl)malonate 41 (463mg, 
1.95mmol).  Yield 1%, MS:  (ESI, pos.) m/z 336.1 [M + Na]+, 1H NMR (500 MHz, 
DMSO-d6):  δ (ppm) 9.13 (d, 1H, J = 8.5Hz) 8.57 (s, 1H), 8.12 (td, 1H, J = 7.5Hz and 
1.5Hz), 7.41 (q, 2H, J = 7.5Hz), 7.59 (d, 1H, J = 4), 6.98 (t, 1H, J = 4Hz), 1.73 (s, 6H).  
HPLC retention time: 8.367min; purity 97.78%. 
 
 
4.2.3.20 Synthesis of 5-benzyl-2-(2-methyloctan-2-yl)pyrimidine-4,6-
diol (57) 
 
Compound 57 was prepared in a similar manner to compound 44 from sodium 
metal (111mg, 4.84mmol), EtOH (6ml), 2,2-dimethyloctanimidamide hydrochloride 29 
(400mg, 1.93mmol), and diethyl 2-benzylmalonate 42 (483mg, 1.93mmol).  Yield 21% 
MS:  (ESI, neg.) m/z 327.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6):  δ (ppm) 11.34 
(br.s), 7.21 (m, 4H) 7.11 (m, 1H), 3.57 (s, 2H), 1.63 (m, 2H), 1.22 (s, 6H), 1.21 to 1.19 
(m, 6H), 1.04 (m, 2H), 0.82 (t, 3H, J = 6.5Hz).  13C NMR (500MHz, DMSO-d6): δ (ppm) 
164.70, 141.19, 128.23, 127.97, 125.49, 99.07, 54.92, 40.37, 39.77, 31.02, 29.03, 27.81, 
25.77, 23.97, 22.02, 13.91.  HPLC retention time: 9.716min; purity 100%. 
 
 
4.2.3.21 Synthesis of 5-hexyl-2-(2-methyloctan-2-yl)pyrimidine-4,6-
diol (58) 
 
Compound 58 was prepared in a similar manner to compound 44 from sodium 
metal (140mg, 6.05mmol), EtOH (6ml), 2,2-dimethyloctanimidamide hydrochloride 29 
(500mg, 2.42mmol), and diethyl 2-hexylmalonate 43 (591mg, 2.42mmol).  Yield 9%, 
MS:  (ESI, neg.) m/z 321.0 [M – H]-, 1H NMR (500 MHz, DMSO-d6):  δ (ppm) 11.47 
(br.s, 2H), 4.10 (q, 1H, J = 7.5Hz) 3.29 (t, 1H, J = 7.5Hz), 2.23 (t, 2H, J = 7.5Hz), 1.71 
(q, 1H, J = 7Hz), 1.62 (m, 2H), 1.36 (t, 2H, J = 6.5Hz), 1.24 (s, 6H), 1.21 to 1.16 (m, 9H), 
1.02 (m, 2H), 0.83 (m, 6H).  13C NMR (500MHz, DMSO-d6): δ (ppm) 170.52, 169.50, 
164.69, 163.88, 99.72, 60.59, 51.39, 40.40, 31.27, 31.06, 29.06, 28.73, 28.34, 27.58, 
26.62, 25.81, 23.99, 22.03, 13.97.  HPLC retention time: 10.616min; purity 97.38%. 
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4.2.4 Synthesis of Furanopyrimidine Cannabinoids 
 
With the successful synthesis of both the pyrimidine hexahydro classical 
cannabinoids and the pyrimidine non-classical cannabinoids, sights were set on 
expansion of the pyrimidine containing series of compounds.  Upon review of the current 
medicinal chemistry literature, a series of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines that 
had been developed by Amgen Inc. as inhibitors of lymphocyte-specific kinase (Lck)178 
caught our attention.  The general structure of this series of compounds (Figure 4.7) has 
aspects of both a conformationally restricted pyrimidine non-classical cannabinoid and a 
ring-contracted pyrimidine classical cannabinoid in which the six-membered pyran ring 
has been replaced by a five-membered furan.  These compounds lacked the side chain at 
the 2-position of the pyrimidine ring found in the previously described pyrimidine 
cannabinoids.  This series of compounds contained two substituents on the furan ring: 
one being an unsubstituted phenyl and the other a substituted phenyl. 
It was decided to design the furanopyrimidine with just one aryl substitution on 
the furan ring in order to form compounds that would occupy similar space to the 
previously described pyrimidine cannabinoids.  These new compounds were also to be 
synthesized with a side chain present similar to the classical and non-classical pyrimidine 
cannabinoids (Figure 4.8).  By adapting the chemistry of DiMauro et al.178a the 
furanopyrimidine cannabinoids were formed by the base catalysed cyclization of a 
substituted dihydroxy pyrimidine with a 2-chloro-2-nitrovinyl substituted aromatic ring 
(Scheme 4.18). 
The substituted dihydroxy pyrimidines used were the same ones formed for the 
pyrimidine hexahydro classical cannabinoids (Scheme 4.12) from substituted amidines 
and diethyl malonate.  The 2-chloro-2nitrovinyl styrenes were formed from substituted 
benzaldehydes, bromonitromethane, dimethylamine hydrochloride, and potassium 
fluoride in xylenes (Scheme 4.19).  The reaction is fitted with a Dean-Stark trap to allow 
for azeotropic removal of water and heated to 125°C for 8 hours.  The styrenes were then 
readily purified by flash column chromatography. 
Four styrenes (phenyl, m-tolyl, 3,5-dichloro phenyl, and 2-thiophenyl) were 
cyclized with four substituted dihydroxy pyrimidines (dimethyl phenyl, dimethyl 
thiophenyl, dimethyl cyclohexyl, and dimethyl heptyl) to form sixteen new 
furanopyrimidine cannabinoids (Figure 4.9). 
 All chemicals were obtained from Sigma Aldrich or Fisher Scientific Inc. 
Anhydrous solvents were obtained by distillation over either calcium hydride or metallic 
sodium and benzophenone.  Final compounds and intermediates were purified using 
column chromatography on the Biotage SP1 system employing Flash column cartridges 
or by crystallization.  NMR spectra were obtained on a Bruker 300MHz or Varian 
500MHz Inova NMR.  HPLC analysis of final products was carried out by gradient 
elution using water/acetonitrile (0.1% TFA) with a gradient of 70% (3min), 50% (2min), 
and 10% (15min).  A reverse-phase ODS Hypersil column, manufactured by Thermo 
Scientific, of dimensions 4.6 x 150mm with 5µm particle size was used for HPLC 
analyses. 
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Figure 4.7: General structure of Lck inhibitors 
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Figure 4.8: General structure of furanopyrimidine cannabinoids 
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Scheme 4.18: General synthesis of furanopyrimidine cannabinoids 
(a) DBU, acetonitrile, µwave, 100watts, 120°C, 15min. 
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Scheme 4.19: Synthesis of 2-chloro-2-nitrovinyl styrenes 
(a) bromonitromethane, dimethylamine hydrochloride, potassium fluoride, xylenes, 
125°C, 8hr. 
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Figure 4.9: Furanopyrimidine cannabinoids 
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4.2.4.1 Synthesis of (2-chloro-2-nitrovinyl)benzene (59) 
 
Benzaldehyde (3.59g, 33.8 mmol), bromonitromethane (9.0g, 64.3 mmol), 
dimethylamine hydrochloride (24.8g, 304.2mmol), potassium fluoride (0.3g, 5.08mmol) 
and m- xylenes (50mL) were combined in a 250mL round bottomed flask fitted with a 
Dean-Stark trap.  The mixture was heated at 125°C with azeotropic removal of water for 
8h.  The reaction mixture was concentrated and the residue was extracted with a mixture 
of 1:1 dicloromethane and water.  After separation of the organic layer, the aqueous layer 
was extracted three times with dicloromethane.  The combined organics were dried over 
anhydrous Na2SO4 and concentrated to a brown oil.  The oily residue thus obtained was 
purified on a silica column (Biotage SP1 system) using a 1:9 ethyl acetate /hexane 
mixture to obtain the product as pale yellow needles (4.8g, 77%). Rf  = 0.66 (1:9 ethyl 
acetate/hexane).  1H NMR (300 MHz, CDCl3): δ (ppm) 8.40 (s,1H), 7.86-7.90 (m,2H), 
7.51-7.5 (m,3H). 
 
 
4.2.4.2 Synthesis of 1-(2-chloro-2-nitrovinyl)-3-methylbenzene (60) 
 
 Compound 60 was prepared in a manner similar to compound 59.  1H NMR (300 
MHz, CDCl3): δ (ppm) 8.38 (s,1H), 7.67 (t,2H), 7.36-7.41 (m,2H), 2.45 (s,3H). 
 
 
4.2.4.3 Synthesis of 1,3-dichloro-5-(2-chloro-2-nitrovinyl)benzene (61) 
 
Compound 61 was prepared in a manner similar to compound 59.  1H NMR (300 
MHz, CDCl3): δ (ppm) 8.23 (s,1H), 7.74 (d,2H), 7.52 (s,1H). 
 
 
4.2.4.4 Synthesis of 2-(2-chloro-2-nitrovinyl)thiophene (62) 
 
Compound 62 was prepared in a manner similar to compound 59.  1H NMR (300 
MHz, CDCl3): δ (ppm) 8.65 (s,1H), 7.81 (d, 1H), 7.69 (d,1H), 7.27-7.28(t,1H). 
 
 
4.2.4.5 Synthesis of 5-phenyl-2-(2-phenylpropan-2-yl)furo[2,3-
d]pyrimidin-4-ol (63) 
 
100mg (0.434mmol) of 2-(2-phenylpropan-2-yl)pyrimidine-4,6-diol 30 and 73mg 
(0.4mmol) of (2-chloro-2-nitrovinyl)benzene 59 were dissolved in 2ml acetonitrile in a 
10ml microwave reaction vessel.  122 mg (0.8mmol) of 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU) was then added and the vessel sealed.  The vessel was irradiated in a CEM 
LabMate microwave reactor (CEM, Matthews, NC USA) at 100watts to 120°C for 15 
minutes.  The reaction mixture was then concentrated and the target compound purified 
by flash chromatography on a Biotage SP1 (Biotage, Charlottesville, VA USA) using a 
methylene chloride / methanol gradient.   Yield: 42.3%.  MS: (ESI, neg) m/z 329.0 [M – 
H]-, 1H NMR (500 MHz, DMSO): δ (ppm) 12.03 (s, 1H), 8.24 (s, 1H), 7.96 (d, 2H, J = 
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7.5Hz), 7.41 (t, 2H, J = 7.5Hz), 7.33 (q, 3H, J = 7.5Hz), 7.26 (t, 3H, J = 8Hz), 1.71 (s, 
6H); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.49, 164.18, 159.79, 145.77, 138.41, 
130.22, 128.37, 128.32, 127.94, 126.57, 129.17, 123.49, 120.92, 44.98, 27.53.  HPLC 
retention time: 10.185min; purity 100%. 
 
 
4.2.4.6 Synthesis of 5-phenyl-2-(2-(thiophen-2-yl)propan-2-yl)furo[2,3-
d]pyrimidin-4-ol (64) 
 
Compound 64 was prepared in a manner similar to compound 63 from 2-(2-
(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-diol 31(100mg, 0.423mmol), (2-chloro-2-
nitrovinyl)benzene 59 (73mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 26.8%.  MS: (ESI, neg.) m/z 335.0 [M – H]-, 1H NMR (500 MHz, DMSO): 
δ (ppm) 12.01 (s, 1H), 8.24 (s, 1H), 7.96 (d, 2H, J = 7.5Hz), 7.42 (q, 3H, J = 8Hz), 7.32 
(t, 1H, J = 7Hz), 7.04 (d, 1H, J = 3Hz), 6.99 (t, 1H, J = 4.5Hz), 1.86 (s, 6H); 13C NMR 
(500 MHz, CDCl3): δ (ppm) 165.38, 162.99, 159.67, 150.22, 138.60, 130.15, 128.38, 
127.94, 127.62, 126.74, 124.98, 124.56, 123.50, 103.02, 43.16, 28.42.  HPLC retention 
time: 10.136min; purity 100%. 
 
 
4.2.4.7 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-phenylfuro[2,3-
d]pyrimidin-4-ol (65) 
 
Compound 65 was prepared in a manner similar to compound 63 from 2-(2-
cyclohexylpropan-2-yl)pyrimidine-4,6-diol 32 (100mg, 0.423mmol), (2-chloro-2-
nitrovinyl)benzene 59 (73mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 43.7%.  MS: (ESI, neg.) m/z 335.0 [M – H]-, 1H NMR (500 MHz, DMSO): 
δ (ppm) 12.02 (s, 1H), 8.19 (s, 1H), 7.98 (d, 2H, J = 8Hz), 7.42 (t, 2H, J = 7.5Hz), 7.32 (t, 
1H, J = 7Hz), 1.94 (t, 1H, J = 11.5Hz), 1.69 (d, 2H, J = 12Hz), 1.60 (d, 2H, J = 12Hz), 
1.39 (d, 2H, J = 12Hz ), 1.25 (s, 6H), 1.07 (m, 5H); 13C NMR (500 MHz, CDCl3): δ 
(ppm) 165.58, 165.54, 159.89, 138.12, 130.29, 128.36, 127.91, 127.55, 123.41, 102.42, 
44.92, 43.61, 27.19, 26.39, 26.01, 22.21.  HPLC retention time: 11.245min; purity 
99.45%. 
 
 
4.2.4.8 Synthesis of 2-(2-methyloctan-2-yl)-5-phenylfuro[2,3-
d]pyrimidin-4-ol (66) 
 
Compound 66 was prepared in a manner similar to compound 63 from 2-(2-
methyloctan-2-yl)pyrimidine-4,6-diol 33 (40mg, 0.168mmol), (2-chloro-2-
nitrovinyl)benzene 59 (28mg, 0.153mmol), DBU (47mg, 46.2µl, 0.308mmol), and 
CH3CN (1ml).  Yield: 32.6%.  MS: (ESI, neg.) m/z 337 [M – H]-, 1H NMR (500 MHz, 
DMSO): δ (ppm) 12.12 (s, 1H), 8.19 (s, 1H), 7.98 (d, 2H, J = 7.5Hz), 7.42 (t, 2H, J = 
8Hz), 7.32 (t, 1H, J = 7.5Hz), 1.73 (m, 2H), 1.31 (s, 6H), 1.19 (m, 6H), 1.06 (m. 2H), 0.8 
(t, 3H, J = 7Hz); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.65, 164.91, 159.91, 138.14, 
149 
 
130.28, 128.36, 127.90, 127.55, 112.34, 102.44, 40.44, 40.33, 30.98, 29.06, 25.90, 23.94, 
22.01, 13.88.  HPLC retention time: 11.846min; purity 100%. 
 
 
4.2.4.9 Synthesis of 2-(2-phenylpropan-2-yl)-5-m-tolylfuro[2,3-
d]pyrimidin-4-ol (67) 
 
Compound 67 was prepared in a manner similar to compound 63 from 2-(2-
phenylpropan-2-yl)pyrimidine-4,6-diol 30 (100mg, 0.434mmol), 1-(2-chloro-2-
nitrovinyl)-3-methylbenzene 60 (79mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and 
CH3CN (2ml).  Yield: 29.2%.  MS: (ESI, neg.) m/z 343.0 [M – H]-, 1H NMR (500 MHz, 
DMSO): δ (ppm) 11.99 (s, 1H), 8.20 (s, 1H), 7.79 (d, 1H, J = 8Hz), 7.74 (s, 1H), 7.29 (m, 
6H), 7.13 (d, 1H, J = 7.5Hz), 2.33 (s, 3H), 1.71 (s, 6H); 13C NMR (500 MHz, CDCl3): δ 
(ppm) 165.44, 164.12, 159.71, 145.78, 138.31, 137.32, 130.10, 128.37, 128.32, 128.26, 
128.23, 126.57, 126.16, 125.30, 123.58, 102.95, 44.96, 27.53, 21.11.  HPLC retention 
time: 10.569min; purity 100%. 
 
 
4.2.4.10 Synthesis of 2-(2-(thiophen-2-yl)propan-2-yl)-5-m-
tolylfuro[2,3-d]pyrimidin-4-ol (68) 
 
Compound 68 was prepared in a manner similar to compound 63 from 2-(2-
(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-diol 31 (100mg, 0.434mmol), 1-(2-chloro-2-
nitrovinyl)-3-methylbenzene 60 (79mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and 
CH3CN (2ml).  Yield: 21.5%.  MS: (ESI, neg.) m/z 349.0 [M – H]-, 1H NMR (500 MHz, 
DMSO): δ (ppm) 12.07 (s, 1H), 8.20 (s, 1H), 7.78 (d, 1H, J = 7.5Hz), 7.73 (s, 1H), 7.43 
(d, 1H, J = 5Hz), 7.30 (t, 1H, J = 7.5Hz), 7.14 (d, 1H, J = 7.5Hz), 7.03 (d, 1H, J = 4Hz), 
6.99 (t, 1H, J = 5Hz), 2.33 (s, 3H), 1.81 (s, 6H); 13C NMR (500 MHz, CDCl3): δ (ppm) 
165.33, 162.94, 159.61, 150.23, 138.49, 137.33, 130.03, 127.94, 128.39, 128.27, 129.74, 
125.30, 124.98, 124.55, 123.55, 103.04, 43.15, 25.42, 21.11.  HPLC retention time: 
10.514min; purity 100%. 
 
 
4.2.4.11 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-m-tolylfuro[2,3-
d]pyrimidin-4-ol (69) 
 
Compound 69 was prepared in a manner similar to compound 63 from 2-(2-
cyclohexylpropan-2-yl)pyrimidine-4,6-diol 32 (100mg, 0.434mmol), 1-(2-chloro-2-
nitrovinyl)-3-methylbenzene 60 (79mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and 
CH3CN (2ml).  Yield: 30.8%.  MS: (ESI, neg.) m/z 349.0 [M – H]-, 1H NMR (500 MHz, 
DMSO): δ (ppm) 11.95 (s, 1H), 8.14 (s, 1H), 7.80 (d, 1H, J = 7.5Hz), 7.54 (s, 1H), 7.30 
(t, 1H, J = 7.5Hz), 7.14 (d, 1H, J = 7Hz), 2.34 (s, 3H), 1.93 (t, 1H, J = 12Hz), 1.69 (d, 2H, 
J = 12.5Hz), 1.60 (d, 1H, J = 12Hz), 1.40 (d, 2H, J = 12Hz), 1.24 (s, 6H), 1.05 (m, 5H); 
13C NMR (500 MHz, CDCl3): δ (ppm) 165.53, 165.49, 138.02, 137.30, 130.17, 128.35, 
128.36, 128.25, 128.19, 128.27, 125.27, 123.49, 102.45, 44.92, 43.60, 27.19, 26.82, 
26.02, 22.21, 21.15.  HPLC retention time: 11.680min; purity 100%. 
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4.2.4.12 Synthesis of 2-(2-methyloctan-2-yl)-5-m-tolylfuro[2,3-
d]pyrimidin-4-ol (70) 
 
Compound 70 was prepared in a manner similar to compound 63 from 2-(2-
methyloctan-2-yl)pyrimidine-4,6-diol 33 (100mg, 0.42mmol), 1-(2-chloro-2-nitrovinyl)-
3-methylbenzene 60 (79mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 36.4%.  MS: (ESI, neg.) m/z 351 [M – H]-, 1H NMR (500 MHz, DMSO): δ 
(ppm) 12.08 (s, 1H), 8.15 (s, 1H), 7.81 (d, 1H, J = 7.5Hz), 7.75 (s, 1H), 7.30 (t, 1H, J = 
7.5Hz), 7.14 (d, 1H, J = 7.5Hz), 2.34 (s, 3H), 1.72 (t, 2H, J = 6.5Hz), 1.31 (s, 6H), 1.19 
(m. 6H), 1.06 (m. 2H), 0.81 (t, 3H, J = 6.5Hz); 13C NMR (500 MHz, CDCl3): δ (ppm) 
165.60, 164.86, 159.85, 138.04, 137.31, 130.16, 128.34, 128.26, 128.20, 125.28, 123.48, 
102.46, 40.43, 40.35, 30.99, 29.07, 25.91, 23.95, 22.02, 21.12, 13.88.  HPLC retention 
time: 12.294min; purity 99.14%. 
 
 
4.2.4.13 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-phenylpropan-2-
yl)furo[2,3-d]pyrimidin-4-ol (71) 
 
Compound 71 was prepared in a manner similar to compound 63 from 2-(2-
phenylpropan-2-yl)pyrimidine-4,6-diol 30 (100mg, 0.42mmol), 1,3-dichloro-5-(2-chloro-
2-nitrovinyl)benzene 61 (101mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 20.4%.  MS: (ESI, neg.) m/z 397.0 [M – H]-, 1H NMR (500 MHz, DMSO): 
δ (ppm) 12.16 (s, 1H), 8.51 (s, 1H), 8.20 (s, 2H), 7.56 (s, 1H), 7.35 (t, 2H, J = 8Hz), 7.27 
(m, 3H), 1.72 (s, 6H); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.62, 164.63, 159.83, 
145.68, 140.20, 134.13, 133.81, 128.34, 126.90, 126.61, 126.25, 126.17, 121.12, 102.55, 
45.06, 27.54.  HPLC retention time: 11.468min; purity 97.36%. 
 
 
4.2.4.14 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-(thiophen-2-
yl)propan-2-yl)furo[2,3-d]pyrimidin-4-ol (72) 
 
Compound 72 was prepared in a manner similar to compound 63 from 2-(2-
(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-diol 31 (100mg, 0.423mmol), 1,3-dichloro-5-
(2-chloro-2-nitrovinyl)benzene 61 (101mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), 
and CH3CN (2ml).  Yield: 32.9%.  MS: (ESI, neg.) m/z 404.9 [M – H]-, 1H NMR (500 
MHz, DMSO): δ (ppm) 12.22 (s, 1H), 8.49 (s, 1H), 8.18 (s, 2H), 7.54 (s, 1H), 7.44 (d, 
1H, J = 5Hz), 7.03 (d, 1H, J = 3Hz), 6.99 (t, H, J = 4.5Hz), 1.81 (s, 6H); 13C NMR (500 
MHz, CDCl3): δ (ppm) 165.50, 163.42, 159.71, 150.08, 140.35, 134.13, 133.72, 126.92, 
126.75, 126.26, 125.01, 124.06, 121.12, 102.64, 43.21, 28.42.  HPLC retention time: 
11.414min; purity 100%. 
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4.2.4.15 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-(3,5-
dichlorophenyl)furo[2,3-d]pyrimidin-4-ol (73) 
 
Compound 73 was prepared in a manner similar to compound 63 from 2-(2-
cyclohexylpropan-2-yl)pyrimidine-4,6-diol 32 (100mg, 0.423mmol), 1,3-dichloro-5-(2-
chloro-2-nitrovinyl)benzene 61 (101mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and 
CH3CN (2ml).  Yield: 24.7%.  MS: (ESI, neg.) m/z 403.0 [M – H]-, 1H NMR (500 MHz, 
CDCl3): δ (ppm) 10.91 (s, 1H), 7.82 (s, 2H), 7.66 (s, 1H), 7.35 (s, 1H), 1.71 (m, 1H,), 
1.64 (m, 2H), 1.55 (d, 1H, J = 10.5Hz), 1.42 (d, 2H, J = 6Hz), 1.36 (s, 6H), 1.00 (m, 5H);  
13C NMR (500 MHz, CDCl3): δ (ppm) 165.55, 160.62, 138.24, 135.21, 133.45, 128.00, 
126.78, 122.63, 110.19, 102.97, 47.23, 44.38, 27.89, 26.83, 26.51, 22.97.  HPLC 
retention time: 13.021min; purity 98.71%.  
 
 
4.2.4.16 Synthesis of 5-(3,5-dichlorophenyl)-2-(2-methyloctan-2-
yl)furo[2,3-d]pyrimidin-4-ol (74) 
 
Compound 74 was prepared in a manner similar to compound 63 from 2-(2-
methyloctan-2-yl)pyrimidine-4,6-diol 33 (100mg, 0.42mmol), 1,3-dichloro-5-(2-chloro-
2-nitrovinyl)benzene 61 (101mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 19.7%.  MS: (ESI, neg.) m/z 405.1 [M – H]-, 1H NMR (500 MHz, CDCl3): 
δ (ppm) 11.41 (s, 1H), 7.82 (s, 2H), 7.66 (s, 1H), 7.35 (s, 1H), 1.72 (m, 2H), 1.43 (s, 6H), 
1.14 (m, 8H), 0.78 (t, 3H, J = 7Hz); 13C NMR (500 MHz, CDCl3): δ (ppm) 166.90, 
166.04, 161.08, 138.29, 135.17, 133.80, 128.02, 126.76, 122.63, 102.98, 41.90, 41.24, 
31.77, 29.78, 26.55, 24.74, 22.77, 14.20.  HPLC retention time: 13.910min; purity 
97.51%. 
 
 
4.2.4.17 Synthesis of 2-(2-phenylpropan-2-yl)-5-(thiophen-2-
yl)furo[2,3-d]pyrimidin-4-ol (75) 
 
Compound 75 was prepared in a manner similar to compound 63 from 2-(2-
phenylpropan-2-yl)pyrimidine-4,6-diol 30 (100mg, 0.434mmol), 2-(2-chloro-2-
nitrovinyl)thiophene 62 (76mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 36.1%.  MS: (ESI, neg.) m/z 335 [M – H]-, 1H NMR (500 MHz, DMSO): δ 
(ppm) 12.07 (s, 1H), 8.22 (s, 1H), 7.97 (d, 1H, J = 3.5Hz), 7.50 (d, 1H, J = 5Hz), 7.34 (t, 
2H, J = 7.5Hz), 7.25 (d, 3H, J = 6.5Hz), 7.10 (t, 1H, J = 5.5Hz), 1.71 (s, 6H); 13C NMR 
(500 MHz, CDCl3): δ (ppm) 165.23, 164.49, 159.60, 145.72, 137.31, 131.43, 128.32, 
128.28, 127.72, 126.58, 126.17, 125.65, 117.49, 102.49, 45.03, 27.51.  HPLC retention 
time: 10.219min; purity 99.69%. 
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4.2.4.18 Synthesis of 5-(thiophen-2-yl)-2-(2-(thiophen-2-yl)propan-2-
yl)furo[2,3-d]pyrimidin-4-ol (76) 
 
Compound 76 was prepared in a manner similar to compound 63 from 2-(2-
(thiophen-2-yl)propan-2-yl)pyrimidine-4,6-diol 31 (100mg, 0.423mmol), 2-(2-chloro-2-
nitrovinyl)thiophene 62 (76mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 19.2%.  MS: (ESI, neg.) m/z 341 [M – H]-, 1H NMR (500 MHz, DMSO): δ 
(ppm) 12.15 (s, 1H), 8.22 (s, 1H), 7.96 (d, 1H, J = 3Hz), 7.51 (d, 1H, J = 5Hz), 7.44 (d, 
1H, J = 5Hz), 7.11 (t, 1H, J = 5Hz), 7.03 (d, 1H, J = 2.5Hz), 6.99 (t, 1H, J = 4Hz), 1.81 (s, 
6H); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.12, 163.29, 159.49, 150.14, 137.49, 
131.35, 128.30, 127.73, 126.75, 125.70, 124.99, 124.59, 117.49, 102.58, 43.21, 28.39.  
HPLC retention time: 10.151min; purity 98.38%. 
 
 
4.2.4.19 Synthesis of 2-(2-cyclohexylpropan-2-yl)-5-(thiophen-2-
yl)furo[2,3-d]pyrimidin-4-ol (77) 
 
Compound 77 was prepared in a manner similar to compound 63 from 2-(2-
cyclohexylpropan-2-yl)pyrimidine-4,6-diol 32 (100mg, 0.423mmol), 2-(2-chloro-2-
nitrovinyl)thiophene 62 (76mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 40.2%.  MS: (ESI, neg.) m/z 341.0 [M – H]-, 1H NMR (500 MHz, DMSO): 
δ (ppm) 12.08 (s, 1H), 8.18 (s, 1H), 8.07 (d, 1H, J = 3.5Hz), 7.51 (d, 1H, J = 4.5Hz), 7.13 
(t, 1H, J = 5Hz), 1.94 (t, 1H, J = 12Hz), 1.70 (d, 2H, J = 12.5Hz), 1.62 (d, 1H, J = 12Hz), 
1.40 (d, 2H, J = 12.5Hz), 1.25 (s, 6H), 1.02 (m, 5H); 13C NMR (500 MHz, CDCl3): δ 
(ppm) 165.91, 165.26, 159.71, 137.01, 131.53, 128.24, 127.71, 125.59, 117.40, 101.99, 
44.95, 43.68, 27.19, 26.38, 26.01, 22.19.  HPLC retention time: 11.285min; purity 100%. 
 
 
4.2.4.20 Synthesis of 2-(2-methyloctan-2-yl)-5-(thiophen-2-yl)furo[2,3-
d]pyrimidin-4-ol (78) 
 
Compound 78 was prepared in a manner similar to compound 63 from 2-(2-
methyloctan-2-yl)pyrimidine-4,6-diol 33 (100mg, 0.42mmol), 2-(2-chloro-2-
nitrovinyl)thiophene 62 (76mg, 0.4mmol), DBU (122mg, 120µl, 0.8mmol), and CH3CN 
(2ml).  Yield: 12.3%.  MS: (ESI, neg.) m/z 343.0 [M – H]-, 1H NMR (500 MHz, DMSO): 
δ (ppm) 12.16 (s, 1H), 8.71 (s, 1H), 8.00 (d, 1H, J = 3Hz), 7.51 (d, 1H, J = 5Hz), 7.12 (t, 
1H, J = 4Hz), 1.72 (m, 2H), 1.30 (s, 6H), 1.19 (m, 6H), 1.05 (m, 2H), 0.81 (t, 3H, J = 
6.5Hz); 13C NMR (500 MHz, CDCl3): δ (ppm) 165.37, 165.24, 159.73, 137.04, 131.52, 
128.26, 127.72, 125.60, 117.41, 102.01, 40.50, 40.35, 30.99, 29.06, 25.08, 23.94, 22.02, 
13.89.  HPLC retention time: 11.881min; purity 100%. 
 
 
4.3 Testing of Novel Compounds 
 
 Select compounds from each of the three series of novel pyrimidine cannabinoid 
ligands were tested for binding affinity to and functional activity at the CB1 and CB2 
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receptors.  Select compounds were also tested for efficacy as anti-glioblastoma agents.  
The complete series are currently undergoing receptor binding assays and functional 
activity screens in order to develop SARs for these new structural classes of 
cannabinoids. 
 
 
4.3.1 Pyrimidine Hexahydro Classical Cannabinoids 
 
 All four of the pyrimidine hexahydro classical cannabinoids were screened for 
receptor binding affinity to the CB1 and CB2 receptors (Table 4.1).  All compounds 
exhibited binding affinity to both receptors with the exception of the phenyl substituted 
34 which showed very little affinity for the CB1 receptor (Ki > 10,000nM).  Compounds 
34 and 35 were > 73.0 and 26.9-fold selective for the CB2 receptor, respectively, which 
is greater than either KM-233 or HB-I-172.  From this small series of compounds it 
would seem that aromatic side-chains (compounds 34 and 35) decrease binding affinity 
for both receptors yet increase CB2 selectivity.  Compounds 36 and 37, which possess 
alkyl side-chains, displayed good binding affinity for both receptors yet lower CB2 
selectivity (9.7 and 6.5, respectively).  All compounds proved to be agonists at both the 
CB1 and CB2 receptor subtypes.  Compounds 35, 36, and 37 were also tested against the 
human glioblastoma cell line LN-229.  All three compounds showed efficacy which was 
comparable to HB-I-172 and KM-233 (Table 4.2). 
 
 
4.3.2 Pyrimidine Non-Classical Cannabinoids 
 
 Compounds 47, 48, 52, and 55 were assayed for receptor binding affinity at CB1 
and CB2.  The results of the binding assays are found in Table 4.3.  Each of the four 
pyrimidine non-classical cannabinoids tested has very little affinity for the CB1 receptor 
with all four having a Ki > 10,000.  They do, however, retain affinity for the CB2 receptor 
in varying degrees.  Compound 55 (dimethyl heptyl side-chain with a cyclohexyl 
replacement of the A ring) possessed the greatest affinity for the CB2 receptor (Ki = 43.3 
(± 19.6)nM) with a high CB2 selectivity ratio of > 230.9-fold.  Six of the compounds 
from this series were tested for functional activity at the cannabinoid receptors and were 
found to be agonists at CB2 with little or no agonist activity at CB1 (probably due to low 
affinity).  Two exceptions were 47 and 55 which exhibited 59 and 68% agonist activity at 
CB1, respectively.  Three compounds 47, 48, and 50 were tested against LN-229 and 
exhibited EC50s (23.5µM – 55.5µM) slightly higher than HB-I-172 and KM-233, but 
much lower than BCNU (Table 4.4). 
 
 
4.3.3 Furanopyrimidine Cannabinoids 
 
 Five furanopyrimidines were screened for receptor binfing affinity at the CB1 and 
CB2 receptors.  All five compounds exhibited low affinity for both CB1 and CB2 (Ki > 
10,000nM).  All sixteen compounds were screened for functional activity at the 
cannabinoid receptors also.  Despite having low affinity, several compounds did exhibit
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Table 4.1: Binding affinity constants (Ki) for compounds 34-37 compared to Δ8-THC, 
KM-233, and HB-I-172 
 
Compound CB1 Ki (nM) CB2 Ki (nM) CB1/CB2 Ratio 
Δ8-THC 28.5 (± 3.3) 25.0 (± 4.8) 1.1 
KM-233 12.3 (± 0.61) 0.91 (± 0.08) 13.5 
HB-I-172 6040 (± 1477) 487 (± 101) 12.4 
34 > 10,000 137 (± 13) > 73.0 
35 1138 (± 227) 42.3 (± 13.9) 26.9 
36 18.8 (± 9.3) 1.94 (± 0.63) 9.7 
37 54.6 (± 5.4) 8.36 (± 1.66) 6.5 
Notes: Values are the mean of three experiments performed in triplicate; standard 
deviation is given in parentheses.  CB1/CB2 ratio is expressed as Ki for CB1 / Ki for 
CB2. 
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Table 4.2: Efficacy of pyrimidine hexahydro classical cannabinoids compared to HB-I-
172, KM-233, and BCNU against LN-229 
 
Compound EC50 (µM) ± S.D. 
BCNU 233 (± 5.1) 
HB-I-172 9.74 (± 0.56) 
KM-233 4.74 (± 0.43) 
35 30.1(± 2.9) 
36 10.6 (± 1.3) 
37 27.3 (± 3.4) 
Notes: Values are the mean of three experiments performed in triplicate; standard 
deviation is given in parentheses.    
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Table 4.3: Binding affinity constants (Ki) for select pyrimidine non-classical 
cannabinoids compared to Δ8-THC, KM-233, and HB-I-172 
 
Compound CB1 Ki (nM) CB2 Ki (nM) CB1/CB2 Ratio 
Δ8-THC 28.5 (± 3.3) 25.0 (± 4.8) 1.1 
KM-233 12.3 (± 0.61) 0.91 (± 0.08) 13.5 
HB-I-172 6040 (± 1477) 487 (± 101) 12.4 
47 > 10,000 9673 (± 566) > 1.0 
48 > 10,000 130 (± 38) > 76.9 
52 > 10,000 621 (± 158) > 16.1 
55 > 10,000 43.3 (± 19.6) > 230.9 
Notes: Values are the mean of three experiments performed in triplicate; standard 
deviation is given in parentheses.  CB1/CB2 ratio is expressed as Ki for CB1 / Ki for 
CB2.   
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Table 4.4: Comparison of selected pyrimidine non-classical cannabinoids to HB-I-172, 
KM-233, and BCNU against LN-229 
 
Compound EC50 (µM) ± S.D. 
BCNU 233 (± 5.1) 
HB-I-172 9.74 (± 0.56) 
KM-233 4.74 (± 0.43) 
47 55.5 (± 4.3) 
48 23.5 (± 2.9) 
50 51.8 (± 6.4) 
Notes: Values are the mean of three experiments performed in triplicate; standard 
deviation is given in parentheses.   
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agonist activity.  Compounds 66 and 78 proved to be agonists at CB1 and CB2 when 
screened at a concentration of 10µM.  Compounds 65, 69, 70, 74, 77, and 78 showed 
agonist activity at only the CB2 receptor when tested at 10µM.  Five of the 
furanopyrimidines were tested against the human glioblastoma cell line T98G.  When 
screened at a concentration of 10µM, five of the compounds displayed cytotoxic activity 
against the GBM cell line (Figure 4.10).  Interestingly, the cells had to experience a 
longer exposure to these compounds (72 hours) in order to manifest the toxic effects 
normally seen in 18 hours with other cannabinoid ligands. 
 
 
4.4 Experimental Procedures 
 
 
4.4.1 Radioligand Binding Assays 
 
Binding affinity studies were carried out using cell membranes from HEK293 
cells transfected with the human CB1 receptor (Kd for tritiated CP-55,940 binding: 4.5 
nM) and membranes from HEK293 cells transfected with the human CB2 receptor (Kd 
for tritiated CP-55,940 binding: 5.1 nM).  Non-specific binding was determined using 10 
µM WIN55, 212-2.  Increasing concentrations of compounds to be tested were made 
ranging from 10-12 M to 10-4 M and were added in triplicate for each experiment and the 
individual molar IC50 values were determined using GraphPad Prism software.  The 
corresponding Ki values for each drug were determined utilizing the Cheng-Prusoff 
equation and final data are presented as Ki ± standard deviation of n = 3 experiments run 
in triplicate. 
 
 
4.4.2 Cytotoxicity Assays 
 
Human glioblastoma cells T98G and LN-229 (American Type Culture Collection) 
were cultured in supplemented media according to the recommendations of the supplier 
at 37°C in an atmosphere of 5% CO2 and 95% air. Cell lines were plated in 96-well 
polystyrene flat-bottom plates (7,500 cells/well) at 70% confluency in a 100 µl total 
volume of supplemented media as indicated, and incubated overnight at 37°C to allow for 
adherence.  The media was then replaced with media containing 1% FBS and the cultures 
were treated with escalating amounts of drug and cell death was analyzed at 18hr or 72hr, 
using the BioTek Synergy 2 Multidetection Microplate Reader (BioTek Instruments, 
Inc.).  The percentage of viable cells present in the culture at each time point was 
calculated by comparing the absorbance value at 450nm from the CCK-8 assay (Dojindo 
Molecular Technologies) for each condition with untreated control cells.  All assays were 
conducted per manufacturer’s protocol.  All described values represent the average of 
three data points per determination and three independent determinations. 
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Figure 4.10: Furanopyrimidine cannabinoids screened against the human glioblastoma 
cell line T98G 
All compounds were screened at 10µM for 48 hours.  * = p < 0.005, ** = p < 0.0005, and 
*** = p < 0.00005. 
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4.4.3 CB1/CB2 Functional Assays 
 
HEK-293 cell lines stably transfected with a cyclic nucleotide-gated channel and 
either human CB1 or CB2 receptors (BD Biosciences,  San Jose, CA USA) were seeded 
in poly-D-lysine coated 96-well plates at a density of 70,000 cells per well.   Plates were 
incubated at 37°C in 5% CO2 overnight prior to assay.  Plates were then removed from 
the incubator and the complete growth medium (DMEM, 10% FBS, 250µg/ml G418 and 
1µg/ml puromycin) was replaced with 100µL DMEM containing 0.25% BSA.  Next, 
100µL membrane potential dye loading buffer (Molecular Devices) was added to each 
well.  The plates were placed back into the incubator for 30 minutes and then the baseline 
fluorescence was read on a BioTek Synergy 2 multi-mode microplate reader with 540nm 
excitation and 590nm emission filters prior to drug addition.   Drugs were added in 50µL 
DPBS containing 2.5% DMSO, 1.25µM 5’-(N-ethylcarboxamido) adenosine and 125µM 
Ro 20-1724.  Plates were then incubated at room temperature for 25 minutes and 
fluorescence measured again at 540nm excitation and 590nm emission. 
 
  
161 
 
Chapter 5: Cannabinoids as Anti-Inflammatory Agents 
 
 
5.1 Introduction 
 
Pharmacologically, cannabinoids can be used to affect a variety of targets such as 
the central nervous system, the cardiovascular system, the immune system and/or 
endocrine system.  More particularly, compounds possessing an affinity for either the 
CB1 or the CB2 receptor, and potentially GPR55, can act on the central nervous system 
or act as immunomodulators.  In addition, these compounds are useful as anticancer 
agents, antiobesity agents, analgesics, myorelaxation agents and antiglaucoma agents.  
Such compounds can also be used for the treatment of thymic disorders, vomiting, 
various types of neuropathy, memory disorders, dyskinesia, migraine, multiple sclerosis, 
asthma, epilepsy, ischemia, orthostatic hypotension, osteoporosis, liver fibrosis, 
inflammation and irritable bowel disease, diabetes, and cardiac insufficiency. 
However, certain cannabinoids such as Δ9-THC also affect normal 
neurotransmission, producing undesirable side effects such as drowsiness, impairment of 
monoamine oxidase function, and impairment of non-receptor mediated brain function.  
The addictive and psychotropic properties of some cannabinoids tend to limit their 
therapeutic value.  The unwanted psychotropic effects are mediated through the CB1 
receptor and are not observed upon activation of CB2.  Many of the desirable effects 
associated with cannabinoids such as antinociception and anti-inflammation are mediated 
through the CB2 receptor. 
Due to the effects mediated by CB2, it appears to be a promising target for the 
treatment of pain, inflammation, and neuro-inflammation.  It is therefore no mystery as to 
why the current trend in the field is the development of CB2 selective compounds that 
will not activate the CB1 receptor and will thus be void of the unwanted psychotropic 
effects.  The expression of CB2 was at one time thought to be limited to the periphery, 
being found mainly in the cells of the immune system.17,43  Recently, however, the CB2 
receptor has also been shown to be present in the CNS in both perivascular microglial 
cells179 and in brainstem neurons.42b  CB2 also appears to be up-regulated in dorsal root 
ganglia and peripheral neurons following injury.180 
CB2 has been validated as a potential target for the treatment of pain and neuro-
inflammation based on preclinical data using CB2 selective agonists and receptor 
knockout mice.  Despite the challenge that lies in developing CB2 selective compounds 
that maintain activity and selectivity across species, several compounds have advanced 
into clinical development.   
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5.2 Evaluation of CB2 Agonists in Preclinical Models 
 
 
5.2.1 Pain 
 
The ability of Cannabis to attenuate the pain response has been known for 
millennia in Asia.  The medical use of marijuana was introduced to the West in 1839 by a 
physician serving with the British in India named W. B. O’Shaughnessy.  He published a 
treatise expounding the usefulness of extracts of the plant in a wide variety of conditions 
including relieving the pain of rheumatism.  The medical use of Cannabis grew rapidly in 
the late 19th and early 20th centuries.  In the United States, the plant was even included in 
the National Formulary and Pharmacopoeia until 1941 when its use was virtually 
brought to a halt due to the Marihuana Tax Act of 1937.181  After the discovery of the 
cannabinoid receptors type I and II and their ligands, both exogenous and endogenous, 
research into the medical use of marijuana and cannabinoids has grown exponentially.  
Recently, the putative cannabinoid receptor GPR55 has been proposed as a target for the 
treatment of pain and inflammation, especially that of neuropathic origin.  The largest 
body of work with cannabinoids in the field of antinociception, however, is with ligands 
that are selective for the CB2 receptor; therefore, the discussion will be limited to those 
compounds. 
Several CB2 agonists such as GW405833 (Figure 5.1), a substituted indole 
derivative, have shown to be efficacious in preclinical models of neuropathic, 
inflammatory, and postoperative pain.  GW405833 is a CB2 agonist with binding 
affinities of 3.92 (± 1.58)nM for the human CB2 versus 4772 (± 1676)nM for CB1 which 
translates into greater than 1000-fold selectivity.182  As with many cannabinoids, binding 
affinity constants and selectivity ratios are found to be variable between species.  When 
assayed against the rat cannabinoid receptors, GW405833 was found to be only 78-fold 
selective for CB2.  Depending on the type of assay used, the compound appears to be a 
partial agonist at the human CB2 receptor182 and has also been reported to be a partial 
inverse agonist at both human and rat CB2 receptors.183 
In a sciatic nerve partial ligation model of neuropathic pain, GW405833 showed a 
63.3% reversal of pain at 1 hour following an i.p. dose of 10mg/kg with an ED50 of 
0.077mg/kg.  This compound also exhibited a reversal of hyperalgesia with ED50s of 
2.58mg/kg and 0.17mg/kg in the hind paw surgical incision model and the Freund’s 
complete adjuvant (FCA) model, respectively.  The target was confirmed in a CB2 
knockout mouse model in which the compound did not reverse inflammatory pain.  
GW405833 was also screened in a number of behavioral tests to determine if the 
compound would elicit unwanted effects due to interaction with CB1.  The well 
established catalepsy assay, rotorod assay examining motor function, and tail flick and 
hot plate tests which test for acute analgesia were used in these studies.  Only the highest 
dose tested (100mg/kg) showed any positive results in these assays.  This suggests that at 
higher doses GW405833 does signal through CB1, but not at lower doses.182 
Data has been published by Abbott regarding two CB2 agonists, A-796260183 and 
A-836339184 (Figure 5.1).  A-796260 is an indole derivative which possesses the same 2-  
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Figure 5.1: CB2 selective agonists used in preclinical studies as antinociceptive agents 
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morpholinoethyl substitution as GW405833.  It exhibits binding affinities for the human 
cannabinoid receptors of 845nM and 4.37nM for CB1 and CB2, respectively, which is a 
selectivity ratio of 193-fold for the human CB2.  Again, selectivity is lessened when 
assayed for affinity to the rat cannabinoid receptors.  Assays obtained the values of 
395nM and 13nM for rat CB1 and CB2, respectively, which is 30-fold selective for the 
rat CB2 receptor.  Functional selectivity of A-796260 for the CB2 receptor is greater than 
binding affinity selectivity for both the human and rat receptors (1380-fold and 175-fold, 
respectively).   
Efficacy of A-796260 as an antinociceptive agent has been evaluated in the FCA-
induced model of hyperalgesia using thermal stimulus.  The compound exhibited dose-
dependent reduction in hyperalgesia following i.p. administration with an ED50 of 
2.8mg/kg.  In this particular model, the target was confirmed pharmacologically using the 
CB2 selective antagonists SR144528185 and AM630.186  In each case, the analgesic 
effects of A-796260 were blocked.  The CB1 selective antagonist SR141716A, however, 
had no effect on the analgesia produced by the compound.  To evaluate the compound’s 
ability attenuate postoperative pain, a skin incision model was performed.  In this study, 
A-796260 was administered i.p. 1.5 hours following surgery; it dose-dependently 
lowered mechanical allodynia with an ED50 of 18mg/kg and with a maximum efficacy of 
68 (± 7%) without the development of tolerance following repeated administration.  In a 
study of neuropathic pain, the chronic constriction injury of the sciatic nerve model was 
used.  In this study, A-796260 also reduced mechanical allodynia with an ED50 of 
15mg/kg with maximum efficacy of 66 (± 9%).  This compound has also shown efficacy 
in an osteoarthritis pain model and performed favorably compared to celecoxib.  A-
796260 displayed 56% efficacy at a dose of 35mg/kg while celecoxib was 62% 
efficacious using a 38mg/kg dose.  This compound was also screened for CNS effects 
and none were found up to a 35mg/kg dose. 
A-836339, a dimethylthiazole carboxamide derivative, displays similar binding 
affinities to A-796260.  The Ki for binding affinity to the human CB2 receptor is 0.64nM 
and a selectivity of 425-fold is observed over the human CB1.  Affinity for the rat CB2 
receptor is very similar to that of the human, Ki = 0.76nM, and again selectivity when 
compared to the CB1 receptor is lower than in the human receptors (189-fold).  Like A-
796260, A-836339 is a full agonist at CB2 with an EC50 of 1.6nM.  Both compounds 
have also been shown to be full agonists at CB1 but, of course, much less potent. 
A-836339 has been shown to be efficacious in the FCA-induced inflammatory 
pain model with an ED50 of 1.96µmol/kg and has also shown efficacy in the skin incision 
model of postoperative pain with an ED50 of 12µmol/kg.  The compound has also yielded 
promising results in a capsaicin-induced model of hyperalgesia and in the chronic 
constriction injury neuropathic pain model with EC50s of 10.4µmol/kg and 12.9µmol/kg, 
respectively.  A-836339 was shown to have some CB1 mediated effects as determined by 
decreased horizontal locomotor activity following both 15µmol/kg and 45µmol/kg doses 
which was reversed by SR141716A treatment.  Although A-796260 has been shown to 
have affinity for the δ-opiod receptor, the antinociceptive effects of A-796260 and A-
836339 are not due to interaction with the µ-opiod receptor as exemplified by the 
inability of naloxone to reverse the analgesic effects of either compound. 
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The phenylamino pyrimidine GW842166X (Figure 5.2) is a clinical candidate 
belonging to GlaxoSmithKline which is being studied for its anti-inflammatory potential.  
The compound has been reported to be fully selective for CB2, both human and rat, with 
EC50s of 63nM and 91nM, respectively.  The compound displayed no significant agonist 
activity at either human or rat CB1 receptors up to 30µM.187  In the FCA-induced model 
of inflammatory pain, the compound was shown to be highly efficacious with an oral 
ED50 of 0.1mg/kg with full reversal of hyperalgesia at an oral dose of 0.3mg/kg.  As with 
A-796260, the development of tolerance was not observed within the timeframe of the 
study. 
 A dihydrobenzofuran developed at the MD Anderson Cancer Center, MDA7 
(Figure 5.2), has shown to be another cross-species CB2 selective compound.159  The 
compound has a Ki of 422 (± 123)nM for human CB2 with no affinity for the human CB1 
up to 10µM.  For rat cannabinoid receptors, the Ki values 2565 (± 695)nM for CB1 and 
238 (± 143)nM for CB2.  The compound was shown to be a weak partial agonist at the 
human CB1 at concentrations above 1µM.  The compound has produced promising 
results in attenuation of mechanical allodynia due to both paclitaxel and spinal nerve 
ligation.  The authors also reported a transient antinociceptive effect from thermal 
stimulus following i.p. administration of a 10mg/kg dose. 
Pfizer has reported a dihydrobenzimidazole, PF-03550096 (Figure 5.2), that has 
also showed promise in preclinical research.188  The compound performed well in a rat 
colonic pain model utilizing 2,4,6-trinitrobenzene sulfonic acid as a gastric irritant.  The 
authors report that the compound significantly suppressed visceral hypersensitivity in this 
model which was reversed by the CB2 antagonist SR144528. 
 
 
5.2.2 Neuro-Inflammation 
 
CB2 selective compounds have also begun to show promise as possible 
therapeutic options for the treatment of neuro-inflammatory diseases such as multiple 
sclerosis (MS), Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and 
encephalitis.  Compounds that do not have CB1 activity would not have been logical 
choices for treatment of these disorders before the discovery that CB2 is indeed 
expressed in the CNS.   
A preclinical model that is used for the study of MS is experimental autoimmune 
encephalomyelitis.  CB2 was found to be a legitimate target in this model by the fact that 
CB2 knockout mice have a more severe disease course upon induction than do wild-type 
mice.189  Furthermore, mice at the peak of disease development that are treated with the 
CB2 agonist HU-210 (Figure 5.3) are scored much lower on severity rating scales 
compared to vehicle treated controls.  This efficacy is reported by the authors to be due to 
reduced microglia activation and reduction in the infiltration of myeloid cells.189a  HU-
210 is an analog of cannabidiol possessing the dimethyl heptyl side chain.  Receptor 
binding affinity for the compound at human CB1 and CB2 is > 10µM and 22.7 (± 
3.9)nM, respectively. 
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Figure 5.2: Further CB2 selective agonists used in preclinical studies as antinociceptive 
agents 
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Figure 5.3: CB2 selective agonists used in preclinical studies as anti-inflammatory 
agents 
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5.2.3 Other Indications 
 
CB2 selective agonists have also shown promise for indications other than the 
inflammatory conditions mentioned above.  GW833972A, another phenylamino 
pyrimidine (Figure 5.3), is a1000-fold selective CB2 agonist that has been shown to 
reduce citric acid-induced cough in a conscious guinea-pig model.190  The role of CB2 in 
the action of GW833972A was verified by pretreatment with antagonists for the CB1 and 
CB2 receptors.  The antitussive effects were blocked by pretreatment with the CB2 
selective antagonist SR144528 while the CB1 selective antagonist SR141716A had no 
effect. 
HU-210 has been studied in other animal models of disease also.  It has been 
reported that observed in vitro effects of HU-210 are suppression of trabecular 
osteoclastogenesis.191  This effect is reported to be due to inhibition of osteoclast 
precursors and also inhibition of receptor activator of NFκB ligand.  The authors of this 
report also tested this compound in a model of postmenopausal osteoporosis using 
ovarectomized mice.  HU-210 lessened trabecular bone loss by 66% compared to 
untreated controls. 
A potential role for CB2 agonists in the treatment of the chronic inflammatory 
disease atherosclerosis has also been identified.  The presence of CB2 receptors was 
verified in both human and mouse atherosclerotic plaques.192  The non-selective 
cannabinoid agonist Δ9-THC showed significant inhibition of disease progression in a 
murine model of established atherosclerosis using apolipoprotein E knockouts.  THC was 
dosed at 1mg/kg orally once a day.192  This dose is below that which is usually associated 
with the CB1 mediated psychotropic effects of THC.  The role of CB2 in this study was 
verified by the observation that the CB2 selective antagonist SR144528 blocks the 
therapeutic effect of THC.  The authors also observed in vitro that THC blocks 
macrophage chemotaxis which is crucial for the formation of atherosclerotic plaques, an 
effect that was also blocked by SR144528. 
 
 
5.3 Evaluation of CB2 Agonists in Clinical Trials 
 
To date, there have been reports of three pharmaceutical companies entering 
clinical trials with CB2 agonists for the treatment of pain.193  Cannabinor, formerly 
known as PRS-211,375 (Figure 5.4) is a fumarate ester derivative of compounds similar 
to HU-308.  In January 2007, Pharmos Corporation reported the results of a Phase IIa 
experimentally induced pain model performed with cannabinor.  In this study the 
compound failed to meet the primary endpoint which was reduction of capsaicin-induced 
pain.194  In this study, however, researchers made the observation that, when compared to 
placebo, intravenous (i.v.) administration of cannabinor did have a significant effect in 
the reduction of both pressure-induced and heat-induced pain.  In April of that same year, 
Pharmos reported the results of a separate Phase IIa trial with Cannabinor.  The study was 
designed to examine the usefulness of i.v. cannabinor to attenuate pain following 3rd 
molar dental extraction.  The results were difficult to interpret.  The lowest dose of 12mg 
demonstrated a significant analgesic effect while the higher doses of 24mg and 48mg  
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Figure 5.4: Cannabinor (PRS-211,375) 
CB2 selective agonist studied in Phase II clinical trials. 
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were not statistically efficacious.  After this unexpected pattern of results the company 
decided to drop further development of i.v. cannabinor as an antinociceptive and 
retargeted the research with this compound to other possible indications and later dropped 
development all together.  One positive note from each of these trials is that cannabinor 
was generally well tolerated with no serious adverse events reported.  Pharmos currently 
has other CB2 selective compounds of undisclosed structure that are currently in pre-
clinical studies for the conditions of neuropathic pain, autoimmune disease, and irritable 
bowel syndrome.195  GlaxoSmithKline has completed three Phase II clinical trials with 
GW842166.196  One trial was for analgesia following 3rd molar extraction and the other 
two trials were examining the efficacy of the compound for treatment of osteoarthritis 
pain.  The company has not reported the results of these studies and currently lists no 
cannabinoids in their list of pipeline drugs.197  In 2009, Glenmark Pharmaceuticals 
announced the completion of Phase I studies in Europe of GRC10693 which is a CB2 
selective agonist (> 4700-fold) that possesses good oral bioavailability and is well 
tolerated.  The company plans to pursue the compound for the treatment of neuropathic 
pain.198  
 
 
5.4 Evaluation of Novel Cannabinoids as Anti-Inflammatory Agents 
 
 
5.4.1 Initial Study 
 
In order to exploit the therapeutic potential of our cannabinoid ligands as possible 
anti-inflammatory agents, we designed a preliminary in vitro study to determine what 
effects we could observe.  We chose to use cytokine and chemokine production as 
markers for inflammation.  We chose six of our novel synthetic cannabinoids (along with 
Δ8-THC) and screened them for anti-inflammatory activity against A-549 cells stimulated 
with tumor necrosis factor alpha (TNF-α).  The six compounds chosen represented six 
different chemical classes (Figure 5.5).  The previously described pyrimidine hexahydro 
classical cannabinoid 37 was selected along with a similar compound that is a pyridine 
hexahydro classical with the same dimethyl heptyl side chain 79 prepared in our 
laboratory by Dr. Suni Mustafa.  The non-classical triaryl compounds were represented 
by HB-I-172, the pyrimidine nonclassical 50, and the equivalent pyridine non-classical 
80 also prepared by Dr. Mustafa.  The furanopyrimidine cannabinoids had not been 
synthesized at this point, but Dr. Mustafa had begun on a series of furanopyridines – one 
of which was included in this group 81.  Cells were treated with vehicle, drug (at the 
toxic EC1 or EC10), TNF-α, or a combination of TNF-α and drug.  The cells were allowed 
to incubate in the presence of the stimulus or drug for periods of 4 or 18 hours.  The 
media was then removed from the cells and flash frozen on dry ice.  The samples were 
then shipped to an independent laboratory for analysis of excreted cytokines and 
chemokines. 
The results of this preliminary study were quite promising.  The efficacies of the 
compounds were evaluated by the levels of the excreted cytokines IL-1β, IL-6, IL-8, 
granulocyte colony stimulating factor (G-CSF), monocyte chemotactic protein-1 (MCP-
1), macrophage migration inhibitory factor (MIF), and RANTES (Regulated upon 
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Figure 5.5: Seven compounds initially screened for anti-inflammatory activity 
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Activation, Normal T-cell Expressed, and Secreted).  All of the compounds screened 
exhibited an attenuation of the inflammatory response manifesting as a reduction in the 
excretion of one or more of the pro-inflammatory cytokines assayed for (data not shown).   
This positive result prompted the design of a study to pick leads from the various 
chemical classes in our library to screen for anti-inflammatory activity.  In order to select 
leads we first had to define criteria which we would use to make the selections.  It was 
decided to use functional activity as the criterion with which to narrow the compounds.  
We would first screen a vast number of compounds from the library for functional 
activity at the CB1 and CB2 receptors.  We would then select compounds that matched 
the functional profiles of the seven compounds screened in the initial study.  The list of 
candidates would then be reduced based on solubility and/or toxicity data.  We would 
then examine the cytokine and chemokine release profiles of human macrophage and 
dendritic cell lines challenged with lipopolysaccharide (LPS, to simulate a gram negative 
infection) or peptidoglycan (PGN, to simulate a gram positive infection) and human 
epithelial and endothelial cell lines challenged with TNF-α or IL-1β.  The candidates 
would then be screened for their ability to modulate the excretion of cytokines and 
chemokines in our in vitro models.  The one or two compounds that proved to be most 
efficacious would then be moved into an in vivo inflammatory model such as bacteremia 
or sepsis.  The overall design of the study is summarized in Figure 5.6. 
 
 
5.4.2 Selection of Compounds to Screen 
 
 In order to select lead compounds from our chemically diverse library of 
cannabinoid ligands, it was necessary to first develop functional profiles for the initial 
seven compounds in order to develop the paradigm used for selection.  It was presumed 
that since all seven compounds exhibited anti-inflammatory activity that they would each 
have similar functional activity patterns.  This proved to be an incorrect assumption.  To 
develop the functional profiles, we screened each compound in our functional assay 
platform for the CB1 and CB2 receptors at 10µM.  The assay determines a compound’s 
ability to affect the alpha-agonist stimulated production of cAMP.  Since CB1 and CB2 
signal through Gαi, an agonist will decrease the amount of cAMP produced, and agonist 
will have no effect, and an inverse agonist will increase the production of cAMP.  The 
profiles for each of the initial seven compounds are shown in Figure 5.7.  The data is 
presented as a percentage of the cAMP production compared to a control.  Higher agonist 
activity presents as a lower percentage.  Lesser agonist activity or antagonism presents a 
percentage closer to 100 and inverse agonist activity will give percentages greater than 
100.  The compounds clearly have varied functional activity at CB1 and CB2.  Δ8-THC 
along with compounds 37 and 79 has greater agonist activity at 10µM at the CB1 
receptor than at CB2.  In fact, THC appears to be an antagonist and possibly even an 
inverse agonist in our assay platform.  HB-I-172, as previously described, is an antagonist 
at CB1 and an inverse agonist at CB2.  The remaining compounds (50, 80, and 81) 
exhibited very little if any agonist activity at CB1 and moderate agonist activity at CB2.  
The observed differences in the functional profiles of these compounds could point to the 
possibility that agonists of either the CB1 or CB2 receptors are efficacious in reducing 
the inflammatory response, or that possibly there is another target involved such as 
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Figure 5.6: Anti-inflammatory study design 
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Figure 5.7: Functional profiles of initial seven compounds screened for anti-
inflammatory activity 
Compounds were screened using the ActOne© whole cell functional assay for the CB1 
and CB2 receptors.  The assay measures a compound’s ability to alter cAMP production 
stimulated by an alpha agonist.  The lower the percentage of control, the greater ability of 
the compound to suppress the formation of cAMP; therefore, the greater the agonist 
activity at the given receptor.  Percentages closer to 100 represent lower agonist activity 
or antagonist activity.  Percentages above 100 represent activity of an inverse agonist.  
Data represents a minimum of three experiments run in triplicate. 
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GPR55.  The fact that HB-I-172 showed preliminary efficacy strengthens the possibility 
that CB2 inverse agonists may be viable candidates for the treatment of inflammatory 
disorders. 
 Since there was no clear pattern with which to use as a screening criterion, we 
chose to develop functional profiles for a large number of our compounds and select a 
number that had a variety of functional activities.  Initially, we screened seventy-five 
compounds from eight distinct structural classes.  The classes were the triaryls, pyridine 
triaryls, pyrimidine triaryls, pyridine hexahydros, pyrimidine hexahydros, benzofurans, 
furanopyridines, and the furanopyrimidines.  Out of the seventy-five screened, forty-four 
compounds were carried forward.  These compounds were then screened for toxicity 
against human dermal fibroblasts at 10, 25, and 50µM (data not shown).  The compounds 
that exhibited the greatest toxicity at the lowest doses were eliminated.  The remaining 
compounds were further narrowed based on solubility.  The compounds that visibly 
precipitated at the 50µM concentration in the cytotoxicity assay were also eliminated.  
This narrowed down the field significantly and one compound was chosen from each 
class (Figure 5.8) to carry forward into the in vitro inflammation assays. 
 
 
5.4.3 Cytokine and Chemokine Release Profiles 
 
 I initially decided to utilize a total of four cell lines in the anti-inflammatory 
study.  Two cell lines were used to model cells of the immune system: THP-1 and KG-1.  
THP-1 is a human monocytic leukemia cell line that can be differentiated into a 
macrophage-like phenotype and KG-1 is a human lymphoblastic leukemia line that can 
be differentiated into a dendritic cell phenotype.  Cells of the epithelial and endothelial 
lineages that also play roles in the inflammatory response were also to be studied.  A-549, 
a human epithelial lung carcinoma cell line, was chosen to model the epithelial response 
and the human vascular endothelial cell line HUV-EC-C was selected to model the 
endothelial inflammatory response. 
 We decided to utilize the previously described MSD® technology to measure the 
cytokine and chemokine levels in-house.  We selected two types of analysis plates for our 
studies.  The first was the Human ProInflammatory 9-PlexTissue Culture Kit which 
measures the quantitative levels of nine cytokines, namely: IL-1β, Il-2, IL-6, IL-8, IL-10, 
IL-12 p70, TNF-α, IFN-γ, and GM-CSF (granulocyte-macrophage colony-stimulating 
factor).  To measure chemokine production, the Human Chemokine 9-PlexTissue Culture 
Kit was chosen which assays for Eotaxin, Eotaxin-3, IL-8, IP-10 (10 kDa interferon-
gamma-induced protein), MCP-1, MCP-4, MDC (macrophage-derived chemokine), MIP-
1β (macrophage inflammatory protein-1 beta), and TARC (thymus and activation 
regulated chemokine). 
 In order to test the ability of our assay design to detect the levels of excreted 
cytokines and chemokines, we initially collected time-course release profiles of each cell 
line challenged with two different stimuli.  This would also give us information as to the 
optimum time point to use for screening our compounds.  The THP-1 and KG-1 cell lines 
grow in suspension and must be transformed to attach and take on the macrophage and  
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Figure 5.8: Eight compounds chosen for anti-inflammatory studies 
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dendritic cell phenotypes, respectively.  This is accomplished by incubating the cells in 
the presence of phorbol 12-myristate 13-acetate (PMA, 10ng/ml) and ionomycin 
(500ng/ml) for a minimum of 5 days.  The transformed cells, along with non-transformed 
THP-1 and KG-1 for comparison, were challenged with LPS or PGN at 1µg/ml and the 
supernatant media was assayed at 10 time points from 1 to 24 hours post stimulus for the 
levels of the previously mentioned cytokines and chemokines.  The same procedure was 
performed with A549 and HUV-EC-C stimulated with TNF-α and IL-1β.  A 
representative graph is shown in Figure 5.9.  This data demonstrates the release of IL-6 
from transformed and non-transformed THP-1 in response to LPS over the 24 hour 
experiment.  The entire data set is included in Appendix A.  From the time-course 
experiments we were able to validate the assay platform and to draw some conclusions 
that helped to shape the remainder of the experiments: 
1. There is a detectable, time-dependent release of cytokines and chemokines 
from the human cell lines THP-1, KG-1, A549, and HUV-EC-C. 
 
2. The cytokines and chemokines reached maximum or near maximum levels at 
18 hours post stimulus. 
 
3. THP-1 exhibited a more pronounced response than did KG-1. 
 
4. LPS elicited a greater response from THP-1 and KG-1 than did PGN. 
 
5. The responses elicited from A549 and HUV-EC-C from TNF-α and IL-1β 
were comparable. 
 
 
5.4.4 Screening of Initial Eight Compounds 
 
 With the information gained from the cytokine/chemokine release profile 
experiments, the screening of the eight selected compounds was planned.  Due to the 
lesser response of the transformed KG-1 cells, it was decided to use only the THP-1 cell 
line to model cells of the immune system and to continue with both A549 and HUV-EC-
C.  Each of the eight compounds was screened for toxicity against the three cell lines, the 
EC50s were determined, and the EC10s calculated.  The compounds were then screened 
for their abilities to attenuate the inflammatory response in THP-1 stimulated with LPS or 
PGN and in A549 and HUV-EC-C stimulated with TNF-α or IL-1β.  The drugs were 
screened at the EC10 or 25µM (whichever was less) and cytokine/chemokine levels were 
measured 18 hours post stimulus and drug treatment. 
 Each compound was capable of attenuating the inflammatory response on 
multiple cell lines as manifested by decreases in the levels of multiple secreted cytokines 
and chemokines.  The entire data set from this series of experiments can be found in 
Appendix B.  Significant effects were seen in a number of inflammatory markers; for 
example, in the transformed THP-1 cell line decreases in the cytokine IFN-γ were 
observed for all compounds tested in the PGN group and five of the eight compounds 
tested in the LPS group (Figure 5.10).  The significance of this effect is that IFN-γ can 
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Figure 5.9: Time-dependent release of IL-6 from THP-1 stimulated with LPS 
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Figure 5.10: Effects of eight compounds on release of IFN-γ from THP-1 in response to 
LPS and PGN 
* = p < 0.05, ** = p < 0.01, and *** = p < 0.005. 
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further activate macrophages and lead to an increased synthesis and release of pro-
inflammatory cytokines and chemokines.199  Significant results were also seen with THP-
1 in the levels of IL-12p70 and IL-6 produced in response to both LPS and PGN (Figures 
5.11 and 5.12, respectively).  IL-12p70 is a cytokine that can further activate 
macrophages; however, its main function is the activation of NK cells200 and 
differentiation of naïve T cells.201  Upon exposure to IL-12, T and NK cells are 
stimulated to produce and release the pro-inflammatory cytokines IFN-γ and TNF-α 
which further perpetuate the inflammatory response.  IL-6 is a major pro-inflammatory 
mediator produced mainly by macrophages that elicits a wide range of responses such as 
lymphocyte activation, increased antibody production, fever, and production of acute 
phase proteins by hepatocytes.  Overproduction of IL-6 has also been implicated in a 
number of autoimmune disorders such as rheumatoid arthritis.202  Still further positive 
results were seen in the PGN stimulated THP-1 cells as evidenced by reductions in GM-
CSF, IL-1β, and TNF-α and increases in the anti-inflammatory cytokine IL-10 (Figures 
5.13 and 5.14).  GM-CSF increases the production of granulocytes and monocytes and 
increases monocyte adhesion.203  TNF-α and IL-1β each produce a wide range of 
inflammatory responses such as increased expression of adhesion molecules on 
endothelial cells and increases in vascular permeability.204  The increased production of 
IL-10 following exposure to PGN and five of the eight compounds tested is of interest 
due to the anti-inflammatory role of IL-10 which inhibits the synthesis of pro-
inflammatory mediators such as IFN-γ, IL-2, IL-3, TNF-α and GM-CSF.205   
 Attenuations in the production of cytokines were also observed in the HUV-EC-C 
endothelial cell line.  Examples are reductions in GM-CSF and IL-6 in response to TNF-α 
(Figure 5.15) and reductions in IFN-γ, IL-12p70, and IL-2 in response to IL-1β (Figure 
5.16).  IL-2 is a cytokine normally produced by activated T cells and stimulates the 
growth and differentiation of antigen-selected cytotoxic T cells and is required for the 
development of T cell immunologic memory.206  The significance of the lower levels of 
IL-2 produced by endothelial cells is not known. 
 There were also several noteworthy observations in the levels of chemokines 
following stimulus and drug exposure.  For example, reductions in the production of 
MIP-1β were detected following both TNF-α and IL-1β challenge in both A549 (Figure 
5.17) and HUV-EC-C (Figure 5.18).  MIP-1β has many varied functions in the 
inflammatory process.  It activates neutrophils, eosinophils, and basophils.  It also attracts 
NK, T, and dendritic cells to sites of infection.207  It also induces the synthesis and release 
of other pro-inflammatory cytokines from fibroblasts and macrophages.208  MIP-1β is 
generally produced by macrophages and T cells, and as previously stated in regards to IL-
2, the significance in the attenuation of the lower levels of MIP-1β produced from 
endothelial and epithelial cells cannot be speculated.  Interestingly, the production of 
MIP-1β from the macrophage-like transformed THP-1 cell line was not significantly 
affected by any of the eight compounds tested.  Significant reductions in the chemokine 
IP-10 were also observed for both A549 and HUV-EC-C after TNF-α challenge (Figure 
5.19).  IP-10 attracts monocytes/macrophages, NK, T, and dendritic cells to sites of 
infection and also promotes T cell adhesion to endothelial cells.209  The triaryl HB-I-172 
was also found to decrease the production of IL-8 from HUV-EC-C stimulated with 
either TNF-α or IL-1β (Figure 5.20).  IL-8 is another major pro-inflammatory mediator.   
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Figure 5.11: Effects of eight compounds on release of IL-12p70 from THP-1 in response 
to LPS and PGN 
* = p < 0.05 and ** = p < 0.01. 
182 
 
 
 
Figure 5.12: Effects of eight compounds on release of IL-6 from THP-1 in response to 
LPS and PGN 
* = p < 0.05, ** = p < 0.005, *** = p < 0.001, and **** = p < 0.0005. 
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Figure 5.13: Effects of eight compounds on release of GM-CSF and IL-1β from THP-1 
in response to PGN 
* = p < 0.05, ** = p < 0.005, *** = p < 0.0005, and **** = p < 0.0001. 
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Figure 5.14: Effects of eight compounds on release of IL-10 and TNF-α from THP-1 in 
response to PGN 
* = p < 0.05, ** = p < 0.01, *** = p < 0.005, and **** = p < 0.001. 
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Figure 5.15: Effects of eight compounds on release of GM-CSF and IL-6 from HUVEC 
in response to TNF-α 
* = p < 0.05, ** = p < 0.01, and *** = p < 0.005. 
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Figure 5.16: Effects of eight compounds on release of IFN-γ, IL-12p70, and IL-2 from 
HUVEC in response to IL-1β 
* = p < 0.05 and ** = p < 0.005. 
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Figure 5.17: Effects of eight compounds on release of MIP-1β from A549 in response to 
TNF-α and IL-1β 
* = p < 0.05, ** = p < 0.005, and *** = p < 0.001. 
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Figure 5.18: Effects of eight compounds on release of MIP-1β from HUVEC in response 
to TNF-α and IL-1β 
* = p < 0.05 and ** = p < 0.005. 
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Figure 5.19: Effects of eight compounds on release of IP-10 from A549 and HUVEC in 
response to TNF-α 
* = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.001, and ***** = p < 0.0005. 
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Figure 5.20: Effects of eight compounds on release of IL-8 from HUVEC in response to 
TNF-α and IL-1β 
* = p < 0.05. 
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One of its main functions in the inflammatory response is to recruit neutrophils.  Upon 
exposure to IL-8, neutrophils are mobilized and activated which is necessary for 
degranulation and the respiratory burst.210  Reductions in the chemokine MCP-1 were 
also observed in THP-1 (Figure 5.21) following LPS stimulation and in HUV-EC-C 
(Figure 5.22) following both TNF-α and IL-1β stimulation.  MCP-1 activates 
macrophages, recruits monocytes, eosinophils, and basophils, and triggers histamine 
release from basophils.211  The action of this chemokine has been implicated in allergy, 
asthma, and arthritis, and a treatment that could effectively reduce the levels of this 
protein could be useful in those conditions.212 
 
 
5.4.5 Dose Response of Four Lead Compounds 
 
 We decided to determine if the observed reductions in cytokines and chemokines 
due to the eight cannabinoids screened were dose dependant.  The eight compounds were 
further narrowed down to four based on the compounds’ overall effects of the cytokine 
and chemokine panels.  The four that were chosen were the triaryl HB-I-172, the 
pyrimidyl and pyridyl hexahydros 37 and 79, and the benzofuran 83 (Figure 5.23).  Two 
cell lines were chosen for the dose response study: THP-1 and HUV-EC-C and the 
compounds were screened in four escalating doses based on each compound’s EC50 
against each cell line.  The highest concentration for each compound was the EC10 or 
25µM, whichever was lower.  
 Many of the drugs exhibited a dose dependent suppression of cytokine and 
chemokine release from THP-1 stimulated with LPS and HUV-EC-C stimulated with 
TNF-α.  The complete data set from this experiment may be found in Appendix C.  
Some examples of the dose dependent reduction are shown in Figures 5.24 and 5.25.  
The first graph depicts the dose dependent reduction in synthesis and secretion of Eotaxin 
and MCP-4 from THP-1 cells in response to HB-I-172 treatment post LPS exposure.  The 
second graph shows the dose dependent reduction in Eotaxin-3 and TARC from THP-1 
cells in response to treatment with the benzofuran 83.  Interestingly, for some cytokines 
and chemokines, there was a greater reduction in levels due to the lowest concentration of 
certain drugs (see Appendix C). 
 
 
5.4.6 Further Evaluation of HB-I-172 
 
 HB-I-172 was selected out of the four compounds screened due to its broad 
spectrum anti-inflammatory activity across the cell lines tested and also due to its novel 
inverse-agonist activity at the CB2 receptor coupled with being an antagonist at CB1.  
The previously described anti-inflammatory studies, with the exception of HUV-EC-C, 
utilized cancerous cell lines.  The known abnormalities in the signaling cascades of 
cancers can overlap with the inflammatory pathways within the cell.  For example the 
Akt and ERK pathways have been shown to be one signaling mechanism leading to NF-
κβ translocation to the nucleus.213 
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Figure 5.21: Effects of eight compounds on release of MCP-1 from THP-1 in response to 
LPS 
* = p < 0.05. 
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Figure 5.22: Effects of eight compounds on release of MCP-1 from HUVEC in response 
to TNF-α and IL-1β 
* = p < 0.05, ** = p < 0.001, and *** = p < 0.0005. 
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Figure 5.23: Four compounds chosen for dose response study 
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Figure 5.24: Examples of dose dependent reductions in chemokines produced by THP-1 
after treatment with HB-I-172 
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Figure 5.25: Examples of dose dependent reductions in chemokines produced by THP-1 
after treatment with compound 83 
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In order to test HB-I-172 in a system that more closely resembles the responses of 
an in vivo environment, three human primary cell lines were used.  HB-I-172 and the  
thiphenyl analog SMM-I-229 (Figure 5.26)  were screened against human lung blood 
microvasculature endothelial cells (HMVEC-LBI, Lonza, Inc.), human small airway 
epithelial cells (SAEC, Lonza, Inc.), and human monocyte derived macrophages (AllCell, 
Inc.).  SMM-I-229 possesses the same inverse agonist activity at CB2 as HB-I-172 and is 
also an antagonist at CB1. 
 Cytokine and chemokine release profiles were determined for the three cell lines, 
as with the initial experiments, and EC50s were then determined for the two compounds 
against the cell lines.  See Appendix D for the complete set of release profiles.  The anti-
inflammatory assays were then carried out as before.  The HMVEC-LBI and SAEC cell 
lines were stimulated with TNF-α and the primary macrophages were stimulated with 
LPS before drug treatment.  The supernatant media was then assayed 18 hours later for 
levels of the same cytokines and chemokines.  The complete set of graphs can be found 
in Appendix E.  While the effects of HB-I-172 on the three primary cell lines were 
different than in the original cell lines tested, there were reductions in several of the pro-
inflammatory cytokines and chemokines assayed for. 
 In order to test the possible contributions of cannabinoids in the treatment of 
neurological inflammatory disorders such as meningitis, Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, and neuropathic pain, we next tested HB-I-
172 and the CB1 agonist/CB2 antagonist classical cannabinoid KM-233 primary human 
microglia (Clonexpress) challenged with LPS.  Again, the first step was to determine 
cytokine and chemokine release profiles for the cell line due to LPS exposure (Appendix 
F).  The EC50s were then determined for the two drugs against the cells and the assay 
performed as before.  HB-I-172 reduced the levels of a majority of the cytokines and 
chemokines assayed including IFN-γ, IL-6, and MCP-1 which have all been found to 
play roles in a number of neuro-inflammatory conditions214 (Appendix G).  KM-233 also 
performed well in this assay.  There were, however, differences in the anti-inflammatory 
profile of the two drugs, probably due to the different functional activities at the 
cannabinoid receptors.   
 In order to strengthen the case for the use of CB2 inverse agonists as anti-
inflammatory agents, we chose to compare HB-I-172 to the clinically utilized anti-
inflammatory drug dexamethasone.  HB-I-172 was compared to dexamethasone in the 
THP-1 cell line stimulated with LPS and in A549 and HMVEC-LBI stimulated with 
TNF-α.  In the majority of cytokines and chemokines assayed for, HB-I-172 performed as 
well or better than dexamethasone (See Appendix H for complete data set).   
 In conclusion, we have demonstrated that HB-I-172 is a viable candidate for 
development as an anti-inflammatory agent.  The compound has exhibited in vitro 
reductions in the production and secretion of a wide range of cytokines and chemokines 
from a variety of cell types involved in the inflammatory process.  Not only have we 
demonstrated that the compound is efficacious in standard inflammatory models using 
cancerous cell lines (THP-1, KG-1, and A549) but that this activity also translates into 
efficacy when normal human primary cells are utilized and when compared to a standard 
therapy.  A number of future studies are planned to further evaluate the utility of HB-I- 
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Figure 5.26: CB2 inverse agonists screened as anti-inflammatory agents against human 
primary macrophages, epithelial, and endothelial cells 
  
Cl
Cl
OH
HO
O
Cl
Cl
OH
HO
O
S
HB-I-172
SMM-I-229
199 
 
172 as an anti-inflammatory agent.  These include an experiment to test the compound’s 
ability to favorably modulate the immune response of T and B cells by observing the 
effects on antigen receptor-dependent activation using murine splenocytes, an in vivo 
endotoxemia model, and murine models of Huntington’s disease, multiple sclerosis, and 
neuropathic pain.  Future studies are also planned to determine the exact molecular target 
of HB-I-172 that is responsible for the anti-inflammatory activity and the signaling 
pathway that this activates.  Knowledge gained from the work with HB-I-172 in the 
treatment of glioblastoma (Chapter 3) gives us some clues as to possible signaling 
mediators involved.  As stated earlier, the Akt and ERK pathways have been shown to be 
one signaling mechanism that leads to NF-κβ translocation to the nucleus during the 
inflammatory response.  The profound effects of HB-I-172 on the PI3K/Akt and 
Raf1/MEK/ERK pathways in glioma may also be found in cells treated with the 
compound following inflammatory challenge.  As observed in glioma, the effects of HB-
I-172 on STAT3 and GSK-3β may also play a role, as each of these proteins has been 
shown to be mediators of inflammation.215  We also believe that the possible interaction 
of HB-I-172 with the GPR55 receptor may contribute to its action as RhoA has been 
shown to contribute to NF-κβ-dependent proinflammatory gene transcription.216 
 
 
5.5 Experimental Methods 
 
 
5.5.1 Transformation of THP-1 and KG-1 
 
 Differentiation of Monocytes: To THP-1 human leukemia monocytes (ATCC 
#TIB-202) or KG-1 human leukemia myeloblasts (ATCC #CCL-246) in suspension was 
added phorbol 12-myristate 13-acetate (PMA Aldrich #P1585) and ionomycin (Aldrich 
#I0634), 10 and 500 ng/ml respectively, to induce differentiation into macrophage-like or 
dendritic-like cells, respectively.  Cells were seeded at 30,000 cells/well in a 96-well 
polystyrene dish and allowed to incubate at 37°C in 5% CO2 / 95% air for 5-10 days to 
complete transformation.  Media was refreshed as needed until assay. 
 
 
5.5.2 Cytokine and Chemokine Assays 
 
 A549 (ATCC #CCL-185), HUV-EC-C (ATCC #CRL-1730), HMVEC-LBI 
(Lonza #CC-2815), SAEC (Lonza #CC-2547), monocyte derived macrophages (AllCells 
#PB-MDM-001F), microglia (Clonexpress #HMG 030), or differentiated THP-1 or KG-1 
cells were maintained according to suppliers recommendations and were seeded on 96-
well polystyrene plates at a density of 300,000 cells/ml (100μL per well) and incubated at 
37°C in 5% CO2 / 95% air for 24 hours to allow cell attachment.  Drug solutions were 
prepared in DMSO at 100x concentration and mixed 1:100 in media containing 1% FBS 
to yield the desired concentration.  Plates were then removed from the incubator and the 
complete growth media was replaced with 50μL media containing 1% FBS and 
lipopolysaccharide or peptidoglycan at 1 μg/ml (for macrophages, microglia, or 
differentiated THP-1 or KG-1), or TNF-α (10ng/ml) or IL-1β (1 ng/ml) in the case of 
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A549, HUV-EC-C, HMVEC-LBI, or SAEC or without stimulus in the case of control 
wells.  Cells were returned to the incubator for 1 hour before drug treatments.  Drug-
media solutions were prepared at 2x desired final concentration in media containing 1% 
FBS and the appropriate stimulus at the previously mentioned concentration.  Control 
media was also prepared which contained only vehicle (DMSO).  50μL of media 
containing drug or vehicle alone was then added to appropriate wells and the plates 
returned to the incubator for 18 hours.  Media supernatants were then assayed for 
cytokines and chemokines using the Human ProInflammatory 9-PlexTissue Culture Kit 
(MSD # K15007B-1) and the Human Chemokine 9-PlexTissue Culture Kit (MSD # 
K15001B-1) according to the manufacturer’s protocol.  The plates were then imaged on 
the SECTOR Imager 2400 (Meso Scale Dscovery) according to the manufacturer’s 
instructions. 
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Appendix A: Cytokine and Chemokine Release Profiles of THP-1, KG-1, A549, and 
HUV-EC-C 
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Appendix B: Effects of Eight Cannabinoids on Cytokine and Chemokine Release of 
THP-1, A549, and HUV-EC-C 
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Appendix C: Dose Response of Four Cannabinoids on Cytokine and Chemokine 
Release of THP-1 and HUV-EC-C 
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Appendix D: Cytokine and Chemokine Release Profiles of HMVEC-LBI, Monocyte 
Derived Macrophages, and SAEC 
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Appendix E: Effects of HB-I-172 and SMM-I-229 on the Cytokine and Chemokine 
Release of HMVEC-LBI, Monocyte Derived Macrophages, and SAEC 
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Appendix F: Cytokine and Chemokine Release Profiles of Primary Human 
Microglia 
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Appendix G: Effects of HB-I-172 and KM-233 on the Cytokine and Chemokine 
Release of Primary Human Microglia 
 
  
281 
 
 
  
282 
 
 
  
283 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix H: Comparison of the Effects of HB-I-172 to Dexamethasone on the 
Cytokine and Chemokine Release of THP-1, A549, and HMVEC-LBI 
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